

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**

**IN RE: VALSARTAN PRODUCTS  
LIABILITY LITIGATION**

No. 1:19-md-2875-RBK  
Hon. Robert Kugler

**JURY TRIAL DEMANDED**

---

**CONSOLIDATED  
THIRD AMENDED MEDICAL MONITORING CLASS ACTION  
COMPLAINT**

## TABLE OF CONTENTS

	Page
I. INTRODUCTION .....	1
II. PARTIES .....	5
A. Class Representatives .....	5
B. The Active Pharmaceutical Ingredient Manufacturer Defendants .....	31
1. Zhejiang Huahai Pharmaceutical Co., Ltd. Entities .....	31
2. Hetero Labs, Ltd. Entities .....	33
3. Mylan Laboratories, Ltd. Entities .....	35
4. Aurobindo Pharma, Ltd. Entities .....	37
C. The Finished-Dose Defendants .....	39
1. The Teva Defendants .....	39
D. Retail Pharmacy Defendants .....	40
1. Walgreens.....	41
2. CVS .....	42
3. Walmart.....	44
4. Rite Aid .....	45
5. Express Scripts.....	46
6. “John Doe” Pharmacies .....	46
E. Wholesaler Defendants .....	47
1. Cardinal Health .....	48
2. McKesson.....	48
3. AmerisourceBergen .....	49
4. “John Doe” Wholesalers .....	49
F. Repackager and Relabeler Defendants.....	50
G. True Names / John Doe Defendants 1-50 .....	51
III. JURISDICTION AND VENUE.....	52
IV. FACTUAL ALLEGATIONS .....	53

**TABLE OF CONTENTS**  
**(continued)**

	<b>Page</b>
A. Generic Drugs Must Be Chemically the Same as Branded Drug Equivalents .....	53
B. Misbranded and Adulterated or Misbranded Drugs.....	55
C. Prescription Drug Product Identification and Tracing.....	58
D. The Drug Supply Chain Security Act Requires Tracing of Product.....	59
E. Manufacturer Defendants’ VCDs Are Identifiable by NDC Information.....	66
F. The Drugs Ingested by Plaintiffs Were Not Valsartan, But New, Unapproved VCDs .....	68
G. Defendants Made False Statements in the Labeling of their VCDs.....	71
H. The Generic Drug Supply Chain in the United States .....	72
I. Background on Current Good Manufacturing Practices (“cGMPs”).....	73
J. The Generic Drug Approval Framework.....	77
1. ANDA Applications Must Demonstrate Bioequivalence.....	78
2. ANDA Applications Must Provide Information About the Manufacturing Plants and Processes.....	79
3. ANDA Applications Must Comply with cGMPs .....	80
4. ANDA Approval is Contingent upon Continuing Compliance with ANDA Representations of Sameness.....	80
K. Approval of ANDAs Related to Valsartan.....	81
1. DIOVAN and EXFORGE Background.....	81
2. ANDA Applications for Generic Valsartan.....	83
L. Starting as Early as 2007, Defendants Were Actively Violating cGMPs in Their Foreign Manufacturing Facilities .....	85
1. ZHP’s Inadequate Manufacturing Processes Results in Contaminated, Adulterated, Misbranded and/or Unapproved VCDs.....	86

**TABLE OF CONTENTS**  
**(continued)**

		<b>Page</b>
2.	Hetero’s Inadequate Manufacturing Processes Results in Contaminated Adulterated, Misbranded and/or Unapproved VCDs.....	93
3.	Mylan’s Inadequate Manufacturing Processes Results in Contaminated, Adulterated, Misbranded and/or Unapproved VCDs.....	97
4.	Aurobindo’s Inadequate Manufacturing Processes Results in Contaminated, Adulterated, Misbranded VCDs...	104
M.	The Contamination of the VCDs.....	110
1.	The Nitrosamine Contaminant NDMA.....	110
2.	The Nitrosamine Contaminant NDEA.....	114
3.	Formation of NDMA and/or NDEA in Defendants’ Contaminated, Adulterated, Misbranded, and/or Unapproved VCDs.....	116
N.	Defendants Had Actual and/or Constructive Notice of NDMA and/or NDEA Contamination of their Contaminated, Misbranded, Adulterated and/or Unapproved VCDs.....	117
O.	Other Contaminants.....	122
P.	FDA Announces Voluntary Recall of Defendants’ Contaminated, Adulterated and/or Misbranded VCDs.....	123
Q.	Defendants’ Warranties and Fraudulent and Deceptive Statements to Consumers Regarding Their Generic VCDs.....	124
1.	Warranties Common to All Manufacturer Defendants.....	124
2.	ZHP Defendants’ Warranties.....	130
3.	Hetero Defendants’ Warranties.....	132
4.	Mylan Defendants’ Warranties.....	135
5.	Aurobindo Defendants’ Warranties.....	137
6.	Teva Defendants’ Warranties.....	138
7.	Warranties Common to All Retail Pharmacy Defendants.....	141
8.	Wholesale Distributor Defendants’ Warranties.....	144

**TABLE OF CONTENTS**  
**(continued)**

	<b>Page</b>
9. Repackager and Relabeler Defendants’ Warranties .....	148
R. Wholesalers and Retail Pharmacy Defendants’ Obligations to Ensure that the Product they Sell and Distribute Throughout the Stream of Commerce is Not Suspected to be Adulterated or Misbranded and therefore Illegal to Sell.....	148
2. <i>Defendant</i> McKesson.....	157
2. <i>Defendant</i> Cardinal Health .....	161
3. <i>Defendant</i> AmerisourceBergen.....	165
4. <i>Defendant</i> CVS Pharmacy .....	167
5. <i>Defendant</i> Walgreens.....	169
6. <i>Defendant</i> Rite Aid .....	172
7. <i>Defendant</i> Walmart.....	174
S. New Revelations Continue to Unfold About Other Manufacturing Plants .....	179
T. Fraudulent Concealment and Tolling.....	179
V. CLASS ACTION ALLEGATIONS.....	181
B. The Classes Meet the Rule 23 Requirements.....	187
VI. CLAIMS FOR RELIEF .....	192
FIRST CLAIM FOR RELIEF NEGLIGENCE (Individually and on Behalf of the Class) .....	192
SECOND CLAIM FOR RELIEF NEGLIGENCE PER SE (Individually and on Behalf of the Class) .....	195
THIRD CLAIM FOR RELIEF NEGLIGENT MISREPRESENTATION AND OMISSION (Individually and on Behalf of the Class) .....	197
FOURTH CLAIM FOR RELIEF MEDICAL MONITORING (Individually and on Behalf of the Class) .....	200
FIFTH CLAIM FOR RELIEF PRODUCTS LIABILITY- MANUFACTURING DEFECT (Individually and on Behalf of the Class) .....	205

**TABLE OF CONTENTS**  
**(continued)**

	<b>Page</b>
SIXTH CLAIM FOR RELIEF FAILURE TO WARN (Individually and on Behalf of the Class) .....	207
SEVENTH CLAIM FOR RELIEF BREACH OF IMPLIED WARRANTY OF MERCHANTABILITY (Individually and on Behalf of the Class) .....	208
EIGHTH CLAIM FOR RELIEF BREACH OF EXPRESS WARRANTIES (Individually and on Behalf of the Class).....	214
NINTH CLAIM FOR RELIEF FRAUD/FRAUDULENT CONCEALMENT (Individually and on Behalf of the Class).....	218
TENTH CLAIM FOR RELIEF STATE-LAW PRODUCT LIABILITY ACT CLAIMS (Individually and on Behalf of the Class).....	223
PRAYER FOR RELIEF .....	230
JURY DEMAND .....	231

Pursuant to Federal Rule of Civil Procedure 15, the Medical Monitoring Class Plaintiffs (“Plaintiffs”), file this Third Consolidated Amended Medical Monitoring Class Action Complaint (“Third Amended Master Class Complaint”)<sup>1</sup> against the below-enumerated Defendants.

## **I. INTRODUCTION**

1. Plaintiffs bring this action on behalf of themselves and all others who consumed Defendants’ generic valsartan-containing drugs (“VCDs”)<sup>2</sup> that were contaminated with an International Agency for Research on Cancer (“IARC”)- and Environmental Protection Agency (“EPA”)-listed probable human carcinogen known as N-nitrosodimethylamine (“NDMA”), and/or an IARC- and EPA-listed probable human carcinogen known as N-nitrosodiethylamine (“NDEA”), in the United States, and who thus suffered cellular damage, genetic harm, and/or are at an increased risk of developing cancer as a result, but have not yet been diagnosed with cancer. Plaintiffs seek injunctive and monetary relief, including creation of a fund to finance independent medical monitoring services, including but not limited to notification to all people exposed to this contamination, examinations, testing,

---

<sup>1</sup> This is one of three master complaints being filed in this multi-district litigation. The filing of three master complaints is to streamline the pleadings and issues for the parties’ mutual convenience only. Medical Monitoring Class Plaintiffs do not waive any claims that are not raised herein, or that are asserted in another master complaint.

<sup>2</sup> All of the various acronyms used throughout this complaint are summarized in the glossary attached as Exhibit A hereto.

preventative screening, and care and treatment of cancer resulting, at least in part, from the exposure to the NDMA or NDEA contamination.

2. This case arises from the marketing and sale of valsartan-containing drugs (“VCDs”) that were contaminated with unintended nitrosamine impurities, that were designed, manufactured, labeled, marketed, distributed, packaged, and sold by Defendants in the United States, and/or for ultimate sale in the United States, in violation of state laws, and that were contaminated, adulterated, misbranded, and unapproved, and which have been and remain the subject of one of the largest ongoing contaminated drug recalls ever in the United States. These VCDs were non-merchantable, and not of the quality or purity represented by Defendants named herein.

3. Valsartan and its combination therapy with hydrochlorothiazide are the generic versions of the registered listed drugs (“RLDs”) Diovan® (“DIOVAN”) and Diovan HCT® (“DIOVAN HCT”), respectively. Amlodipine-valsartan and its combination therapy with hydrochlorothiazide are the generic versions of the RLDs of Exforge® (“EXFORGE”) and Exforge HCT® (“EXFORGE HCT”), respectively. These RLDs are indicated for, among other things, the treatment of high blood pressure, a condition affecting approximately



103 million Americans according to the American Heart Association.<sup>3</sup> Several million U.S. patients pay for (in whole or in part) and consume generic valsartan each year.

4. At all times during the period alleged herein, Defendants represented and warranted to consumers that their VCDs were therapeutically equivalent to and otherwise the same as their RLDs, were otherwise fit for their ordinary uses, and were otherwise manufactured and distributed in accordance with applicable laws and regulations. In fact, Defendants' generic VCDs were not Food and Drug Administration ("FDA")-approved generic versions of these drugs, did not meet the quality standards and match the ingredients listed on the labels and package inserts, did not satisfy the criteria to be accurately described as generic equivalents, did not meet the applicable USP and Orange Book standards, and were instead of a lesser quality and were adulterated and/or misbranded (and thereby rendered worthless) by contamination with FDA, EMEA, EQDM, IARC- and EPA-listed probable human carcinogens known as N-nitrosodimethylamine ("NDMA") and N-nitrosodiethylamine ("NDEA").

---

<sup>3</sup> American Heart Association News, More than 100 million Americans have high blood pressure, AHA says, Heart.org (Jan. 31, 2018), <https://www.heart.org/en/news/2018/05/01/more-than-100-million-americans-have-high-blood-pressure-aha-says>.

5. According to the testing performed by the Defendants and the FDA, Defendants' generic VCDs contained NDMA and/or NDEA contamination levels that were unacceptable under all applicable standards, and in some cases hundreds of times higher than the FDA's February 28, 2019 updated interim limits for NDMA and/or NDEA impurities. The FDA has yet to release testing results for other impurities such as N-Nitroso-N-methyl-4-aminobutyric acid ("NMBA").

6. The contamination of Defendants' VCDs began in or around 2011 when Manufacturing Defendants changed the manufacturing process to include a solvent(s) that produced or contained NDMA, NDEA, and potentially other nitrosamine contaminants and impurities. Defendants had actual and constructive notice of the contamination as early as 2011.

7. Defendants have been illegally manufacturing, designing, packaging, selling, labeling, marketing, and distributing the misbranded and/or adulterated VCDs in the United States since September 2012, when Defendant Mylan launched a DIOVAN HCT generic after its valsartan HCT Abbreviated New Drug Application ("ANDA") was approved by the FDA.

8. Defendants willfully ignored deficiencies and warning signs regarding the operating standards and manufacturing and testing conditions at several of the overseas manufacturing plants where Defendants' generic VCDs were manufactured for use and consumption in the United States, and knowingly and

fraudulently manufactured, sold, labeled, marketed, and/or distributed contaminated, adulterated, and/or misbranded VCDs for consumption in the United States.

9. Medical Monitoring Class Plaintiffs are natural persons who are reasonably expected to use, consume, or be affected by the goods and were injured by the breach of Defendants' Warranties.

10. Plaintiffs thus consumed Defendants' VCDs that were illegally introduced into the market by Defendants, exposing Plaintiffs to highly dangerous and potentially fatal carcinogenic substances. Defendants' conduct requires medical monitoring and constitutes negligence, defective manufacture, failure to warn, breach of implied warranty of merchantability, breach of express warranty, fraudulent concealment, and other legal violations as set forth herein.

## II. PARTIES

### A. Class Representatives

11. The Master Complaints in this MDL are divided among Personal Injury, Medical Monitoring, and Economic Reimbursement for administrative purposes, as noted in Footnote 1. The below-identified Medical Monitoring Class Plaintiffs are absent Class Members in the Economic Reimbursement Class, and do not waive their status as absent Class Members by dint of serving as proposed Class Representatives for the medical monitoring class or classes. Furthermore, the

parties below identified as Medical Monitoring Class Plaintiffs, in filing this Third Amended Master Complaint, which is limited to medical monitoring per the administrative structure, do not waive, forego, or otherwise relinquish any entitlement they have to economic remedies for all harms alleged. Plaintiffs preserve their entitlement to any economic remedy for all harms alleged.

12. Plaintiff John Judson is a resident of the State of California. From 2014 to 2018, Plaintiff Judson was prescribed and used one or more of Defendants' VCDs, including VCDS manufactured, distributed, or sold by one or more ZHP Defendants (as defined *infra* Part II.C.). This product ("ZHP Product") bore a unique National Drug Code ("NDC"), which denoted that it was indeed sold, manufactured, or distributed into the United States drug supply chain by the ZHP Defendants. Specifically, the ZHP Product that Plaintiff Judson was prescribed and used was manufactured by Defendant ZHP and sold in the United States with the assistance of Defendant Huahai US, Defendant Prinston, Defendant Solco, Defendant Hetero, and Defendant Camber, who facilitated the regulatory approval of the ZHP Product necessary for sale. At least some of the ZHP Product ultimately prescribed to and used by Plaintiff Judson was purchased from Defendant ZHP by Defendants McKesson and AmerisourceBergen. Defendants McKesson and AmerisourceBergen in turn distributed and sold this ZHP Product to Defendant Express Scripts (among other Retail Pharmacy Defendants).

Defendant Express Scripts in turn sold this ZHP Product to Plaintiff Judson. Each Defendant mentioned in this paragraph expressly and implied warranted to Plaintiff Judson (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. But in fact, Plaintiff Judson used a product that was not the same as the RLD. Had Plaintiff Judson known the product he used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff Judson would not have used or purchased Defendants' VCDs. Plaintiff Judson consumed a Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

13. Plaintiff Sarah Zehr is a resident of the State of Florida. From 2012 to May 2016, Plaintiff Zehr was prescribed and used one or more of Defendants' VCDs. From May 2016 until November 2018, Plaintiff Zehr was prescribed and used one or more of Defendants' VCDs, including VCDs manufactured, distributed, or sold by one or more ZHP Defendants (as defined *infra* Part II.C.). This ZHP Product bore a unique National Drug Code, which denoted that it was indeed sold, manufactured, or distributed into the United States drug supply chain by the ZHP Defendants. Specifically, the ZHP Product that Plaintiff Zehr was

prescribed and used was manufactured by Defendant ZHP and sold in the United States with the assistance of Defendant Huahai US, Defendant Princeton, Defendant Solco, and Defendant Aurobindo, who facilitated the regulatory approval of the ZHP Product necessary for sale. At least some of the ZHP Product ultimately prescribed to and used by Plaintiff Zehr was purchased from Defendant ZHP by Defendant McKesson. Defendant McKesson in turn distributed and sold this ZHP Product to Defendant Walmart (among other Retail Pharmacy Defendants). Defendant Walmart in turn sold this ZHP Product to Plaintiff Zehr. Each Defendant mentioned in this paragraph expressly and implied warranted to Plaintiff Zehr (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. But in fact, Plaintiff Zehr used a product that was not the same as the RLD. Had Plaintiff Zehr known the product she used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff Zehr would not have used or purchased Defendants' VCDs. Plaintiff Zehr consumed a Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

14. Plaintiff Robert Kruk is a resident of the State of Illinois. Plaintiff Kruk was prescribed and used one or more of Defendants' VCDs, including VCDs manufactured, distributed, or sold by one or more ZHP Defendants (as defined *infra* Part II.C.). This ZHP Product bore a unique National Drug Code, which denoted that it was indeed sold, manufactured, or distributed into the United States drug supply chain by the ZHP Defendants. Specifically, the ZHP Product that Plaintiff Kruk was prescribed and used was manufactured by Defendant ZHP and sold in the United States with the assistance of Defendant Huahai US, Defendant Princeton, and Defendant Solco, who facilitated the regulatory approval of the ZHP Product necessary for sale. At least some of the ZHP Product ultimately prescribed to and used by Plaintiff Kruk was purchased from Defendant ZHP by Defendant McKesson. Defendant McKesson in turn distributed and sold this ZHP Product to Defendant Walmart (among other Retail Pharmacy Defendants). Defendant Walmart in turn sold this ZHP Product to Plaintiff Kruk. Each Defendant mentioned in this paragraph expressly and implied warranted to Plaintiff Kruk (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. But in fact, Plaintiff Kruk used a product that was not the same as the RLD. Had Plaintiff Kruk known the product he used was contaminated with

NDMA, NDEA, or another nitrosamine, Plaintiff Kruk would not have used or purchased Defendants' VCDs. Plaintiff Kruk consumed a Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer..

15. Plaintiff Michael Rives is a resident of the State of Illinois. Plaintiff Rives was prescribed and used one or more of Defendants' VCDs, including VCDs manufactured, distributed, or sold by one or more ZHP Defendants (as defined *infra* Part II.C.). This ZHP Product bore a unique National Drug Code, which denoted that it was indeed sold, manufactured, or distributed into the United States drug supply chain by the ZHP Defendants. Specifically, the ZHP Product that Plaintiff Rives was prescribed and used was manufactured by Defendant ZHP and sold in the United States with the assistance of Defendant Huahai US, Defendant Princeton, Defendant Solco, Defendant Teva, Defendant Actavis, and Defendant Aurobindo, who facilitated the regulatory approval of the ZHP Product necessary for sale. At least some of this ZHP Product was ultimately prescribed to and used by Plaintiff Rives. Each Defendant mentioned in this paragraph expressly and implied warranted to Plaintiff Rives (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs



were the same as their RLDs. But in fact, Plaintiff Rives used a product that was not the same as the RLD. Had Plaintiff Rives known the product he used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff Rives would not have used or purchased Defendants' VCDs. Plaintiff Rives consumed a Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

16. Plaintiff Robert Fields is a resident of the State of Maryland. From 2014 until 2018, Plaintiff Fields was prescribed and used one or more of Defendants' VCDs, including VCDs manufactured, distributed, or sold by one or more ZHP Defendants (as defined *infra* Part II.C.). This ZHP Product bore a unique National Drug Code, which denoted that it was indeed sold, manufactured, or distributed into the United States drug supply chain by the ZHP Defendants. Specifically, the ZHP Product that Plaintiff Fields was prescribed and used was manufactured by Defendant ZHP and sold in the United States with the assistance of Defendant Huahai US, Defendant Teva, and Defendant Actavis, who facilitated the regulatory approval of the ZHP Product necessary for sale. At least some of this ZHP Product was ultimately prescribed to and used by Plaintiff Fields. Each Defendant mentioned in this paragraph expressly and implied warranted to

Plaintiff Fields (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. But in fact, Plaintiff Fields used a product that was not the same as the RLD. Had Plaintiff Fields known the product he used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff Fields would not have used or purchased Defendants' VCDs. Plaintiff Fields consumed a Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

17. Plaintiff Celestine Daring is a resident of the State of Maryland. From 2007 until 2018, Plaintiff Daring was prescribed and used one or more of Defendants' VCDs, including VCDs manufactured, distributed, or sold by one or more ZHP Defendants (as defined *infra* Part II.C.). This ZHP Product bore a unique National Drug Code, which denoted that it was indeed sold, manufactured, or distributed into the United States drug supply chain by the ZHP Defendants. Specifically, the ZHP Product that Plaintiff Daring was prescribed and used was manufactured by Defendant ZHP and sold in the United States with the assistance of Defendant Mylan and Defendant Aurobindo, who facilitated the regulatory approval of the ZHP Product necessary for sale. At least some of the ZHP Product

ultimately prescribed to and used by Plaintiff Daring was purchased from Defendant ZHP by Defendant Cardinal. Defendant Cardinal in turn distributed and sold this ZHP Product to Defendant CVS (among other Retail Pharmacy Defendants). Defendant CVS in turn sold this ZHP Product to Plaintiff Daring. Each Defendant mentioned in this paragraph expressly and implied warranted to Plaintiff Daring (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. But in fact, Plaintiff Daring used a product that was not the same as the RLD. Had Plaintiff Daring known the product she used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff Daring would not have used or purchased Defendants' VCDs. Plaintiff Daring consumed a Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

18. Plaintiff Josephine Bell is a resident of the State of Arkansas. She was prescribed and used Valsartan from approximately November 2016 until July 2018, at doses of 80mg per day. The Valsartan she used during that time was manufactured, distributed, or sold by Defendants ZHP as defined below. Plaintiff Rice was provided, by her pharmacy Medicine Man Pharmacy in Little Rock, AR,

the manufacturer information of each Valsartan prescription that she took. Each product (“ZHP Product”), therefore, presumably had a unique National Drug Code which denoted that they were indeed sold, manufactured, or distributed into the United States drug supply chain by ZHP Defendants. Specifically, the ZHP Product that Plaintiff Bell purchased was manufactured by Defendant ZHP and sold in the United States by Defendant Solco with the assistance of Defendant Huahai US and Defendant Princeton, who facilitated the regulatory approval of the ZHP product necessary for sale. At least some of this ZHP Product, ultimately purchased by Plaintiff Bell, was purchased by either a potential John Doe Wholesaler Defendant and subsequently sold to Medicine Man Pharmacy or else directly sold to said pharmacy. Medicine Man Pharmacy, in turn, sold this ZHP product to Plaintiff Bell and other consumers. Each Defendant mentioned in this paragraph expressly and impliedly warranted to Plaintiff Bell (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. However, these ZHP Products, the Valsartan consumed by Plaintiff Bell, were contaminated with NDMA, NDEA, or another nitrosamine. Had Plaintiff Bell known the product she used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff Bell would not have used or purchased Defendants’ VCDs. Plaintiff Bell consumed a

Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

19. Plaintiff Valerie Rodich-Annese is a resident of the State of Pennsylvania. She was prescribed and used Valsartan from approximately January 2016 until July 2018, at doses of 160 mg and 320 mg per day. The Valsartan she used during that time was manufactured, distributed, or sold by Defendants ZHP and Aurobindo as defined below. Plaintiff Rodich-Annese was provided, by her pharmacy Giant Eagle in Pittsburgh, PA, the manufacturer information of each Valsartan prescription that she took. Each product ("ZHP Product" and "Aurobindo Product"), therefore, presumably had a unique National Drug Code which denoted that they were indeed sold, manufactured, or distributed into the United States drug supply chain by ZHP Defendants and Aurobindo Defendants. Specifically, the ZHP Product that Plaintiff Rodich-Annese purchased was manufactured by Defendant ZHP and sold in the United States by Defendant Solco with the assistance of Defendant Huahai US and Defendant Prinston, who facilitated the regulatory approval of the ZHP product necessary for sale. At least some of this ZHP Product, ultimately purchased by Plaintiff Rodich-Annese, was purchased by either a potential John Doe Wholesaler Defendant and subsequently

sold to Giant Eagle Pharmacy or else directly sold to said pharmacy. Giant Eagle Pharmacy, in turn, sold this ZHP product to Plaintiff Rodich-Annese and other consumers. Similarly, the Aurobindo Product that Plaintiff Rodich-Annese purchased was manufactured by Defendant Aurobindo Pharma Limited, Aurobindo Pharma USA and Aurolife Pharma, LLC, and sold in the United States by Defendants Aurobindo Pharma USA and Aurolife Pharma, LLC. Just as the ZHP was, at least some of this Aurobindo Product was purchased by either a potential John Doe Wholesaler Defendant and subsequently sold to Giant Eagle Pharmacy or else directly sold to this pharmacy. Giant Eagle Pharmacy then sold this Aurobindo product to Plaintiff Rodich-Annese and other consumers. Each Defendant mentioned in this paragraph expressly and impliedly warranted to Plaintiff Rodich-Annese (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. However, these ZHP and Aurobindo Products, the Valsartan consumed by Plaintiff Rodich-Annese, were contaminated with NDMA, NDEA, or another nitrosamine. Had Plaintiff Rodich-Annese known the product she used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff Rodich-Annese would not have used or purchased Defendants' VCDs. Plaintiff Rodich-Annese consumed a Cumulative Lifetime Threshold of at least XXX units. As a

result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

20. Plaintiff Roger Tasker is a resident of the State of West Virginia. He was prescribed and used Valsartan from approximately 2014 through the present, at a dose starting at 40 mg and ultimately 320 mg per day. The Valsartan that he used during that time was manufactured, distributed, or sold by Defendants ZHP and Mylan as defined below. Each product ("ZHP Product" and "Mylan Product") had a unique National Drug Code which denoted that they were indeed sold, manufactured, or distributed into the United States drug supply chain by ZHP and Mylan Defendants. Specifically, the ZHP Product that Plaintiff R. Tasker purchased was manufactured by Defendant ZHP and sold in the United States by Defendant Solco, with the assistance of Defendant Huahai US and Defendant Princeton, who facilitated the regulatory approval of the ZHP product necessary for sale. At least some of this ZHP Product, ultimately purchased by Plaintiff R. Tasker, was purchased by McKesson who then distributed and resold that ZHP Product to Retail Pharmacy Defendant Wal-Mart (among other Retail Pharmacy Defendants). Wal-Mart in turn, sold this ZHP product to Plaintiff R. Tasker and other consumers. Similarly, the Mylan Product that Plaintiff R. Tasker purchased was manufactured by Defendant Mylan Laboratories Limited and Pharmaceuticals,

Inc., and sold in the United States by Defendant Mylan Pharmaceuticals, Inc. At least some of this Mylan Product, ultimately purchased by Plaintiff R. Tasker, was purchased by McKesson who then distributed and resold that Mylan Product to Retail Pharmacy Defendant Wal-Mart (among other Retail Pharmacy Defendants). Wal-Mart in turn, sold this Mylan product to Plaintiff R. Tasker and other consumers. Each Defendant mentioned in this paragraph expressly and impliedly warranted to Plaintiff R. Tasker (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. However, these ZHP and Mylan Products, the Valsartan consumed by Plaintiff R. Tasker, were contaminated with NDMA, NDEA, or another nitrosamine. Had Plaintiff R. Tasker known the product he used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff R. Tasker would not have used or purchased Defendants' VCDs. Plaintiff R. Tasker consumed a Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

21. Plaintiff Judy Tasker is a resident of the State of West Virginia. She was prescribed and used Valsartan from approximately June 2016 through August



2018, at a dose of 40 mg per day. The Valsartan that she used during that time was manufactured, distributed, or sold by Defendants ZHP and Mylan as defined below. Each product (“ZHP Product” and “Mylan Product”) had a unique National Drug Code which denoted that they were indeed sold, manufactured, or distributed into the United States drug supply chain by ZHP and Mylan Defendants.

Specifically, the ZHP Product that Plaintiff J. Tasker purchased was manufactured by Defendant ZHP and sold in the United States by Defendant Solco, with the assistance of Defendant Huahai US and Defendant Princeton, who facilitated the regulatory approval of the ZHP product necessary for sale. At least some of this ZHP Product, ultimately purchased by Plaintiff J. Tasker, was purchased by McKesson who then distributed and resold that ZHP Product to Retail Pharmacy Defendant Wal-Mart (among other Retail Pharmacy Defendants). Wal-Mart in turn, sold this ZHP product to Plaintiff J. Tasker and other consumers. Similarly, the Mylan Product that Plaintiff J. Tasker purchased was manufactured by Defendant Mylan Laboratories Limited and Pharmaceuticals, Inc., and sold in the United States by Defendant Mylan Pharmaceuticals, Inc. At least some of this Mylan Product, ultimately purchased by Plaintiff J. Tasker, was purchased by McKesson who then distributed and resold that Mylan Product to Retail Pharmacy Defendant Wal-Mart (among other Retail Pharmacy Defendants). Wal-Mart in turn, sold this Mylan product to Plaintiff J. Tasker and other consumers. Each

Defendant mentioned in this paragraph expressly and impliedly warranted to Plaintiff J. Tasker (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. However, these ZHP and Mylan Products, the Valsartan consumed by Plaintiff J. Tasker, were contaminated with NDMA, NDEA, or another nitrosamine. Had Plaintiff J. Tasker known the product she used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff J. Tasker would not have used or purchased Defendants' VCDs. Plaintiff J. Tasker consumed a Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

22. Plaintiff Roland Butler is a resident of the State of Maryland. He was prescribed and used Valsartan from approximately May 2014 to February 2018, at a dose of 80 mg per day. The Valsartan he used during that time was manufactured, distributed, or sold by Defendant Aurobindo as defined below. Specifically, the Aurobindo Product that Plaintiff Butler purchased was manufactured by Defendant Aurobindo Pharma Limited, Aurobindo Pharma USA and Aurolife Pharma, LLC, and sold in the United States by Defendants Aurobindo Pharma USA and Aurolife Pharma, LLC. At least some of this Aurobindo Product

was purchased by either a potential John Doe Wholesaler Defendant(s) who then distributed and resold that Aurobindo Product to Retail Pharmacy Defendant Rite Aid (among other Retail Pharmacy Defendants) or was purchased directly by Rite Aid. Rite Aid, in turn, sold this Aurobindo product to Plaintiff Butler and other consumers. Each Defendant mentioned in this paragraph expressly and impliedly warranted to Plaintiff Butler (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. However, these ZHP and Mylan Products, the Valsartan consumed by Plaintiff Butler, were contaminated with NDMA, NDEA, or another nitrosamine. Had Plaintiff Butler known the product he used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff Butler would not have used or purchased Defendants' VCDs. Plaintiff Butler consumed a Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

23. Plaintiff Anthony Martinez is a resident of the State of Colorado. From 2014 until 2019, Plaintiff Martinez was prescribed and used one or more of Defendants' VCDs, including VCDs manufactured, distributed, or sold by one or

more ZHP Defendants (as defined *infra* Part II.C.). This ZHP Product bore a unique National Drug Code, which denoted that it was indeed sold, manufactured, or distributed into the United States drug supply chain by the ZHP Defendants. Specifically, the ZHP Product that Plaintiff Martinez was prescribed and used was manufactured by Defendant ZHP and sold in the United States with the assistance of Defendant Mylan, who facilitated the regulatory approval of the ZHP Product necessary for sale. At least some of this ZHP Product was ultimately prescribed to and used by Plaintiff Martinez. Each Defendant mentioned in this paragraph expressly and implied warranted to Plaintiff Martinez (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. But in fact, Plaintiff Martinez used a product that was not the same as the RLD. Had Plaintiff Martinez known the product he used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff Martinez would not have used or purchased Defendants' VCDs. Plaintiff Martinez consumed a Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

24. Plaintiff Kenneth Berkson is a resident of the State of Illinois. He was prescribed and used Valsartan from approximately 2014 to the present, at a dose ranging from 40 mg to 320 mg per day. The Valsartan he used during that time was manufactured, distributed, or sold by Defendant ZHP as defined below. Each product (“ZHP Product”) had a unique National Drug Code which denoted that they were indeed sold, manufactured, or distributed into the United States drug supply chain by Defendant ZHP. Specifically, the ZHP Product that Plaintiff Berkson purchased was manufactured by Defendant ZHP and sold in the United States by Defendant Solco, with the assistance of Defendant Huahai US and Defendant Princeton, who facilitated the regulatory approval of the ZHP product necessary for sale. At least some of this ZHP Product, ultimately purchased by Plaintiff Berkson, was purchased by John Doe Wholesaler Defendant(s) who then distributed and resold that ZHP Product to Retail Pharmacy Defendant Walgreens who sold this ZHP product to Plaintiff Berkson and other consumers. Each Defendant mentioned in this paragraph expressly and impliedly warranted to Plaintiff Berkson (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. However, the ZHP Product, the Valsartan consumed by Plaintiff Berkson, was contaminated with NDMA, NDEA, or another nitrosamine. Had

Plaintiff Berkson known the product he used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff Berkson would not have used or purchased Defendants' VCDs. Plaintiff Berkson consumed a Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

25. Plaintiff Richard O'Neill is a resident of the State of Kansas. During the class period, Plaintiff O'Neill was prescribed and used Valsartan. The Valsartan he used during that time was manufactured, distributed, or sold by Defendant ZHP and Defendant Aurobindo as defined below. Each product ("ZHP Product") had a unique National Drug Code which denoted that they were indeed sold, manufactured, or distributed into the United States drug supply chain by Defendant ZHP. Specifically, the ZHP Product that Plaintiff O'Neill purchased was manufactured by Defendant ZHP and sold in the United States by Defendant Solco, with the assistance of Defendant Huahai US and Defendant Princeton, who facilitated the regulatory approval of the ZHP product necessary for sale. At least some of this ZHP Product, ultimately purchased by Plaintiff O'Neill, was purchased by Wholesaler Defendant Cardinal Health who then distributed and resold that ZHP Product to Retail Pharmacy Defendant CVS (among other Retail Pharmacy Defendants) who sold this ZHP product to Plaintiff O'Neill and other

Class Members. Each product manufactured by the Aurobindo Defendants (“Aurobindo Product”) bore a unique National Drug Code which denoted that it was indeed sold, manufactured, or distributed into the United States drug supply chain by the Aurobindo Defendants. Specifically, the Aurobindo Product that Plaintiff O’Neill consumed was manufactured by Defendant Aurobindo Pharma Ltd., Aurobindo Pharma USA and Aurolife Pharma, LLC, and sold in the United States by Defendants Aurobindo Pharma USA and Aurolife Pharma, LLC. At least some of this Aurobindo Product ultimately consumed by Plaintiff O’Neill was purchased from Defendant Aurobindo by Retail Pharmacy Defendant CVS (among other Retail Pharmacy Defendants). Defendant CVS, in turn, sold the ZHP and Aurobindo Products to Plaintiff O’Neill and other Class Members. Each Defendant mentioned in this paragraph expressly and impliedly warranted to Plaintiff O’Neill (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs.

However, the ZHP Product and the Aurobindo Product, the Valsartan consumed by Plaintiff O’Neill, was contaminated with NDMA, NDEA, or another nitrosamine. Had Plaintiff O’Neill known the product he used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff O’Neill would not have used or purchased Defendants’ VCDs. Plaintiff O’Neill consumed a Cumulative Lifetime Threshold

of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

26. Plaintiff Jo Ann Hamel is a resident of the State of California. During the class period, Plaintiff Hamel was prescribed and used Valsartan. The Valsartan she used during that time was manufactured, distributed, or sold by Defendants Teva as defined below. Each product ("Teva Product") had a unique National Drug Code which denoted that they were indeed sold, manufactured, or distributed into the United States drug supply chain by Defendants Teva. Specifically, the Teva Product that Plaintiff Hamel purchased was manufactured by Defendants Teva. At least some of this Teva Product, ultimately purchased by Plaintiff Hamel, was purchased by John Doe Wholesaler Defendants who then distributed and resold that Teva Product to retail pharmacies (including Retail Pharmacy Defendants) who sold this Teva Product to Plaintiff Hamel and other Class Members. Each Defendant mentioned in this paragraph expressly and impliedly warranted to Plaintiff Hamel (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. However, the Teva Product, the Valsartan consumed by Plaintiff Hamel, was contaminated with NDMA, NDEA, or another nitrosamine. Had



Plaintiff Hamel known the product she used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff Hamel would not have used or purchased Defendants' VCDs. Plaintiff Hamel consumed a Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

27. Plaintiff Paulette Silberman is a resident of the State of New Jersey. She was prescribed and used Valsartan from approximately December 2008 to June 2018, at a dose of 160 mg. The Valsartan she used during that time was purchased was manufactured by Defendant ZHP and sold in the United States by Defendant Solco, with the assistance of Defendant Huahai US and Defendant Princeton, who facilitated the regulatory approval of the ZHP product necessary for sale. At least some of this ZHP Product, ultimately purchased by Plaintiff Silberman, was purchased by Defendant Cardinal who then distributed and resold that ZHP Product to Retail Pharmacy Defendant CVS (among other Retail Pharmacy Defendants). CVS, in turn, sold this ZHP product to Plaintiff Silberman and other consumers. The Aurobindo Product that Plaintiff Silberman purchased was manufactured by Defendant Aurobindo Pharma Limited, Aurobindo Pharma USA and Aurolife Pharma, LLC, and sold in the United States by Defendants Aurobindo Pharma USA and Aurolife Pharma, LLC. At least some of this

Aurobindo Product was purchased directly by Retail Pharmacy Defendant CVS (among other Retail Pharmacy Defendants). CVS, in turn, sold this Aurobindo product to Plaintiff Silberman and other consumers. Much the same as the ZHP and Aurobindo Products, the Hetero Product that Plaintiff Silberman purchased was manufactured by Defendant Hetero Labs Ltd., and sold in the United States by Defendant Camber, with the assistance of Defendant Hetero USA, who facilitated the necessary regulatory filings for sale. At least some of this Hetero Product was purchased by Wholesaler Defendant McKesson who then distributed and resold that Hetero Product to Retail Pharmacy Defendant Express Scripts (among other Retail Pharmacy Defendants). Express Scripts, in turn, sold this Hetero product to Plaintiff Silberman and other consumers. Each Defendant mentioned in this paragraph expressly and impliedly warranted to Plaintiff Silberman (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. However, these ZHP, Aurobindo and Hetero Products, the Valsartan consumed by Plaintiff Silberman, were contaminated with NDMA, NDEA, or another nitrosamine. Had Plaintiff Silberman known the product she used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff Silberman would not have used or purchased Defendants' VCDs. Plaintiff Silberman consumed a Cumulative Lifetime

Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

28. Plaintiff Sylvia Cotton is a resident of the State of Texas. She was prescribed and used Valsartan from approximately November 2011 to the present, at a dose of 320 mg per day. The Valsartan that she used during that time was manufactured, distributed, or sold by Defendants ZHP, Aurobindo, and Mylan as defined below. Each product ("ZHP Product," "Aurobindo Product," and "Mylan Product") had a unique National Drug Code which denoted that they were indeed sold, manufactured, or distributed into the United States drug supply chain by the ZHP, Aurobindo, and Mylan Defendants. Specifically, the ZHP Product that Plaintiff Cotton purchased was manufactured by Defendant ZHP and sold in the United States by Defendant Solco, with the assistance of Defendant Huahai US and Defendant Prinston, who facilitated the regulatory approval of the ZHP product necessary for sale. The Aurobindo Product that Plaintiff Cotton purchased was manufactured by Defendant Aurobindo Pharma Limited, Aurobindo Pharma USA and Aurolife Pharma, LLC, and sold in the United States by Defendants Aurobindo Pharma USA and Aurolife Pharma, LLC. The Mylan Product that Plaintiff Cotton purchased was manufactured by Defendant Mylan Laboratories Limited and Pharmaceuticals, Inc., and sold in the United States by Defendant Mylan

Pharmaceuticals, Inc. At least some of the ZHP, Aurobindo, and Mylan Products, were purchased either purchased by John Doe Wholesaler Defendant(s) who then distributed and resold that ZHP Product to Retail Pharmacy Defendants CVS and Wal-Mart or they were purchased directly by these Retail Pharmacy Defendants CVS and Wal-Mart each subsequently sold the above products to Plaintiff Cotton and other consumers. Each Defendant mentioned in this paragraph expressly and impliedly warranted to Plaintiff Cotton (either directly, or indirectly by adopting warranties that were passed along to and incorporated by another Defendant further downstream and mentioned in this paragraph) that their respective generic VCDs were the same as their RLDs. However, these ZHP, Aurobindo, and Mylan Products, consumed by Plaintiff Cotton, were contaminated with NDMA, NDEA, or another nitrosamine. Had Plaintiff Cotton known the product she used was contaminated with NDMA, NDEA, or another nitrosamine, Plaintiff Cotton would not have used or purchased Defendants' VCDs. Plaintiff Cotton consumed a Cumulative Lifetime Threshold of at least XXX units. As a result of Defendants' deception about the impurities within their products, Plaintiff suffered cellular and genetic injury that creates and/or increases the risk that Plaintiff will develop cancer.

**B. The Active Pharmaceutical Ingredient Manufacturer Defendants**

29. For ease of reading, this Third Amended Master Complaint generally organizes Defendants by the distribution level at which they principally operate. The following Defendants manufacture the active pharmaceutical ingredient (“API”) for Defendants’ VCDs, or were closely affiliated with an entity that does so. The inclusion of certain Defendants in this section does not mean they are not properly classifiable as another type of defendant, or vice versa (e.g., a Defendant listed in this subsection may also be a distributor; a Defendant listed in the distributor subsection may also be an API manufacturer).

**1. Zhejiang Huahai Pharmaceutical Co., Ltd. Entities**

30. Defendant Zhejiang Huahai Pharmaceutical Co., Ltd. (“ZHP”) is a Chinese corporation, with its principal place of business at Xunqiao, Linhai, Zhejiang 317024, China. The company also has a United States headquarters located at 2009 and 2002 Eastpark Blvd., Cranbury, NJ 08512. ZHP on its own and/or through its subsidiaries regularly conducts business throughout the United States and its territories and possessions. At all times material to this action, ZHP has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated, and/or misbranded generic VCDs throughout the United States.

31. Defendant Huahai US Inc. (“Huahai US”) is a New Jersey corporation, with its principal place of business located at 2002 Eastpark Blvd.,

Cranbury, New Jersey 08512. Huahai US is the wholly-owned subsidiary of ZHP. Huahai US “focus[es] on the sales and marketing of [ZHP’s] APIs and Intermediates.”<sup>4</sup> At all times material to this case, Huahai US has been engaged in the manufacture, sale, and distribution of contaminated, adulterated, and/or misbranded generic VCDs in the United States.

32. Defendant Princeton Pharmaceutical Inc. d/b/a Solco Healthcare LLC (“Princeton”) is a Delaware corporation with its principal place of business located at 2002 Eastpark Blvd., Cranbury, New Jersey 08512. Defendant Princeton is a majority-owned subsidiary of ZHP. At all times material to this case, Princeton has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated, and/or misbranded generic VCDs in the United States.

33. Defendant Solco Healthcare US, LLC (“Solco”) is a Delaware limited liability company with its principal place of business located at 2002 Eastpark Blvd., Cranbury, New Jersey 08512. Solco is a wholly-owned subsidiary of Princeton and ZHP. At all times material to this case, Solco has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated, and/or misbranded generic VCDs in the United States.

---

<sup>4</sup> Huahai US, Homepage, <https://www.huahaius.com/index.html> (last visited Apr. 5, 2019).

34. Collectively, ZHP, Huahai US, Prinston, and Solco will be referred to as the ZHP Defendants. Much of the VCDs manufactured by the ZHP Defendants contained NDMA levels *hundreds of times* higher than acceptable limits for human consumption, according to laboratory results published by the FDA.<sup>5</sup> Some of its VCDs also contained unacceptable levels of NDEA.

35. The ZHP Defendants also manufactured valsartan-containing API for sale to the following other finished-dose manufacturers: Defendants Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc.

36. In turn, the finished-dose manufacturer defendants' VCDs have unique labelers/distributors, as well as repackagers.

## **2. Hetero Labs, Ltd. Entities**

37. Defendant Hetero Labs, Ltd. (“Hetero Labs”) is a foreign corporation, with its principal place of business at 7-2-A2, Hetero Corporate, Industrial Estates, Sanath Nagar, Hyderabad – 500 018, Telangana, India. Hetero Labs on its own and/or through its subsidiaries regularly conducts business throughout the United States and its territories and possessions. At all times material to this action, Hetero Labs has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated generic VCDs throughout the United States.

---

<sup>5</sup> FDA, LABORATORY ANALYSIS OF VALSARTAN PRODUCTS, <https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-analysis-valsartan-products> (last visited June 13, 2019).

38. Defendant Hetero Drugs, Limited (“Hetero”) is a foreign corporation, with its principal place of business at 7-2-A2, Hetero Corporate, Industrial Estates, Sanath Nagar, Hyderabad - 500 018, Telangana, India. “Hetero has a strong established global presence with 36 manufacturing facilities and a robust network of business partners and marketing offices strategically located across the world.”<sup>6</sup> Hetero on its own and/or through its subsidiaries regularly conducts business in New Jersey and throughout the United States and its territories and possessions. Hetero Labs is the wholly-owned subsidiary of Hetero. At all times material to this action, Hetero has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated and/or misbranded generic VCDs throughout the United States.

39. Defendant Hetero USA Inc. (“Hetero USA”) is “the US representation of HETERO, a privately owned; researched based global pharmaceutical company.”<sup>7</sup> Hetero USA is a Delaware corporation with its principal place of business located at 1035 Centennial Avenue, Piscataway, New Jersey 08854. Hetero USA is the wholly-owned subsidiary of Hetero. At all times material to this action, Hetero USA has been engaged in the manufacturing, sale, and distribution

---

<sup>6</sup> Hetero, GLOBAL FOOTPRINT, <https://www.heteroworld.com/global-footprint.php> (last visited June 6, 2019).

<sup>7</sup> Hetero USA, LINKEDIN, <https://www.linkedin.com/company/hetero-usa-inc/about/> (last visited June 5, 2019).



of contaminated, adulterated and/or misbranded generic VCDs throughout the United States.

40. Defendant Camber Pharmaceuticals, Inc. (“Camber”) is a Delaware corporation, with its principal place of business at 1031 Centennial Avenue, Piscataway, NJ 08854. Camber is the wholly owned subsidiary of Hetero Drugs. At all times material to this action, Camber has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated, misbranded, and/or unapproved VCDs throughout the United States.

41. Collectively, Hetero Labs, Hetero, Hetero USA, and Camber will be referred to as the Hetero Defendants in this Third Amended Master Complaint.

42. The valsartan-containing API manufactured by the Hetero Defendants was distributed to Hetero’s U.S. subsidiaries or affiliates including Hetero USA and Camber. In turn, Camber supplied Hetero-manufactured valsartan API to at least three repackagers, including AvKARE, Inc., and RemedyRepack, Inc.

### **3. Mylan Laboratories, Ltd. Entities**

43. Defendant Mylan Laboratories, Ltd. (“Mylan Laboratories”) is a foreign corporation, with its principal place of business at Plot No. 564/A/22, Road No. 92, Jubilee Hills 500034, Hyderabad, India. Mylan Laboratories on its own and/or through its subsidiaries regularly conducts business throughout the United States and its territories and possessions. At all times material to this action, Mylan

Laboratories has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated and/or misbranded generic VCDs throughout the United States.

44. Defendant Mylan N.V. (“Mylan”) is a global generic and specialty pharmaceuticals company registered in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a Global Center in Canonsburg, Pennsylvania. According to Mylan’s website: “The Chief Executive Officer and other executive officers of Mylan carry out the day-to-day conduct of Mylan’s worldwide businesses at the company’s principal offices in Canonsburg, Pennsylvania.” Mylan Laboratories is a wholly owned subsidiary of Mylan. At all times material to this action. Mylan on its own and/or through its subsidiaries regularly conducted business and throughout the United States and its territories and possessions. Mylan has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated and/or misbranded generic VCDs throughout the United States.

45. Defendant Mylan Pharmaceuticals, Inc. (“Mylan Pharmaceuticals”) is a West Virginia corporation, with its principal place of business at 1500 Corporate Drive, Canonsburg, Pennsylvania 15317. Mylan Pharmaceuticals is the registered holder of Mylan Laboratories’ ANDA for its VCDs. At all times material to this action, Mylan Pharmaceuticals has been engaged in the manufacturing, sale, and

distribution of contaminated, adulterated and/or misbranded generic VCDs throughout the United States.

46. Collectively, Mylan Laboratories, Mylan, and Mylan Pharmaceuticals will be referred to as the Mylan Defendants in this Third Amended Master Complaint.

47. The Mylan Defendants' valsartan-containing API was supplied in large part to itself due to Mylan's vertically integrated supply chain. According to Mylan's website, "[b]eing a manufacturer of API makes Mylan one of the few global generics companies with a comprehensive, vertically integrated supply chain" that Mylan touts as "provid[ing] us with an extra measure in the quality process that we can own[.]"<sup>8</sup>

48. Some of the Mylan Defendants' valsartan-containing API was also supplied to Defendant Teva Pharmaceuticals USA, Inc., which is named and identified below.

#### **4. Aurobindo Pharma, Ltd. Entities**

49. Defendant Aurobindo Pharma, Ltd. ("Aurobindo") is a foreign corporation with its principal place of business at Plot no. 2, Maitrivihar, Ameerpet, Hyderabad-500038 Telangana, India, and a United States headquarters

---

<sup>8</sup> Mylan, ACTIVE PHARMACEUTICAL INGREDIENTS, <https://www.mylan.com/en/products/active-pharmaceutical-ingredients> (last visited June 6, 2019).

at 279 Princeton Hightstown Road, East Windsor, New Jersey 08520. Aurobindo on its own and/or through its subsidiaries regularly conducts business throughout the United States and its territories and possessions. At all times material to this case, Aurobindo has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated, and/or misbranded VCDs in the United States.

50. Defendant Aurobindo Pharma USA, Inc. (“Aurobindo USA”) is a Delaware corporation with its principal place of business at 279 Princeton Hightstown Road, East Windsor, New Jersey 08520. It is a wholly-owned subsidiary of Aurobindo. At all times material to this case, Aurobindo USA has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated, and/or misbranded VCDs in the United States.

51. Defendant Aurolife Pharma, LLC (“Aurolife”) is a Delaware limited liability company with its principal place of business at 2400 US- 130, North, Dayton, New Jersey 08810. It is a wholly-owned subsidiary of Aurobindo USA. At all times material to this case, Aurolife has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated, and/or misbranded VCDs in the United States.

52. Aurobindo, Aurobindo USA, and Aurolife are collectively referred to as the Aurobindo Defendants in this Third Amended Master Complaint.

53. Aurobindo’s valsartan-containing API was supplied in large part to itself due to its vertically integrated supply chain. “Aurobindo adds value through superior customer service in the distribution of a broad line of generic pharmaceuticals, leveraging vertical integration and efficient controlled processes.”<sup>9</sup>

**C. The Finished-Dose Defendants**<sup>10</sup>

**1. The Teva Defendants**

54. Defendant Teva Pharmaceutical Industries Ltd. (“Teva”) is a foreign company incorporated and headquartered in Petah Tikvah, Israel. Teva on its own and/or through its subsidiaries regularly conducts business throughout the United States and its territories and possessions. At all times material to this case, Teva has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated, and/or misbranded generic VCDs in the United States.

55. Defendant Teva Pharmaceuticals USA, Inc. (“Teva USA”) is a Delaware corporation, with its principal place of business at 400 Interpace Parkway, Parsippany, New Jersey 07054, and is a wholly owned subsidiary of Teva. At all times material to this case, Teva USA has been engaged in the

---

<sup>9</sup> Aurobindo USA, OUR STORY, <https://www.aurobindousa.com/company/our-story/> (last visited June 5, 2019).

<sup>10</sup> The ZHP, Hetero, Mylan, and Aurobindo Defendants also qualify as finished dose Defendants, but the party allegations are listed above.

manufacturing, sale, and distribution of contaminated, adulterated, and/or misbranded generic VCDs in the United States.

56. Actavis, LLC (“Actavis”) is a Delaware corporation with its principal place of business at 400 Interpace Parkway, Parsippany, New Jersey 07054, and is Teva’s wholly owned subsidiary. At all times material to this case, Actavis has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated, and/or misbranded VCDs in the United States, including in the State of New Jersey.

57. Actavis Pharma, Inc. (“Actavis Pharma”) is a Delaware corporation with its principal place of business at 400 Interpace Parkway, Parsippany, New Jersey 07054, and is Teva’s wholly owned subsidiary. At all times material to this case, Actavis Pharma has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated, and/or misbranded VCDs in the United States.

58. Teva, Teva USA, Actavis and Actavis Pharma are collectively referred to as the Teva Defendants in this Third Amended Master Complaint.

**D. Retail Pharmacy Defendants**

59. Retail pharmacies have supply arrangements with finished-dose manufacturers. They stand in direct contractual privity with consumers, insofar as retail pharmacies (be they brick-and-mortar or mail-order) are the entities that dispensed and received payments for the contaminated, adulterated, and/or

misbranded VCDs for which consumers paid and consumed. The retail pharmacy defendants failed to take any steps to test or otherwise confirm the quality, purity, generic equivalence, therapeutic equivalence, or bioequivalence of the contaminated, adulterated and/or misbranded VCDs.

60. Retail pharmacies contract directly with Defendant Manufacturers, as well as wholesalers, for the sale of VCDs.

61. The following Defendants are collectively referred to as the “Pharmacy Defendants.”

**1. Walgreens**

62. Defendant Walgreens Co. (“Walgreens”) is a national retail pharmacy chain incorporated in the State of Delaware with its principal place of business located at 108 Wilmot Road, Deerfield, Illinois.

63. Walgreens is one of the retail pharmacy chains in the United States, offering retail pharmacy services and locations in all 50 states including the District of Columbia, Puerto Rico, and the U.S. Virgin Islands. As of August 31, 2018, Walgreens operated 9,560 retail pharmacies across the United States, with 78% of the U.S. population living within five 5 miles of a store location. In addition, Walgreens recently purchased an additional 1,932 store locations from rival Rite Aid Corporation, further consolidating the industry. Walgreens’ sales amounted to a staggering \$98.4 billion in 2018, most of which are generated for

prescription sales. Walgreens accounts for nearly 20% of the U.S. market for retail prescription drug sales.

64. Walgreens is one of the largest purchasers of pharmaceuticals in the world, and according to its Form 10-K for 2018, the wholesaler AmerisourceBergen “supplies and distributes a significant amount of generic and branded pharmaceutical products to the [Walgreens] pharmacies.”

65. In or about 2017, Walgreens acquired control of Diplomat Pharmacy. “Walgreens,” as defined herein, includes any current or former Diplomat pharmacy.

66. Defendant Walgreens sold a large portion of the contaminated, adulterated, and/or misbranded VCDs to U.S. consumers during the class period as defined below.

67. These sales included sales made to Plaintiff Berkson.

## 2. CVS

68. Defendant CVS Pharmacy, Inc. (“CVS Pharmacy” or “CVS”) is a national retail pharmacy chain incorporated in Delaware with its principal place of business located at One CVS Drive, Woonsocket, Rhode Island.

69. As of March 31, 2019, Defendant CVS Pharmacy maintained approximately 9,900 retail pharmacy locations across the United States, making it one of the largest in the country. Defendant CVS also operates approximately



1,100 walk-in medical clinics and a large pharmacy benefits management service with approximately 94 million plan members.

70. According to its 2018 Annual Report, Defendant CVS' "Pharmacy Services" segment provides a full range of pharmacy benefit management ("PBM") solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services, mail order pharmacy, specialty pharmacy and infusion services, Medicare Part D services, clinical services, disease management services and medical spend management. The Pharmacy Services segment's clients are primarily employers, insurance companies, unions, government employee groups, health plans, Medicare Part D prescription drug plans ("PDPs"), Medicaid managed care plans, plans offered on public health insurance exchanges and private health insurance exchanges, other sponsors of health benefit plans and individuals throughout the United States.

71. CVS' Pharmacy Services segment generated U.S. sales of approximately \$134.1 billion in 2018.

72. CVS' Retail/LTC segment is responsible for the sale of prescription drugs and general merchandise. The Retail/LTC segment generated approximately \$84 billion in U.S. sales in 2018, with approximately 75% of that attributed to the sale of pharmaceutical products. During 2018 the Retail/LTC segment filled approximately 1.3 billion prescriptions on a 30-day equivalent basis. In December

2018, CVS's share of U.S. retail prescriptions accounted for 26% of the United States retail pharmacy market.

73. In or about 2015, CVS acquired all of Target Corporation's pharmacies. "CVS," as defined herein, includes any current or former Target pharmacy.

74. In 2014, CVS and wholesaler Defendant Cardinal Health, Inc. ("Cardinal") established a joint venture to source and supply generic pharmaceutical products through a generic pharmaceutical sourcing entity named Red Oak Sourcing, LLC ("Red Oak"), of which CVS and Cardinal each own fifty percent. Most or all of the valsartan-containing drugs purchased by CVS were acquired through this joint venture with Cardinal.

75. Defendant CVS sold a large portion of the contaminated, adulterated, and/or misbranded VCDs to U.S. consumers during the class period as defined below.

76. These sales included sales made to Plaintiffs Daring, O'Neill, Silberman, and Cotton.

### **3. Walmart**

77. Defendant Walmart Stores, Inc. ("Wal-Mart") is a Delaware corporation with its principal place of business in Bentonville, Arkansas.

78. According to Defendant Wal-Mart's 2018 Form 10-K, Wal-Mart maintains approximately 4,769 retail locations in all fifty states nationwide and the District of Columbia and Puerto Rico (including supercenters, discount stores, neighborhood markets and other small format locations). Most or all of these locations have Wal-Mart health and wellness products and services, which include prescription pharmaceutical services. There are another approximately 600 Sam's Club locations across the United States, all or nearly all offering prescription pharmaceutical services.

79. Defendant Wal-Mart (including Sam's Club) sold a large portion of the contaminated, adulterated, and/or misbranded VCDs to U.S. consumers across the country during the class period as defined below.

80. These sales included sales made to Plaintiffs Cotton, Roger Tasker, Judy Tasker, Zehr and Kruk.

#### **4. Rite Aid**

81. Defendant Rite Aid Corporation ("Rite Aid") is a Delaware corporation with its principal place of business in Camp Hill, Pennsylvania.

82. Defendant Rite Aid sold a large portion of the contaminated, adulterated, and/or misbranded VCDs to U.S. consumers during the class period as defined below.

83. These sales included sales made to Plaintiff Butler.

**5. Express Scripts**

84. Defendant Express Scripts, Inc. is a corporation with its principal place of business at One Express Way, St. Louis, MO 63121. Defendant Express Scripts, Inc. is a subsidiary of Express Scripts Holding Company

85. Defendant Express Scripts Holding Company is a corporation with its principal place of business at One Express Way, St. Louis, MO 63121.

86. Collectively, Express Scripts, Inc. and Express Scripts Holding Company are referred to as “Express Scripts.”

87. Express Scripts sold a large portion of the contaminated, adulterated, and/or misbranded VCDs to U.S. consumers during the class period as defined below.

88. These sales included sales made to Plaintiffs Judson and Silberman.

**6. “John Doe” Pharmacies**

89. Upon information and belief, one or more additional pharmacies distributed contaminated, adulterated, misbranded, and/or unapproved VCDs that were ultimately purchased by consumer Class Members. The true names, affiliations, and/or capacities of John Doe Pharmacies are not presently known. However, each John Doe proximately caused damages to Plaintiffs as alleged herein, and each John Doe is liable to Plaintiffs for the acts and omissions alleged herein as well as the resulting damages. Plaintiffs will amend this Consolidated

Third Amended Medical Monitoring Class Complaint to allege the true names and capacities of the John Does when evidence reveals their identities.

**E. Wholesaler Defendants**

90. Wholesalers are entities that purchase, among other things, drugs from finished-dose manufacturers and sell or provide those drugs to retail pharmacies and others.<sup>11</sup> The wholesaler defendants failed to take any steps to test or otherwise confirm the quality, purity, generic equivalence, therapeutic equivalence or bioequivalence of the contaminated, adulterated and/or misbranded VCDs.

91. Wholesalers act as the intermediary between the Manufacturer Defendants and the Retail Pharmacy Defendants.

92. Wholesalers contract with the Manufacturer Defendants for the purchase of VCDs. Upon information and belief, these contracts include indemnification agreements with the Manufacturer Defendants.

93. Wholesalers contract with the Retail Pharmacy Defendants for the sale of VCDs.

---

<sup>11</sup> Plaintiffs have used VCDs that were distributed by each of these Wholesaler Defendants, as set forth above, who comprise at least 90% of the wholesale drug market, and as such, were the entities that distributed the vast majority of the contaminated, adulterated, misbranded, and/or unapproved VCDs.

94. At all times, Plaintiffs, as the consumers of VCDs, were the intended beneficiaries of the contracts between the Manufacturers, Wholesalers, and Retail Pharmacies.

95. The following Defendants are collectively referred to as the “Wholesaler Defendants.”

**1. Cardinal Health**

96. Cardinal is an Ohio corporation with its principal place of business at 7000 Cardinal Place, Dublin, Ohio 43017. Cardinal has been engaged in the manufacturing, sale, and distribution of contaminated, adulterated, and/or misbranded generic VCDs in the United States, including in the State of New Jersey.

97. Defendant Cardinal Health, Inc., received large quantities of VCDs manufactured by the ZHP Defendants from 2015 until the recall

98. The VCDs distributed by Defendant Cardinal Health, Inc. included VCDs manufactured by all Manufacturer Defendants and ultimately sold to Plaintiffs Daring, Silberman, O’Neill and other similarly situated individuals.

**2. McKesson**

99. Defendant McKesson Corporation (“McKesson”) is a Delaware corporation with its principal place of business in San Francisco, California. McKesson distributes pharmaceuticals to retail pharmacies and institutional

providers to customers in all 50 states. McKesson – either directly or through a subsidiary or affiliated – distributed contaminated, adulterated, and/or misbranded VCDs in the United States, including in the State of New Jersey.

100. The VCDs distributed by Defendant McKesson included VCDs manufactured by all Manufacturer Defendants and ultimately sold to Plaintiffs Judson, Zehr, Kruk, Roger Tasker, Judy Tasker, Silberman, and other similarly situated individuals.

### **3. AmerisourceBergen**

101. Defendant AmerisourceBergen Corporation (“Amerisource”) a Delaware corporation with its principal place of business in Chesterbrook, Pennsylvania. Amerisource distributes pharmaceuticals to retail pharmacies and institutional providers to customers in all 50 states. Amerisource – either directly or through a subsidiary or affiliated – distributed contaminated, adulterated, and/or misbranded VCDs in the United States, including in the State of New Jersey.

102. The VCDs distributed by Defendant Amerisource included VCDs manufactured by all Manufacturer Defendants and ultimately sold to Plaintiff Judson, and other similarly situated individuals.

### **4. “John Doe” Wholesalers**

103. Upon information and belief, one or more wholesalers distributed contaminated, adulterated, misbranded, and/or unapproved VCDs that were

ultimately purchased by consumer Class Members. The true names, affiliations, and/or capacities of John Doe Wholesalers are not presently known. However, each John Doe proximately caused damages to Plaintiffs as alleged below, and each John Doe is liable to Plaintiffs for the acts and omissions alleged below as well as the resulting damages. Plaintiffs will amend this Master Class Complaint to allege the true names and capacities of the John Does when evidence reveals their identities.

**F. Repackager and Relabeler Defendants**

104. Drug repackagers and relabelers purchase or obtain drugs from manufacturers or wholesalers, and then repackage and/or relabel the drugs in small quantities for sale to pharmacies, doctors, or others.

105. [paragraph withdrawn]

106. [paragraph withdrawn]

107. Defendant RemedyRepack, Inc. is a Pennsylvania corporation, with its principal place of business at 625 Kolter Drive, Suite 4, Indiana, PA 15701.

108. RemedyRepack is a repackager for VCDs manufactured by Prinston Pharmaceutical, Inc., with API coming from Defendant Zhejiang Huahai Pharmaceutical Co., Ltd.

109. Upon information and belief, RemedyRepack sold contaminated, adulterated and/or misbranded VCDs during the class period.



110. Defendant AvKARE, Inc. is a Tennessee corporation with its principal place of business at 615 N 1st Street, Pulaski, TN 38478-2403. Defendant AvKARE, Inc. serves as a repackager for the Hetero/Camber Defendants, as well as the Teva and Actavis Defendants.

111. Upon information and belief, AvKARE, Inc. sold contaminated, adulterated and/or misbranded VCDs during the class period.

**G. True Names / John Doe Defendants 1-50**

112. The true names, affiliations, and/or capacities, whether individual, corporate, partnership, associate, governmental, or otherwise, of John Does 1 through 50 are unknown to Plaintiffs at this time. Plaintiffs therefore sue these defendants using fictitious names. Each John Doe proximately caused damages to Plaintiffs as alleged below, and each John Doe is liable to Plaintiffs for the acts and omissions alleged below as well as the resulting damages. Plaintiffs will amend this Third Amended Master Complaint to allege the true names and capacities of the John Does when evidence reveals their identities.

113. At all times relevant to this Third Amended Master Complaint, each of the John Does was the agent, servant, employee, affiliate, and/or joint venturer of the other co-defendants and other John Does. Moreover, each Defendant and each John Doe acted in the full course, scope, and authority of that agency, service, employment, and/or joint venture.

### **III. JURISDICTION AND VENUE**

114. This Court has original jurisdiction pursuant to the Class Action Fairness Act, 28 U.S.C. § 1332(d), because (a) at least one member of the proposed class is a citizen of a state different from that of Defendants, (b) the amount in controversy exceeds \$5,000,000, exclusive of interest and costs, (c) the proposed class consists of more than 100 Class Members, and (d) none of the exceptions under the subsection apply to this action.

115. This Court has personal jurisdiction over Defendants pursuant to 28 U.S.C. § 1407, and because Defendants have sufficient minimum contacts in New Jersey, and because Defendants have otherwise intentionally availed themselves of the markets within New Jersey through their business activities, such that the exercise of jurisdiction by this Court is proper and necessary.

116. Venue is proper in this District on account of the MDL consolidation pursuant to 28 U.S.C. § 1407 and because Defendants reside in this District, 28 U.S.C. § 1391(b)(1); “a substantial part of the events or omissions giving rise to the claim occurred” in this District, 28 U.S.C. § 1391(b)(2); and Defendants are subject to the personal jurisdiction of this Court, 28 U.S.C. § 1391(b)(3).

#### IV. FACTUAL ALLEGATIONS

##### A. Generic Drugs Must Be Chemically the Same as Branded Drug Equivalents

117. According to the FDA, “[a] generic drug is a medication created to be the same as an already marketed brand-name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use.

These similarities help to demonstrate bioequivalence, which means that **a generic medicine works in the same way and provides the same clinical benefit as its brand-name version.** In other words, you can take a generic medicine as an equal substitute for its brand-name counterpart.”<sup>12</sup>

118. While brand-name medications undergo a more rigorous review before being approved, generic manufacturers are permitted to submit an ANDA, which only requires a generic manufacturer to demonstrate that the generic medicine is equivalent to the brand name version in the following ways:

a. The active ingredient(s) in the generic medicine is/are the same as in the brand-name drug/innovator drug.

---

<sup>12</sup> FDA, **GENERIC DRUGS: QUESTIONS & ANSWERS**, <https://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm> (last visited June 135, 2019) (emphasis in original).

b. The generic medicine has the same strength, use indications, form (such as a tablet or an injectable), and route of administration (such as oral or topical).

c. The inactive ingredients of the generic medicine are acceptable.

d. The generic medicine is manufactured under the same strict standards as the brand-name medicine.

e. The container in which the medicine will be shipped and sold is appropriate, and the label is the same as the brand-name medicine's label.<sup>13</sup>

119. The drugs ingested by Plaintiffs were approved by the FDA, based upon Defendants' representations that they met the above criteria and were equivalent to the RLDs.

120. ANDA applications do not require drug manufacturers to repeat animal studies or clinical research on ingredients or dosage forms already approved for safety and effectiveness.<sup>14</sup>

---

<sup>13</sup> FDA, GENERIC DRUG FACTS, <https://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/GenericDrugs/ucml67991.htm> (last visited June 13, 2019).

<sup>14</sup> FDA, GENERIC DRUGS: QUESTIONS & ANSWERS, <https://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm> (last visited June 13, 2019).

121. Further, because generic drugs are supposed to be nearly identical to their brand-name counterparts, they are also supposed to have the same risks and benefits.<sup>15</sup>

**B. Misbranded and Adulterated or Misbranded Drugs**

122. The manufacture of any adulterated or misbranded drug is prohibited under federal law.<sup>16</sup>

123. The introduction into commerce of any adulterated or misbranded drug is also prohibited.<sup>17</sup>

124. Similarly, the receipt in interstate commerce of any adulterated or misbranded drug is likewise unlawful.<sup>18</sup>

125. Among the ways a drug may be adulterated and/or misbranded are:

a. “if it has been prepared, packed, or held under insanitary conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health;”<sup>19</sup>

b. “if ... the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not

---

<sup>15</sup> *Id.*

<sup>16</sup> 21 U.S.C. § 331(g).

<sup>17</sup> 21 U.S.C. § 331(a).

<sup>18</sup> 21 U.S.C. § 331(c).

<sup>19</sup> 21 U.S.C. § 351(a)(2)(A).

operated or administered in conformity with current good manufacturing practice...as to safety and has the identity and strength, and meets the quality and purity characteristics, which it purports or is represented to possess;”<sup>20</sup>

c. “If it purports to be or is represented as a drug the name of which is recognized in an official compendium, and ... its quality or purity falls below, the standard set forth in such compendium. ...”<sup>21</sup>

d. “If ... any substance has been (1) mixed or packed therewith so as to reduce its quality or strength or (2) substituted wholly or in part therefor.”<sup>22</sup>

126. A drug is misbranded:

a. “If its labeling is false or misleading in any particular.”<sup>23</sup>

b. “If any word, statement, or other information required...to appear on the label or labeling is not prominently placed thereon...in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.”<sup>24</sup>

c. If the labeling does not contain, among other things, “the proportion of each active ingredient...”<sup>25</sup>

---

<sup>20</sup> 21 U.S.C. § 351(a)(2)(B).

<sup>21</sup> 21 U.S.C. § 351(b).

<sup>22</sup> 21 U.S.C. § 351(d).

<sup>23</sup> 21 U.S.C. § 352(a)(1).

<sup>24</sup> 21 U.S.C. § 352(c).

<sup>25</sup> 21 U.S.C. § 352(e)(1)(A)(ii)

d. “Unless its labeling bears (1) adequate directions for use; and (2) such adequate warnings ... against unsafe dosage or methods or duration of administration or application, in such manner and form, as are necessary for the protection of users. ...”<sup>26</sup>

e. “If it purports to be a drug the name of which is recognized in an official compendium, unless it is packaged and labeled as prescribed therein.”<sup>27</sup>

f. “if it is an imitation of another drug;”<sup>28</sup>

g. “if it is offered for sale under the name of another drug.”<sup>29</sup>

h. “If it is dangerous to health when used in the dosage or manner, or with the frequency or duration prescribed, recommended, or suggested in the labeling thereof.”<sup>30</sup>

i. If the drug is advertised incorrectly in any manner;<sup>31</sup> or

j. If the drug’s “packaging or labeling is in violation of an applicable regulation...”<sup>32</sup>

---

<sup>26</sup> 21 U.S.C. § 352(f).

<sup>27</sup> 21 U.S.C. § 352(g).

<sup>28</sup> 21 U.S.C. § 352(i)(2).

<sup>29</sup> 21 U.S.C. § 352(i)(3).

<sup>30</sup> 21 U.S.C. § 352(j).

<sup>31</sup> 21 U.S.C. § 352(n).

<sup>32</sup> 21 U.S.C. § 352(p).

127. As articulated in this Third Amended Master Complaint, Defendants' VCDs were contaminated, adulterated and/or misbranded in violation of all of the above-cited reasons.

**C. Prescription Drug Product Identification and Tracing**

128. For each approved product (whether brand or generic) the FDA issues a unique 10-digit code (the National Drug Code, or NDC) that follows the product from manufacturing through retail dispensing. The NDC embeds details about the specific product, including the identity of the manufacturer (or labeler), the strength, dosage form, and formulation of the drug, and the package size and type.<sup>33</sup>

129. The NDC is a critical component of each and every transfer of a prescription drug (from the manufacturer to the wholesaler; from the wholesaler to the retailer; and from the retailer to the consumer) and therefore every transaction is accompanied by and labeled with the NDC.

130. Retail prescription labels display the NDC of the dispensed product and this is part of the electronic dispensing record. In many cases, the Lot number will also appear on the prescription bottle provided to the consumer and, thus,

---

<sup>33</sup> United States Food and Drug Administration, "National Drug Code Directory," accessed January 30, 2019 at <https://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm>; FDA, "National Drug Codes Explained," accessed March 7, 2020 at <https://www.drugs.com/ndc.html>.



specifically indicate information including whether a recall applies to the particular pills in the bottle.<sup>34</sup>

131. The Lot number is also used to report issues arising around a particular drug. For example, lot numbers are used by pharmacists to report Adverse Events (patient-specific side effects or complications associated with the use of a prescription drug). This is an important part of drug safety monitoring in the United States and has led to recalls or relabeling of numerous drugs. Pharmacists make such reports using the FDA's MedWatch system using Form 3500.<sup>35</sup>

**D. The Drug Supply Chain Security Act Requires Tracing of Product**

132. The Drug Supply Chain Security Act ("DSCSA")<sup>36</sup> was enacted in 2013, and requires prescription drug manufacturers, wholesalers, repackagers, and pharmacies to "Exchange information about a drug and who handled it each time it is sold in the U.S. market."

---

<sup>34</sup> A lot number is an identification number tied to a particular lot of pills from a single manufacturer.

<sup>35</sup> FDA, "Instructions for Completing Form FDA 3500," accessed March 9, 2020 at <https://www.fda.gov/safety/medwatch-forms-fda-safety-reporting/instructions-completing-form-fda-3500#Section%20B:%20Adverse%20Event%20or%20Product%20Problem>.

<sup>36</sup> 21 U.S. Code § 360eee.

133. The DSCSA was implemented as one part of the Drug Quality and Security Act (DQSA), aimed at addressing vulnerabilities in the drug supply chain, and facilitating tracing of certain prescription drugs in finished dosage form through the supply chain.<sup>37</sup>

134. While the DSCSA was enacted in 2013, participants in the pharmaceutical supply chain (including the Manufacturer Defendants, Wholesaler Defendants and Retail Pharmacy Defendants) maintained similar information as a part of their ordinary course of business prior to the enactment of the DSCSA, and thus undertook a duty to do so in a reasonable manner.

135. The DSCSA generally requires participants in the drug supply manufacturing chain (starting from the manufacturer, through the wholesaler, to the retail pharmacy) to retain, for every pharmaceutical drug transaction, the following information about that transaction: product name; National Drug Code; container size; number of containers; lot number; date of transaction; date of shipment; and name and address of the entity transferring ownership and taking ownership of the product.

136. The DSCSA requires that this data be kept in a manner to allow these authorized participants to respond within 48 hours to requests from appropriate

---

<sup>37</sup> U.S. Department of Health and Human Services, Drug Supply Chain Security: Dispensers Received Most Tracing Information, March 2018, accessed March 11, 2020 at <https://oig.hhs.gov/oei/reports/oei-05-16-00550.pdf>, at p. 2.

federal or state officials — in the event of a recall or for the purpose of investigating suspect product or an illegitimate product — for the transaction history of the pharmaceutical product.<sup>38</sup>

137. The supply chain for distribution of prescription drugs in the U.S. is highly concentrated. This means that data obtained from a relatively small number of market participants can provide detailed information about the large majority of VCD sales, transfers and prescription fills.

138. The entire process of reimbursing pharmacies and consumers for end-purchases depends upon the ability to know the precise drug and packaging that was dispensed, as well as the manufacturer of that drug. Making this system work has necessarily resulted in very high levels of data standardization in this industry. Although pharmacies maintain their own “pharmacy log” data reflecting dispensing, sales and return activity, the key elements are fundamentally similar.

139. Because pharmacies require similar information for their own tracking and inventory systems, and wholesalers sell to multiple pharmacy chains, the key elements are fundamentally the same.

140. Further, all pharmacies must use the basic data fields, definitions and formats provided in the Telecommunications Guidelines developed by the National

---

<sup>38</sup> FDA, Title II of the Drug Quality and Security Act, December 16, 2014, accessed March 11, 2020 at <https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/title-ii-drug-quality-and-security-act>.

Council for Prescription Drug Programs, the use of which was made mandatory in 2003 under regulations implementing the Health Insurance Portability and Accountability Act (HIPAA).<sup>39</sup> Because of these HIPAA requirements, all of these inter-related systems (Manufacturers, Wholesalers, Retailers, and TPPs) use a common language to identify products.

141. As a general matter, for Medicare and Medicaid compliance, pharmacies typically keep prescription records for ten years.<sup>40</sup>

142. For instance, in its Pharmacy Manual, Defendant Walgreens states the following: “Unless otherwise set forth in your Pharmacy Network Agreement with Walgreens Health Initiatives, records are required to be maintained and accessible for: (i) ten years following each year of the term in which the pharmacy provides services under the Pharmacy Network Agreement or longer as mandated by CMS (Centers for Medicare and Medicaid), for Medicare Part D; (ii) six years for the Medicare Drug Discount Card; and (iii) five years or per applicable federal or state

---

<sup>39</sup> Federal Register, August 17, 2000 (Volume 65, Number 160), at pp. 50311-50372; NCPDP, *Pharmacy: A Prescription for Improving the Healthcare System*, October 2009, accessed January 30, 2019 at <https://www.ncdp.org/NCPDP/media/pdf/wp/RxforImprovingHealthcare.pdf>, at p. 14.

<sup>40</sup> CFR § 423.505(d)

law, whichever is longer, for any other Walgreens Health Initiatives' business records.”<sup>41</sup>

143. In discussing its Medicare Part D network standards, Defendant CVS says that each of its pharmacies is required to “maintain its books and records relating to [its] services, for a period of at least ten (10) years, or longer as otherwise required by law”.<sup>42</sup>

144. A key part of the DSCSA is the requirement that “product tracing information should be exchanged” for each transaction and retained for at least six years,<sup>43</sup> including the following transaction information (“TI”):<sup>44</sup>

- Proprietary or established name or names of the product
- Strength and dosage form of the product
- National Drug Code (NDC) number of the product
- Container size
- Number of containers
- **Lot number of the product**
- Date of the transaction
- Date of the shipment, if more than 24 hours after the date of the transaction

---

<sup>41</sup> Walgreens Pharmacy Manual, page 6, available at [https://www.walgreenshealth.com/pdf/forms/Revised\\_Pharmacy\\_Manual\\_2010\\_Revised\\_04072010.pdf](https://www.walgreenshealth.com/pdf/forms/Revised_Pharmacy_Manual_2010_Revised_04072010.pdf).

<sup>42</sup> CVS/Caremark Medicare Part D Compliance / Fraud, Waste & Abuse, page 30, available at <https://www.caremark.com/portal/asset/MedicarePartD.pdf>

<sup>43</sup> FDA, *Protect Your Patients*, accessed February 25, 2020 at <https://www.fda.gov/media/113114/download>; DSCSA, Sections 582 (b)(1)(A)(ii), 582 (c)(bb)(BB)(II)(v)(I), 582 (d)(1)(A)(iii).

<sup>44</sup> FDA, *Drug Supply Chain Security Act (Title II of the Drug Quality and Security Act) Overview of Product Tracing Requirements*, September 2015, accessed March 4, 2020 at <https://www.fda.gov/media/93779/download>, at pp. 8-9.

- Business name and address of the person from whom and to whom ownership is being transferred

145. For example, the DSCSA additionally mandates use of a composite “product identifier” that Manufacturer Defendants were required to begin applying to prescription drug packages and cases.<sup>45</sup>

146. The term “product identifier” “means a standardized graphic that includes, in both human-readable form and on a machine-readable data carrier . . . , the standardized numerical identifier, lot number, and expiration date of the product.”<sup>46</sup>

147. Publicly available Guidelines published by Defendant AmerisourceBergen require that “each Prescription Drug lowest saleable unit” it receives from a manufacturer must have the clearly indicated product identifier on the unit label.<sup>47</sup> In addition, case labels, and partial case labels must list the lot

---

<sup>45</sup> Enforcement of this rule was delayed by the FDA until November 2018. DA, Product Identifier Requirements Under the Drug Supply Chain Security Act – Compliance Policy Guidance for Industry, September 2018, accessed March 4, 2020 at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/product-identifier-requirements-under-drug-supply-chain-security-act-compliance-policy-guidance>.

<sup>46</sup> 21 U.S. Code § 360eee.(14).

<sup>47</sup> AmerisourceBergen, *AmerisourceBergen Manufacturer Packaging and Logistics Requirements Guide*, accessed February 25, 2020 at <https://www.amerisourcebergen.com/-/media/assets/amerisourcebergen/manufacturer/manufacturer-logistics-guideline-final-v14.pdf?la=en&hash=5297B4C716DBBE9A956F31CD2B194BD165F97465>, at p. 14.

number and expiration date.<sup>48</sup> The Guidelines illustrate these requirements as reproduced below.

***AmerisourceBergen Manufacturer Labeling Requirements***<sup>49</sup>




DSCSA RX Serialized Unit Label

---

<sup>48</sup> AmerisourceBergen, *AmerisourceBergen Manufacturer Packaging and Logistics Requirements Guide*, accessed February 25, 2020 at <https://www.amerisourcebergen.com/-/media/assets/amerisourcebergen/manufacturer/manufacturer-logistics-guideline-final-v14.pdf?la=en&hash=5297B4C716DBBE9A956F31CD2B194BD165F97465>, at pp. 15-16.

<sup>49</sup> AmerisourceBergen, *AmerisourceBergen Manufacturer Packaging and Logistics Requirements Guide*, accessed February 25, 2020 at <https://www.amerisourcebergen.com/-/media/assets/amerisourcebergen/manufacturer/manufacturer-logistics-guideline-final-v14.pdf?la=en&hash=5297B4C716DBBE9A956F31CD2B194BD165F97465>, at pp. 14, 15, 16.



Example of Rx Serialized Homogenous Case Label



Example Partial Case Labeled with SSCC

**E. Manufacturer Defendants' VCDs Are Identifiable by NDC Information**

148. The Manufacturer Defendants' VCDs were no exception to the requirements of the federal regulations requiring the products to bear a unique NDC Code.

149. Indeed, when Manufacturer Defendants' initiated their unprecedented consumer level recall of their VCDs, they did so by identifying them by NDC code.



150. The information kept and maintained by all participants in the supply chain was so accurate that both Wholesaler Defendants and Retail Pharmacy Defendants were able to communicate with their customers about which recalled VCDs were in their customers' possessions and should be returned and recalled.

151. For example, on May 14, 2018, Plaintiff Zehr purchased a prescription of the ZHP Defendants' VCDs (160 mg of Valsartan) for \$10.71 from Defendant Walmart.

152. This ZHP VCD purchased by Plaintiff Zehr bore the following NDC Code: 43547-369-09.

153. On July 18, 2018, the ZHP Defendants issued a nation-wide recall<sup>50</sup> for all ZHP VCDs bearing this NDC code.

154. On July 25, 2018, Defendant Walmart issued a letter to consumers who purchased ZHP Product bearing NDC No. 43547-369-09, including to Plaintiff Zehr.

---

<sup>50</sup> <https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/princeton-pharmaceutical-inc-issues-voluntary-nationwide-recall-valsartan-and-valsartan-hctz-tablets> (last accessed January 24, 2021)



July 25, 2018

**Solco Healthcare U.S. Announces a Nationwide Voluntary Recall of Multiple Strengths of Valsartan and Valsartan HCTZ tablets.**

Dear Sara A Zehr,

Our records indicate that the person to whom this letter is addressed may have received a prescription for **Valsartan** or **Valsartan/HCTZ**. We are writing to inform patients of an important voluntary recall concerning this product.

**Recall Information:**

This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), in an active pharmaceutical ingredient by the manufacturer, Zhejiang Huashai Pharmaceutical Co., Ltd.—in the manufacture of the subject product lots. This impurity has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. However, at present Princeton is unaware of any evidence that NDMA has resulted in any harm to patients taking drugs subject to this recall. To date, Princeton Pharmaceutical Inc. has not received any reports of adverse events related to this recall.

**The affected products include:**

Product Description	NDC#	Lot#	Expiry Date
Valsartan 40 mg tablets 30CT	43547-367-03	All lots	From Jul 18 to Jan 20
Valsartan 80 mg tablets 90CT	43547-368-09	All lots	From Jul 18 to Jan 20
Valsartan 160 mg tablets 90CT	43547-369-09	All lots	From Jul 18 to Jan 20
Valsartan 320 mg tablets 90CT	43547-370-09	All lots	From Jul 18 to Jan 20
Valsartan/HCTZ 80mg/12.5mg 90CT	43547-311-09	All lots	From Jul 18 to Jan 20
Valsartan/HCTZ 160mg/12.5mg 90CT	43547-312-09	All lots	From Jul 18 to Jan 20
Valsartan/HCTZ 160mg/25mg 90CT	43547-313-09	All lots	From Jul 18 to Jan 20
Valsartan/HCTZ 320mg/12.5mg 90CT	43547-314-09	All lots	From Jul 18 to Jan 20
Valsartan/HCTZ 320mg/25mg 90CT	43547-315-09	All lots	From Jul 18 to Jan 20

**What does this mean?**

Valsartan and Valsartan/HCTZ are indicated for the treatment of hypertension. Patients who are on Valsartan or Valsartan/HCTZ should continue taking their medication as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment.

**What you should do:**

- If you have an affected product, contact your local Walmart Pharmacy during normal business hours for return and replacement. The pharmacist may need to contact your prescriber to obtain a prescription for an alternative treatment option.

02086-0718-0740

=

155. The process occurred every time one of the Manufacturer Defendants' proceeded to recall their VCDs.

**F. The Drugs Ingested by Plaintiffs Were Not Valsartan, But New, Unapproved VCDs**

156. The FDA's website provides the definition for a drug:

The Federal Food Drug and Cosmetic Act (FD&C Act) and FDA regulations define the term drug, in part, by reference to its intended use, as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease” and “articles (other than food) intended to affect the structure or any function of the body of man or other animals.” Therefore, almost any ingested or topical or injectable product that, through its label or labeling (including internet websites, promotional pamphlets, and other marketing material), is claimed to be beneficial for such uses will be regulated by FDA as a drug. The definition also includes

components of drugs, such as active pharmaceutical ingredients.<sup>51</sup>

157. 21 C.F.R. § 210.3(b)(7) defines an “active ingredient” in a drug as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or other animals. The term includes those components that may undergo chemical change in the manufacture of the drug product and be present in the drug product in a modified form intended to furnish the specified activity or effect.”

158. NDMA and NDEA both cause cellular and genetic injury triggering genetic mutations in humans that can ultimately develop into cancer. These injuries affect the structure of the human body, and thus, NDMA and NDEA are, by definition, active ingredients in a drug.

159. FDA further requires that whenever a new active ingredient is added to a drug, the drug becomes an entirely new drug, necessitating a submission of a New Drug Application by the manufacturer. Absent such an application, followed by a review and approval by the FDA, this new drug remains a distinct, unapproved product.<sup>52</sup>

---

<sup>51</sup> FDA, HUMAN DRUGS, <https://www.fda.gov/ForIndustry/ImportProgram/ImportBasics/RegulatedProducts/ucm511482.htm#drug> (last visited June 13, 2019).

<sup>52</sup> See 21 C.F.R. § 310.3(h).

160. This new and unapproved drug with additional active ingredients (such as nitrosamines in the subject VCDs) cannot be required to have the same label as the brand-name drug, as the two products are no longer the same.

161. At the very least and alternatively, drugs contaminated with different and dangerous ingredients than their brand-name counterparts are defective, and adulterated or misbranded under federal and state law, and the sale or introduction into commerce of adulterated or misbranded drugs is illegal.<sup>53</sup>

162. Because the VCDs ingested by Plaintiffs were never approved or even reviewed by the FDA, the FDA never conducted an assessment of safety or effectiveness for these drugs. Further, if such an assessment were performed, the drugs would not have been approved with the NDMA and NDEA contamination.

163. The inclusion of additional active ingredients (NDMA and NDEA), and potentially other deviations from Defendants' ANDA approvals rendered Defendants' VCDs of a lesser quality, purity and distinctly different from a chemical standpoint than FDA-approved generic valsartan.

164. Plaintiffs reference federal law in this Third Amended Master Complaint not in any attempt to enforce it, but to demonstrate that their state-law

---

<sup>53</sup> See generally Department of Justice, *Generic Drug Manufacturer Ranbaxy Pleads Guilty and Agrees to Pay \$500 Million to Resolve False Claims Allegations, cGMP Violations and False Statements to the FDA* (May 13, 2013), <https://www.justice.gov/opa/pr/generic-drug-manufacturer-ranbaxy-pleads-guilty-and-agrees-pay-500-million-resolve-false>.

tort claims do not impose any additional obligations on Defendants, beyond what was already required of them under federal law.

**G. Defendants Made False Statements in the Labeling of their VCDs**

165. A manufacturer is required to give adequate directions for the use of a pharmaceutical drug such that a “layman can use a drug safely and for the purposes for which it is intended,”<sup>54</sup> and conform to requirements governing the appearance of the label.<sup>55</sup>

166. “Labeling” encompasses all written, printed or graphic material accompanying the drug or device,<sup>56</sup> and therefore broadly encompasses nearly every form of promotional activity, including not only “package inserts” but also advertising.

167. “Most, if not all, labeling is advertising. The term ‘labeling’ is defined in the FDCA as including all printed matter accompanying any article. Congress did not, and we cannot, exclude from the definition printed matter which constitutes advertising.”<sup>57</sup>

---

<sup>54</sup> 21 C.F.R. § 201.5.

<sup>55</sup> 21 C.F.R. § 801.15.

<sup>56</sup> *Id.*; 65 Fed. Reg. 14286 (March 16, 2000).

<sup>57</sup> *U.S. v. Research Labs.*, 126 F.2d 42, 45 (9th Cir. 1942).

168. If a manufacturer labels a drug but omits ingredients, that renders the drug misbranded.<sup>58</sup>

169. In addition, by referring to their drugs as “valsartan” or “valsartan HCT” or “amlodipine-valsartan” or “amlodipine-valsartan HCT,” as well as in including the USP designation indicating compliance with compendial standards, Defendants were making false statements regarding their VCDs.

170. Because NDMA and/or NDEA were not disclosed by Defendants as ingredients in the VCDs ingested by Plaintiffs, the Defendants failed to warn consumers and physicians of the true ingredients, and the subject drugs were misbranded.

171. It is unlawful to introduce a misbranded drug into interstate commerce.<sup>59</sup> Thus, the VCDs ingested by individual Plaintiffs were unlawfully distributed and sold.

#### **H. The Generic Drug Supply Chain in the United States**

172. The generic drug supply chain from manufacturer to end consumer involves several groups of actors and links.

173. At the top of the supply chain are generic drug manufacturers (and whomever they contract with to manufacture components of pharmaceuticals

---

<sup>58</sup> 21 C.F.R. § 201.6; 201.10.

<sup>59</sup> 21 U.S.C. § 331(a).

including, for example, the active pharmaceutical ingredient manufacturer (“API”). Generic drug manufacturers may sell to other manufacturers or to so-called repackagers or labelers who sell a particular generic drug formulation.

174. Generic drug manufacturers contract directly with wholesalers and retail pharmacies for the sale of pharmaceutical products, and Plaintiffs are the intended third-party beneficiaries of these contracts, including all representations and warranties provided, and are the intended consumers of these products.

175. Wholesalers in turn purchase bulk generic drug product from the generic manufacturers and/or labelers and repackager entities. The wholesaler market is extremely concentrated, with three entities holding about 92% of the wholesaler market: Cardinal Health, Inc.; McKesson Corporation; and Amerisource Bergen Corporation.

176. Wholesalers sell the generic drug products they acquire to retail pharmacies, who sell them to patients with prescriptions in need of fulfillment. The retail pharmacy market is also dominated by several major companies.

**I. Background on Current Good Manufacturing Practices (“cGMPs”)**

177. Under federal law, pharmaceutical drugs must be manufactured in accordance with “current Good Manufacturing Practices” (“cGMPs”) to ensure they meet safety, quality, purity, identity, and strength standards. *See* 21 U.S.C. § 351(a)(2)(B). Defendants violated cGMP’s in the manufacture of the VCD’s,

including the failure to ensure that the VCD's met required safety, quality, purity, and identity standards, both under state law and parallel federal law.

178. 21 C.F.R. § 210.1(a) states that the cGMPs establish “minimum current good manufacturing practice for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug to assure that such drug meets the requirements of the act as to safety, and has the identity and strength and meets the quality and purity characteristics that it purports or is represented to possess.” In other words, entities at all phases of the design, manufacture, and distribution chain are bound by these requirements.

179. The FDA's cGMP regulations are found in 21 C.F.R. §§ 210 and 211. These detailed regulations set forth minimum standards regarding: organization and personnel (Subpart B); buildings and facilities (Subpart C); equipment (Subpart D); control of components and drug product containers and closures (Subpart E); production and process controls (Subpart F); packaging and label controls (Subpart G); holding and distribution (Subpart H); laboratory controls (Subpart I); records and reports (Subpart J); and returned and salvaged drug products (Subpart K). The FDA has worldwide jurisdiction to enforce these regulations if these regulations are applicable to any facility manufacturing drugs intended to be distributed in the United States.



180. Any drug not manufactured in accordance with cGMPs is deemed “adulterated and/or misbranded” or “misbranded” and may not be distributed or sold in the United States. *See* 21 U.S.C. §§ 331(a), 351(a)(2)(B). States have enacted laws adopting or mirroring these federal standards.

181. The cGMPs necessary to ensure that product is not contaminated, adulterated, and/or misbranded under state law require “the implementation of oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.” 21 U.S.C. § 351(j). Accordingly, it is a cGMP violation for a manufacturer to contract out prescription drug manufacturing without sufficiently ensuring continuing quality of the subcontractors’ operations.

182. FDA regulations require a “quality control unit” to independently test drug product manufactured by another company on contract:

183. There shall be a quality control unit that shall have the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling, and drug products, and the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated. The quality control unit shall be responsible for approving or rejecting drug products

manufactured, processed, packed, or held under contract by another company.

21 C.F.R. § 211.22(a).

184. Indeed, FDA regulations require a drug manufacturer to have “written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.” 21 C.F.R. § 211.100.

185. A drug manufacturer’s “[l]aboratory controls shall include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity.” 21 C.F.R. § 211.160.

186. “Laboratory records shall include complete data derived from all tests necessary to assure compliance with established specifications and standards, including examinations and assays” and a “statement of the results of tests and how the results compare with established standards of identity, strength, quality, and purity for the component, drug product container, closure, in-process material, or drug product tested.” 21 C.F.R. § 211.194.

**J. The Generic Drug Approval Framework**

187. The Drug Price Competition and Patent Term Restoration Act of 1984 – more commonly referred to as the Hatch-Waxman Act – is codified at 21 U.S.C. § 355(j).

188. The stated purpose of Hatch-Waxman is to strike a balance between rewarding genuine innovation and drug discovery by affording longer periods of brand drug marketing exclusivity while at the same time encouraging generic patent challenges and streamlining generic drug competition so that consumers gain the benefit of generic drugs at lower prices as quickly as possible.

189. Brand drug companies submitting a New Drug Application (“NDA”) are required to demonstrate clinical safety and efficacy through well-designed clinical trials. 21 U.S.C. § 355 *et seq.*

190. By contrast, generic drug companies submit an Abbreviated New Drug Application (“ANDA”). Instead of demonstrating clinical safety and efficacy, generic drug companies need only demonstrate equivalence, including bioequivalence to the brand or reference listed drug (“RLD”). Bioequivalence is the “absence of significant difference” in the pharmacokinetic profiles of two pharmaceutical products. 21 C.F.R. § 320.1(e).

**1. ANDA Applications Must Demonstrate Bioequivalence**

191. The bioequivalence basis for ANDA approval is premised on the generally accepted proposition that equivalence of pharmacokinetic profiles of two drug products is evidence of therapeutic equivalence. In other words, if (1) the RLD is proven to be safe and effective for the approved indication through well-designed clinical studies accepted by the FDA, and (2) the generic company has shown that its ANDA product is bioequivalent to the RLD, then (3) the generic ANDA product must be safe and effective for the same approved indication as the RLD.

192. As part of its showing of bioequivalence pursuant to 21 C.F.R. § 314.50(d), the ANDA must also contain specific information establishing the drug's stability, including:

a full description of the drug's substance, including its physical and chemical characteristics and stability; and

the specifications necessary to ensure the identify strength, quality and purity of the drug substance and the bioavailability of the drug products made from the substance, including, for example, tests, analytical procedures, and acceptance criteria relating to stability.

193. Generic drug manufacturers have an ongoing federal duty of sameness in their products. Under 21 U.S.C. § 355(j), the generic manufacturer must show the following things as relevant to this case: the active ingredient(s) are the same as the RLD, § 355(j)(2)(A)(ii); and, that the generic drug is "bioequivalent" to the

RLD and “can be expected to have the same therapeutic effect,” *id.* at (A)(iv). A generic manufacturer (like a brand manufacturer) must also make “a full statement of the composition of such drug” to the FDA. *Id.* at (A)(vi); *see also* § 355(b)(1)(C).

194. A generic manufacturer must also submit information to show that the “labeling proposed for the new drug is the same as the labeling approved for the [RLD][.]” 21 U.S.C. § 355(j)(2)(A)(v).

**2. ANDA Applications Must Provide Information About the Manufacturing Plants and Processes**

195. The ANDA application must also include information about the manufacturing facilities of the product, including the name and full address of the facilities, contact information for an agent of the facilities, and the function and responsibility of the facilities.

196. The ANDA application must include a description of the manufacturing process and facility and the manufacturing process flow chart showing that there are adequate controls to ensure the reliability of the process.

197. Furthermore, the ANDA application must contain information pertaining to the manufacturing facility’s validation process, which ensures that the manufacturing process produces a dosage that meets product specifications.

**3. ANDA Applications Must Comply with cGMPs**

198. Additionally, the ANDA applications must include certain representations pertaining to compliance with cGMPs.

199. The ANDA application is required to contain cGMP certifications for both the ANDA applicant itself, and also and the drug product manufacturer (if they are different entities).

**4. ANDA Approval is Contingent upon Continuing Compliance with ANDA Representations of Sameness**

200. Upon granting final approval for a generic drug, the FDA will typically state that the generic drug is “therapeutically equivalent” to the branded drug. The FDA codes generic drugs as “A/B rated” to the RLD<sup>60</sup> branded drug. Pharmacists, physicians, and patients can expect such generic drugs to be therapeutically interchangeable with the RLD, and generic manufacturers expressly warrant as much through the inclusion of the same labeling as the RLD delivered to consumers in each prescription of its generic products. Further, by simply marketing generic drugs pursuant to the brand-name drug’s label under the generic

---

<sup>60</sup> The FDA’s Drug Glossary defines an RLD as follows: “A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.”

name (e.g., valsartan or valsartan HCT), generic manufacturers warrant and represent that the generic drug is therapeutically equivalent to the brand-name drug.

201. If a generic drug manufacturer ceases to manufacture a drug that meets all terms of its ANDA approval, or in other words, when the drug is not the same as its corresponding brand-name drug, then the manufacturer has created an entirely new and unapproved drug.

202. If a generic drug manufacturer ceases to manufacture a drug that meets all terms of its ANDA approval, or in other words, when the drug is not the same as its corresponding brand-name drug, the generic manufacturer may no longer rely on the brand-name drug's labeling.

203. According to the FDA, there are at least sixteen ANDAs approved for generic DIOVAN, nine for generic DIOVAN HCT, nine for generic EXFORGE, and five for generic EXFORGE HCT.

**K. Approval of ANDAs Related to Valsartan**

**1. DIOVAN and EXFORGE Background**

204. Valsartan is a potent, orally active nonpeptide tetrazole derivative which causes a reduction in blood pressure, and is used in the treatment of hypertension, heart failure, and post-myocardial infarction. Millions of American consumers use VCDs for the treatment of these medical conditions.

205. Valsartan and its combination therapy are the generic versions of DIOVAN and DIOVAN HCT, which were marketed in tablet form by Novartis AG (“Novartis”) beginning in July 2001 (in tablet form) and March 1998, respectively, upon approval by the FDA. Valsartan’s combination therapy with amlodipine, as well as the combination therapy of valsartan, amlodipine and hydrochlorothiazide, are the generic versions of Novartis’s branded products EXFORGE and EXFORGE HCT. Novartis received the FDA’s approval for EXFORGE in June 2007 and for EXFORGE HCT in April 2009.

206. These Valsartan based branded drugs proved to be blockbuster products for Novartis. Globally, DIOVAN and DIOVAN HCT generated \$5.6 billion in sales in 2011 according to Novartis’s Form 20-F for that year, of which \$2.33 billion was from the United States. The same year, EXFORGE and EXFORGE HCT had \$325,000,000 in U.S. sales and \$884,000,000 globally.

207. DIOVAN’s, DIOVAN HCT’s, EXFORGE’s, and EXFORGE HCT’s FDA-approved labels specify the active and inactive ingredients. None of the contaminants at issue here (including NDMA, NDEA, or other nitrosamines) are FDA-approved ingredients of DIOVAN, DIOVAN HCT, EXFORGE, or EXFORGE HCT. Nor are any of these contaminants FDA-approved ingredients of any generic valsartan-containing product approved pursuant to an ANDA.



208. Novartis's DIOVAN and EXFORGE patents expired in September 2012. Defendant Mylan launched a DIOVAN HCT generic in or about September 2012 when its valsartan HCT ANDA was approved by the FDA. Generic versions of the other drugs followed in the intervening years.

## 2. ANDA Applications for Generic Valsartan

209. Almost a full decade before the DIOVAN patents were set to expire, generic drug manufacturers started filing ANDA applications for their own generic versions of the Valsartan drug.

210. Hatch-Waxman rewards the first generic company to file a substantially complete ANDA containing a Paragraph IV certification with a 180-day period of marketing exclusivity. 21 U.S.C. § 355(j)(5)(B)(iv). The 180-day exclusivity period is triggered upon either a first commercial marketing of the drug (including of the RLD) by the 180-day exclusivity holder or the date on which a court has entered a judgment finding that the patent subject to the Paragraph IV certification is invalid, unenforceable, or not infringed.

211. On December 24, 2004, Ranbaxy Labs ("Ranbaxy") filed the first ANDA application for Valsartan (the generic equivalent of the DIOVAN product).

212. On January 7, 2005, Teva filed the second ANDA application for Valsartan (the generic equivalent of the DIOVAN product), for which it received tentative approval on January 7, 2005.

213. On September 15, 2008, Mylan filed an ANDA application for Valsartan (the generic equivalent of the DIOVAN product).

214. Upon information and belief, in the intervening years after these three initial ANDA applications, all other Defendants filed ANDA applications for either Valsartan (the generic equivalent of the DIOVAN product), Valsartan hydrochlorothiazide (the generic equivalent of the DIOVAN HCT product), Valsartan Amlodipine (the generic equivalent of the EXFORGE product), and Valsartan Amlodipine Hydrochlorothiazide (the generic equivalent of the EXFORGE HCT product).

215. Despite the number of ANDAs that had been filed as early as 2004, when DIOVAN's patent expired in 2012, no generic entered the market.

216. As the first to have filed their ANDA application in December of 2004, Ranbaxy was entitled to exclusivity, and as such, no other ANDAs would be approved until Ranbaxy received final approval.

217. Defendants Mylan and Teva were among those who had tentative approval and were ready to launch their generic DIOVAN Product upon expiration of the DIOVAN patent in 2012.

218. Indeed, Defendant Mylan launched its generic DIOVAN HCT product, for which it had filed an ANDA and received approval, on September 21, 2012, the same day the DIOVAN patent was set to expire.

219. After delaying its approval due to gross manufacturing defects plaguing Ranbaxy's Indian API manufacturing facilities, the FDA finally approved Ranbaxy's generic Valsartan in June of 2014.

220. Six months later, after Ranbaxy's period of exclusivity expired, Mylan's generic DIOVAN product launched on January 5, 2015, and Teva's generic VCDs launched January 6, 2015. The entry of the rest of the purported generic equivalents of these drugs followed thereafter.

221. Par Pharmaceuticals received approval of the first generic EXFORGE in September 2014, and Teva received approval of the first generic EXFORGE HCT in December 2014. The entry of the rest of the generic equivalents of these drugs followed thereafter.

**L. Starting as Early as 2007, Defendants Were Actively Violating cGMPs in Their Foreign Manufacturing Facilities**

222. For some time, Defendants have known that generic drugs manufactured overseas, particularly in China and India, were found or suspected to be less safe and effective than their branded equivalents or domestically-made generics due to their grossly inadequate manufacturing and quality processes, procedures and compliance with cGMPs.

223. Defendants' own foreign manufacturing operations were no exception to this.

1. **ZHP's Inadequate Manufacturing Processes Results in Contaminated, Adulterated, Misbranded and/or Unapproved VCDs**

224. ZHP has Active Pharmaceutical Ingredient (“API”) manufacturing facilities located in Linhai City, Zhejiang Province, China. According to ZHP’s website, ZHP was one of the first Chinese companies approved to sell generic drugs in the United States, and it remains one of China’s largest exporters of pharmaceuticals to the United States and the European Union.

225. ZHP serves as a contract API manufacturer of numerous defendants’ VCDs as set forth *supra* at Section II, and Defendants thus have a quality assurance obligation with respect to ZHP’s processes and finished products as set forth above pursuant to federal and state law.

226. ZHP has a history of deviations from safe and reasonable manufacturing practices, and FDA’s cGMP standards that were documented almost as soon as ZHP was approved to export pharmaceuticals to the United States.

227. On or about March 27-30, 2007, the FDA inspected ZHP’s Xunqiao Linhai City facilities. That inspection revealed “deviations from current good manufacturing processes (CGMP)” at the facility. Those deviations supposedly were later corrected by ZHP. The results of the inspection and the steps purportedly taken subsequent to it were not made fully available to the public.

228. The FDA inspected ZHP's same Xunqiao facility again on November 14-18, 2016. The inspection revealed four violations of cGMPs. First, "[w]ritten procedures designed to prevent contamination of drug products purporting to be sterile are not followed." Second, ZHP had failed "to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity." Third, "[p]rocessing areas are deficient regarding the system for cleaning and disinfecting the equipment." Last, "data is not recorded contemporaneously."

229. On May 15-19, 2017, the FDA inspected ZHP's facility at Coastal Industrial Zone, Chuannan No. 1 Branch, Linhai City, Zhejiang Province, China. ZHP manufactures all of its valsartan API at this Chuannan facility. That inspection resulted in the FDA's finding that ZHP repeatedly re-tested out of specification ("OOS") samples until obtaining a desirable result. This practice allegedly dated back to at least September 2016 per the FDA's letter and investigation up to that point. The May 2017 inspection also resulted in FDA's finding that "impurities occurring during analytical testing are not consistently documented/quantitated." These findings were not made fully available to the public. However, this information was shared or available to ZHP's finished-dose

manufacturers, as well as those Defendants further down the distribution chain, all of whom were on notice of these defects and lack of adequate quality control.

230. Furthermore, for OOS sampling results, ZHP routinely invalidated these results without conducting any kind of scientific investigation into the reasons behind the OOS sample result. In fact, in one documented instance, the OOS result was attributed to “pollution from the environment” surrounding the facility. These manipulations of sampling were components of a pattern and practice of systematic data manipulation designed to fail to detect and/or intentionally conceal and recklessly disregard the presence of harmful impurities such as NDMA and NDEA.

231. The May 2017 inspection also found that ZHP’s “facilities and equipment [were] not maintained to ensure [the] quality of drug product” manufactured at the facility. These issues included the FDA’s finding that: equipment that was rusting and rust was being deposited into drug product; equipment was shedding cracking paint into drug product; there was an accumulation of white particulate matter; and there were black metallic particles in API batches.

232. The FDA inspector “noted reoccurring complaints pertained to particulate matter in API ... and for discrepancies in testing between [ZHP] and their consignees.... To address the firm’s handling of complaints describing testing

disparities, [the inspector] had the firm generate a list of such complaints, as well as associated pie charts.... From 2015 until May 2017, 13 complaints related to discrepancies between [ZHP]'s test results and their consignees were listed. Of these complaints 85% had what the firm termed 'Customer has no subsequent feedback or treatment.' Specifically, this 85% was further broken down into 3 categories: the batch subject to the complaint was sent to other consignees who did not report a complaint, there is a test method discrepancy and feedback was provided to the consignee without a response, and the consignee failed to respond but continued to purchase API from [ZHP]."

233. On November 29, 2018, the FDA issued Warning Letter 320-19-04 to ZHP based on its July 23 to August 3, 2018 inspection of its Chuannan facility.<sup>61</sup> The letter summarized "significant deviations from [cGMPs] for [APIs]." The FDA consequently informed ZHP that its "API are adulterated and/or misbranded within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B)."

234. The FDA explained that ZHP repeatedly failed "to ensure that quality-related complaints are investigated and resolved," including complaints related to peaks of NDMA in its products as early as 2012, which ZHP willfully ignored

---

<sup>61</sup> FDA, *Zhejiang Huahai Pharmaceutical 11/29/18*, <https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm628009.htm>.

rather than utilize existing technology to identify the nitrosamine contamination that would have been easily identified.

235. ZHP also failed “to evaluate the potential effect that changes in the manufacturing process may have on the quality of [its] API.” More specifically, ZHP “approved a [V]alsartan API process change ... that included the use of the solvent [redacted]. [ZHP’s] intention was to improve the manufacturing process, increase product yield, and lower production costs. However, [ZHP] failed to adequately assess the potential formation of mutagenic impurities[, such as NDMA,] when [it] implemented the new process. Specifically, [it] did not consider the potential for mutagenic or other toxic impurities to form from [redacted] degradants, including the primary [redacted] degradant, [redacted]. According to [ZHP’s] ongoing investigation, [redacted] is required for the probable human carcinogen NDMA to form during the valsartan API manufacturing process.”

236. The FDA added that ZHP “also failed to evaluate the need for additional analytical methods to ensure that unanticipated impurities were appropriately detected and controlled in [its] [V]alsartan API before [it] approved the process change. [ZHP is] responsible for developing and using suitable methods to detect impurities when developing, and making changes to, [its] manufacturing processes.”



237. ZHP claimed that it had followed “common industry practice.”

Importantly, the FDA rejected ZHP’s attempt to evade responsibility for its gross violations of safe and reasonable manufacturing and quality processes, and reminded ZHP that “common industry practice may not always be consistent with CGMP requirements and that [it is] responsible for the quality of drugs [it] produce[s].” The FDA “strongly” recommended that ZHP hire a cGMP consultant and referred ZHP to four guides on cGMPs.

238. On September 28, 2018, the FDA stopped allowing ZHP to deliver drugs made at its Chuannan facility into the United States. The Warning Letter stated that “[f]ailure to correct these deviations may also result in FDA continuing to refuse admission of articles manufactured at [ZHP’s Chuannan facility] into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Under the same authority, articles may be subject to refusal of admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).”

239. After the recalls of ZHP’s VCDs, FDA Laboratory Analysis testing would later reveal that valsartan API manufactured by ZHP at its Linhai City facilities contained NDMA levels hundreds of times in excess of the FDA’s

interim limits<sup>62</sup> of 96 ng/day or 0.3 ppm.<sup>63</sup> Specifically, VCDs manufactured at ZHP for ZHP's subsidiary Princeton Pharmaceutical contained NDMA levels of between 15,180 and 16,300 ng, while Valsartan HCT manufactured at ZHP contained NDMA levels of between 13,180 and 20,190 ng.<sup>64</sup> ZHP valsartan API manufactured for Teva Pharmaceuticals contained similarly high levels of NDMA.

240. In addition, FDA Laboratory Analysis testing would later reveal that valsartan API manufactured by ZHP at ZHP's Linhai City facilities contained NDEA levels upwards of fifty times in excess of the FDA's interim limits<sup>65</sup> of 26.5 ng/day or 0.083 ppm. Specifically, FDA testing reveals up to 770 ng of NDEA in Teva Pharmaceuticals' VCDs.

---

<sup>62</sup> To be clear, ZHP's valsartan products should not contain any NDMA.

<sup>63</sup> FDA, LABORATORY ANALYSIS OF VALSARTAN PRODUCTS, <https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-analysis-valsartan-products> (last visited June 13, 2019); *see also* FDA, FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan), <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan> (last visited June 13, 2019).

<sup>64</sup> *Id.*

<sup>65</sup> To be clear, eva's valsartan products should not contain any NDEA.

2. **Hetero's Inadequate Manufacturing Processes Results in Contaminated Adulterated, Misbranded and/or Unapproved VCDs**

241. Defendant Hetero maintains six API manufacturing facilities in India, which have been approved by the FDA to produce active ingredients for drugs being sold and marketed in the United States.

242. Hetero has a history of deviations from FDA's cGMP standards.

243. In December of 2016, during an inspection of an oral solid dose drug product manufacturing facility, the FDA observed, through closed circuit TV surveillance, that Hetero Quality Assurance technicians and "other individuals" were recorded destroying and altering records pertaining to commercial batch manufacturing immediately before the FDA's onsite regulatory inspection.

According to a scathing letter, the FDA noted that the following occurred:

- a. Hetero employees brought in a document shredder into the "DOCUMENTS STORAGE AREA" four days prior to the FDA inspection;
- b. The FDA observed extensive shredding of what appeared to be "controlled documents" as well as "extensive signing of documents" by Quality Assurance technicians. The FDA noted that the documents were of a color consistent with batch packaging records and batch manufacturing record. Hetero failed to maintain documentation of what had been shredded;

c. One day prior to the FDA inspection a Hetero contract employee in the Quality Assurance division removed documents from the shredder and placed them in his pocket; and

d. At 1:13 am the morning the FDA inspectors were set to arrive at Hetero for their regulatory inspections, individuals were seen shredding documents.

244. In addition to the documented destruction of these manufacturing records, the FDA further observed that production and control records were not prepared for each batch of drug product produced and did not include complete information relating to the production and control of each batch.

245. Additionally, data derived from Hetero's programmable logic controller for compression machines was inconsistent with batch records and validation reports that were submitted to the FDA in support of applications to manufacture and market drugs in the United States.

246. Hetero also failed to include findings of any investigations and follow-up that occurred as a result of investigations into complaints about their drugs.

247. During the December 2016 inspection, equipment at Hetero was found to have not been cleaned and maintained at appropriate intervals to "prevent

contamination that would alter the safety, identity, strength, quality and purity” of Hetero drug products.

248. During the December 2016 visit, FDA inspectors found that “accuracy, sensitivity and reproducibility of test methods” were not established and documented.

249. In an August 15, 2017, warning letter, the FDA strongly recommended that Hetero engage “a consultant, qualified as set forth in 21 CFR 211.34” to assist Hetero Labs in meeting cGMP requirements, but emphasized that, ultimately, “executive management remains responsible for fully resolving all deficiencies and ensuring ongoing cGMP compliance.”

250. In February of 2018, FDA investigators discovered other manufacturing flaws at an API Manufacturing facility.

251. For example, the FDA found that there was a “failure” by Hetero to “thoroughly review any unexplained discrepancy and failure of a batch or any of its components to meet any of its specifications,” whether or not the batch had been already distributed.

252. The FDA investigators further found during that February 2018 inspection that Hetero employees who were engaged in the processing, holding and testing of a drug product lacked the training and experience required to perform their assigned functions. Indeed, in a walk-through with FDA investigators, several

quality-control personnel could not explain their assigned functions and processes after “repeated opportunities” to do so.

253. Additionally, FDA investigators concluded that there was “no assurance” that equipment used in API production was being maintained and/or kept under proper conditions for manufacturing operations “to prevent the contamination of the products handled and/or processed in the equipment.” Likewise, equipment at the Hetero was found to have not been cleaned and maintained at appropriate intervals to “prevent contamination that would alter the safety, identity, strength, quality and purity” of Hetero’s drug products.

254. After the recalls of Hetero’s VCDs, FDA Laboratory Analysis testing would later reveal that valsartan 320mg API manufactured by Hetero contained NDMA levels in excess of the FDA’s interim limits<sup>66</sup> of 96 ng/day or 0.3 ppm.<sup>67</sup>

---

<sup>66</sup> To be clear, Hetero’s valsartan products should not contain any NDMA.

<sup>67</sup> FDA, LABORATORY ANALYSIS OF VALSARTAN PRODUCTS, <https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-analysis-valsartan-products> (last visited June 13, 2019); *see also* FDA, FDA UPDATES AND PRESS ANNOUNCEMENTS ON ANGIOTENSIN II RECEPTOR BLOCKER (ARB) RECALLS (VALSARTAN, LOSARTAN, AND IRBESARTAN), <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan> (last visited June 13, 2019).

3. **Mylan's Inadequate Manufacturing Processes Results in Contaminated, Adulterated, Misbranded and/or Unapproved VCDs**

255. While ZHP and Aurobindo began as foreign companies who eventually expanded their operations to the United States, Mylan's history begins in the United States back in 1961, in White Sulfur Springs, West Virginia.

256. From the founding of the company, to roughly the mid-2000s, Mylan either manufactured their own products domestically in the United States, or contracted with foreign companies to order API for their finished dosage products.

257. However, in late 2005, Mylan's CEO at the time, Robert Coury, was facing a crisis due to the fact that the US-based company was losing market share to Indian drug companies that made their own API in-house and operated at rock-bottom costs. At the time, Mylan had to order API from Chinese and Indian suppliers.

258. Consequently, in December of 2005, Coury hammered out a deal to acquire Matrix Laboratories, an India-based company which had been of Mylan's ingredient suppliers. At the time of the acquisition of Matrix Laboratories, a former Ranbaxy employee named Rajiv Malik was the CEO of Matrix.

259. After the Mylan acquisition in 2006, Malik became the executive vice president in charge of global technical operations.

260. Malik's impact on Mylan was immediate – he reoriented the company towards India. Very quickly, the number of drug applications for generics Mylan submitted to the FDA tripled, and the approvals doubled.

261. Indeed, Malik's compensation structure was based, in part, on the number of ANDA applications filed with global regulators.

262. As the focus shifted to bringing more and more drugs to market, employees in both India and the United States began to experience a shift in the company, where speed was prized above all else. Employees who insisted on adhering to cGMPs felt sidelined and were tagged as slow.

263. In 2013, Malik was tasked with overseeing Mylan's biggest foreign acquisition yet – a \$1.6 billion purchase of Agila Specialties, a manufacturing facility in India.

264. In comments regarding the potential acquisition, Mylan CEO Heather Bresch (daughter of US Senator Joe Manchin) touted the “state-of-the-art, high quality” manufacturing platforms in the industry.

265. However, months after Mylan announced the acquisition, the FDA conducted an investigation of the facility in June of 2013. In a scathing investigation report, it found that key pieces of equipment were stored in non-sterile areas, and then never resanitized before use; employees failed to wash their hands in the bathroom; technicians were wearing gloves that were flaking and had



pinholes; and supposedly sterile gloves were found to be stored in boxes with crushed insects.

266. Making matters worse, after the June inspection, in a letter written by the FDA in September, the FDA found that Agila's written response "minimizes the importance of ensuring glove integrity and its potential impact on product quality." It also found that the issues led the FDA to "question [Agila's] understanding of basic microbiology and microbial controls that are critical for the manufacture of sterile products."

267. However, despite these gross manufacturing issues, Mylan moved forward on its billion-dollar acquisition, eventually obtaining the company and their manufacturing facilities.

268. Throughout 2014 and 2015, the FDA continued to investigate Mylan's Indian manufacturing facilities, routinely uncovering a multitude of violations of the cGMPs, and finding that Mylan responded with letters that lacked corrective action. These violations included failure to establish and follow written procedures to prevent microbiological contamination of drug products, lack of assurance that the manufacturing facilities were sterile, and failures to thoroughly investigate unexplained discrepancies in batches or whether the components met specifications.

269. In 2015, a former Mylan employee sat down with FDA employees and alleged that the research and development centers in Hyderabad had become a hub for data fraud.<sup>68</sup>

270. The Mylan whistleblower identified specific applications for drugs that were due to be launched into the American market, claiming that in order to generate passing results for some drug products, Mylan had manipulated the testing, by switching the tests from batch testing to pilot batches (which were easier to control, but not as reliable in ensuring the results as they were smaller in size).<sup>69</sup>

271. The Mylan whistleblower also claimed that the Mylan team had evolved its fraudulent methods to evade detection. For example, instead of deleting manipulated data from the plant's software systems, which would have left a trail of metadata that could be uncovered by the FDA, plant managers were deliberately corrupting the data they wanted to hide.<sup>70</sup>

272. In July of 2016, upset by the failure of the FDA to investigate, the Mylan whistleblower sent an email to FDA officials that said: "I learned that Mylan's strategy of providing employment to FDA members has been working

---

<sup>68</sup> See Katherine Eban, *Bottle of Lies* (2019) at p. 328.

<sup>69</sup> *Id.*

<sup>70</sup> *Id.*

very well...Perhaps the agency awaits a definitive tragedy to occur on U.S. soil due to sub-standard generic products not meeting the safety & efficacy standards.”<sup>71</sup>

273. The email had the intended effect. Two months later, in September 2016, the FDA inspected the Mylan India facilities.<sup>72</sup>

274. Over the course of the week-long inspection, the FDA found evidence that the plant’s software system was riddled with error messages showing “instrument malfunction,” or “power loss,” as though Mylan was literally pulling the plug from the wall to stop the creation of metadata showing failed testing.

275. In confidential correspondence with the FDA, Mylan tried to explain the high number of data error messages (42 over a seven-day period), saying there was accidental knocking of cables off of tables, or through electronic loss of signals. For another error that was observed (150 times over seven days), the partial explanation given by Mylan was that some software settings led to the “unintended consequence of a number of repetitive error messages.”<sup>73</sup>

276. The FDA didn’t accept these excuses. In a stern warning letter sent to Malik in April of 2017, the FDA effectively froze the site’s applications until the

---

<sup>71</sup> See Katherine Eban, *Bottle of Lies* (2019) at p. 329.

<sup>72</sup> *Id.*

<sup>73</sup> See Katherine Eban, *Bottle of Lies* (2019) at p. 331.

company took corrective actions. The letter noted that Mylan's quality systems did not "adequately ensure the accuracy and integrity of the data."<sup>74</sup>

277. But Mylan's issues were not solely limited to its India operations. Several months after the April 2017 letter regarding the India operations, Mylan operations in West Virginia were under scrutiny. The allegations were that laboratory technicians had failed to investigate anomalous results and had instead falsified records to cover-up any anomalous results. Regulators were "stunned" by the lapses, finding the practices "egregious," and questioned whether Mylan was being "transparent at all of its sites."<sup>75</sup>

278. The inspectors also found bins full of shredded documents, including quality-control records, in Parts of the factory where every piece of paper is supposed to be saved.<sup>76</sup>

279. The list of alleged infractions became so long that a fourth inspector was added. A warning letter, the FDA's strongest rebuke, was drafted.<sup>77</sup>

280. Ultimately, the FDA's director of the Office of Manufacturing Quality, Tom Cosgrove, made the controversial decision, over the strenuous

---

<sup>74</sup> *Id.*

<sup>75</sup> See Katherine Eban, *Bottle of Lies* (2019) at p. 332.

<sup>76</sup> <https://www.bloomberg.com/news/features/2019-01-29/america-s-love-affair-with-cheap-drugs-has-a-hidden-cost>

<sup>77</sup> Anna Edney, *America's Love Affair With Cheap Drugs Has a Hidden Cost*, BLOOMBERG (Jan. 29, 2019), <https://www.bloomberg.com/news/features/2019-01-29/america-s-love-affair-with-cheap-drugs-has-a-hidden-cost>.

objections of staff in two separate FDA divisions, to downgrade the investigators' negative findings at Morgantown, from Official Action Indicated to Voluntary Action Indicated.<sup>78</sup>

281. In an email to FDA colleagues, Cosgrove acknowledged their view that the company's practices were "more widespread and that Mylan's investigation was insufficient," but ultimately defended his decision and said that he had no reason to believe that Mylan would not "remediate voluntarily."

282. However, while Mylan's Morgantown plant was no longer receiving intensive agency scrutiny, it did little to resolve the issues.

283. In early 2018, a whistleblower from inside the Morgantown plant reached out to the FDA to report deteriorating conditions, from understaffing to cleaning lapses. The whistleblower from inside the plant claimed that Mylan management was focused on creating a "façade of documents" to fend off the FDA, according to an agency memo that detailed the allegations. The whistleblower also notified the FDA that Mylan had brought in a team of employees from India to the Morgantown, WV facility, to rapidly close a backlog of company investigations, and that employees were instructed not to question their work.<sup>79</sup>

---

<sup>78</sup> See Katherine Eban, *Bottle of Lies* (2019) at p. 333.

<sup>79</sup> *Id.*

284. Consequently, the FDA inspected the Morgantown, WV facility again in March and April of 2018. The inspectors found a host of new violations, including that Mylan’s manufacturing equipment was not cleaned at appropriate intervals to prevent contamination, and that Mylan’s attempts to address the purported testing from the 2016 inspection was “not adequate.”<sup>80</sup>

285. On November 20, 2018, Mylan initiated a recall on the consumer level of select lots of VCDs, due to adulteration of the products with NDEA.

**4. Aurobindo’s Inadequate Manufacturing Processes Results in Contaminated, Adulterated, Misbranded VCDs**

286. Aurobindo has API manufacturing facilities located in Hyderabad, Telangana, India.

287. Aurobindo manufactures VCD for each Aurobindo Defendant at these facilities, and Aurobindo Defendants thus have quality assurance obligations with respect to Aurobindo’s processes and finished products as set forth above pursuant to federal law.

288. Aurobindo has a history of deviations from FDA’s cGMP standards.

289. After an inspection of a Hyderabad facility from June 27 to July 1, 2016, the FDA told Aurobindo that its “[i]nvestigations are inadequate.” The FDA

---

<sup>80</sup> Anna Edney, *America’s Love Affair With Cheap Drugs Has a Hidden Cost*, BLOOMBERG (Jan. 29, 2019), <https://www.bloomberg.com/news/features/2019-01-29/america-s-love-affair-with-cheap-drugs-has-a-hidden-cost>.

explained that Aurobindo failed to initiate stability testing, and “[t]he deviation record contains field ‘Number of previous deviations in this product/system.’ This field requires previous deviations of the same product or deviation type to be reported, no previous deviations were reported in this field.” Moreover, “[t]his is a repeat observation from the 2014 inspection.”

290. Three months later, the FDA returned to Aurobindo’s Hyderabad facilities and found four noteworthy manufacturing problems. First, “[a]n [redacted] Field Alert was not submitted within three working days of receipt of information concerning significant chemical, physical, or other change or deterioration in a distributed drug product.” Second, “[l]aboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that conform [sic] to appropriate standards of identity, strength, quality and purity.” Third, “[t]here are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.” Fourth, the “use of instruments and recording devices not meeting established specifications was observed.”

291. In October 2016, the FDA observed that Aurobindo’s nearby Borpatla facility had inadequately validated equipment cleaning procedures.

292. In April 2017, the FDA observed that the manufacturing equipment in Aurobindo's Hyderabad facilities "is not always maintained to achieve its intended purposes." "Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity." "Changes to written procedures are not drafted, reviewed and approved by the appropriate organizational unit." "[C]orrective and preventative actions (CAPAs), identified and initiated because of out of specifications (OOS) laboratory investigations, do not correlate to the identified root cause. In certain cases, CAPAs are not initiated at all." "Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use." "Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel." "Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established."

293. Four months later, the FDA reiterated that "[t]here are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess." Second, "[c]ontrol procedures are not established which



validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.”

294. In February 2018, the FDA made nine more disturbing observations at Aurobindo’s Hyderabad facilities. First, “Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.” Second, “[e]quipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.” Third, “[e]quipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.” Fourth, “[b]uildings used in manufacture, processing, packing or holding of drug products are not free of infestation by rodents, birds[,], insects, and other vermin.” Fifth, “[p]rocedures for the cleaning and maintenance of equipment are deficient regarding sufficient detail of the methods, equipment, and materials used in the cleaning and maintenance operation, and the methods of disassembly and reassembling equipment as necessary to assure proper cleaning and maintenance.” Sixth, “[e]mployees engaged in the manufacture, processing, packing and holding of a drug product lack the training required to perform their assigned functions.” Seventh, the “statistical quality control criteria fail to include appropriate

acceptance levels and rejection levels.” Eighth, “[e]stablished laboratory control mechanisms are not followed and documented at the time of performance.” Lastly, “[a]ppropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.”

295. After the recalls of Aurobindo’s VCDs, FDA Laboratory Analysis testing would later reveal that valsartan API manufactured by Aurobindo contained NDEA exceedances well in excess of the FDA’s interim limits<sup>81</sup> of 26.5 ng/day or 0.083 ppm.<sup>82</sup>

296. Aurobindo has made no efforts or grossly inadequate efforts to correct the previously identified errors, and continues to engage in grossly inadequate manufacturing processes. During an inspection *one month ago this year* (May 2019), an investigator made note of a panoply of serious issues which called the integrity of the API manufacturing operations into question.

---

<sup>81</sup> To be clear, Aurobindo’s valsartan products should not contain any NDEA.

<sup>82</sup> FDA, LABORATORY ANALYSIS OF VALSARTAN PRODUCTS, <https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-analysis-valsartan-products> (last visited June 13, 2019); *see also* FDA, FDA UPDATES AND PRESS ANNOUNCEMENTS ON ANGIOTENSIN II RECEPTOR BLOCKER (ARB) RECALLS (VALSARTAN, LOSARTAN, AND IRBESARTAN), <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan> (last visited June 13, 2019).

297. For example, in determining that the Medchal, Telangana facility was not following quality control measures, and likewise did not have quality control procedures in place, the investigator observed “loose handwritten notebooks with what appears to be laboratory test data results.”

298. Additionally, while Aurobindo claimed to have performed tests and quality control activities on API as a result of the FDA’s investigation into adulterated VCDs, during the inspection, the investigator found that the API was not being adequately retained and/or appropriately identified, calling Aurobindo’s testing of this API into question. More troubling, this API sampled and analyzed by the investigator was to set to be shipped into the United States.

299. The investigator also found a slew of data integrity issues. The investigator observed “multiple sequences where interrupted sample injections were injected and showed that the sample did not run, shown on the chromatogram as “incomplete data.” The testing systems also allowed certain employees to “verify incomplete data in raw data file.” The investigator found that the quality control reviewers attested to practices which “contradict actual review practices performed by reviews.” Were these baseline data issues not enough, the investigator also noted that the facility did not retain adequate backup of the data.

300. The investigator also noted that in addition to all of the gross processing and data integrity issues, *even the building itself* did not have the

“suitable construction to facility cleaning, maintenance and proper operations.”

The investigator noted that in a stability sample storage room, they observed a “PVC pipe connected to an air conditioner unit on one end, and paced in a blue plastic bucket on the other end with approximate 50% of the bucket filled with condensate water.” There were four other similar setups in other critical rooms in the facility.

301. After the recalls of Aurobindo’s VCDs, FDA Laboratory Analysis testing would later reveal that valsartan API manufactured by Aurobindo contained NDEA exceedances well in excess of the FDA’s interim limits<sup>83</sup> of 26.5 ng/day or 0.083 ppm.<sup>84</sup>

**M. The Contamination of the VCDs**

**1. The Nitrosamine Contaminant NDMA**

302. N-nitrosodimethylamine, commonly known as NDMA, is an odorless, yellow liquid.<sup>85</sup>

---

<sup>83</sup> To be clear, Aurobindo’s valsartan products should not contain any NDEA.

<sup>84</sup> FDA, LABORATORY ANALYSIS OF VALSARTAN PRODUCTS, <https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-analysis-valsartan-products> (last visited June 13, 2019); *see also* FDA, FDA UPDATES AND PRESS ANNOUNCEMENTS ON ANGIOTENSIN II RECEPTOR BLOCKER (ARB) RECALLS (VALSARTAN, LOSARTAN, AND IRBESARTAN), <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan> (last visited June 13, 2019).

<sup>85</sup> U.S. Public Health Service, *Toxicological Profile For N-Nitrosodimethylamine* (Dec 1989), <https://www.atsdr.cdc.gov/toxprofiles/tp141.pdf>.

303. According to the U.S. Environmental Protection Agency (“EPA”), “NDMA is a semi-volatile chemical that forms in both industrial and natural processes.”<sup>86</sup>

304. NDMA can be unintentionally produced in and released from industrial sources through chemical reactions involving other chemicals called alkylamines.

305. The American Conference of Governmental Industrial Hygienists classifies NDMA as a confirmed animal carcinogen.<sup>87</sup>

306. The US Department of Health and Human Services (DHHS) similarly states that NDMA is reasonably anticipated to be a human carcinogen.<sup>88</sup> This classification is based upon DHHS’s findings that NDMA caused tumors in numerous species of experimental animals, at several different tissue sites, and by several routes of exposure, with tumors occurring primarily in the liver, respiratory tract, kidney, and blood vessels.<sup>89</sup>

---

<sup>86</sup> EPA, *Technical Fact Sheet – N-Nitroso-dimethylamine (NDMA)* (Nov. 2017), [https://www.epa.gov/sites/production/files/2017-10/documents/ndma\\_fact\\_sheet\\_update\\_9-15-17508.pdf](https://www.epa.gov/sites/production/files/2017-10/documents/ndma_fact_sheet_update_9-15-17508.pdf).

<sup>87</sup> *Id.*

<sup>88</sup> *Id.*

<sup>89</sup> *Id.*

307. Exposure to NDMA can occur through ingestion of food, water, or medication containing nitrosamines.<sup>90</sup>

308. Exposure to high levels of NDMA has been linked to liver damage in humans.<sup>91</sup> Anecdotally, NDMA has also been used in intentional poisonings.<sup>92</sup>

309. According to the Agency for Toxic Substances and Disease Registry, “NDMA is very harmful to the liver of humans and animals. People who were intentionally poisoned on one or several occasions with unknown levels of NDMA in beverage or food died of severe liver damage accompanied by internal bleeding.”<sup>93</sup>

310. Other studies showed an increase in other types of cancers, including but not limited to stomach, colorectal, intestinal, kidney, liver, and other digestive tract cancers.

311. On July 27, 2018, the FDA put out a press release, explaining the reason for its concern regarding the presence of NDMA found in VCDs. In that statement, the FDA provided, in relevant part:

NDMA has been found to increase the occurrence of cancer in animal studies...Consuming up to 96

---

<sup>90</sup> *Id.*

<sup>91</sup> *Id.*

<sup>92</sup> See Chase Purdy, *A common blood-pressure medicine is being recalled because of a toxic ingredient*, QUARTZ (July 18, 2018), <https://qz.com/1330936/the-fda-is-recalling-a-common-blood-pressure-drug-because-it-was-mixed-with-ndma/>.

<sup>93</sup> U.S. Public Health Service, *Toxicological Profile For N-Nitrosodimethylamine* (Dec 1989), <https://www.atsdr.cdc.gov/toxprofiles/tp141.pdf>.

nanograms NDMA/day is considered reasonably safe for human ingestion.

...

The amounts of NDMA found in the recalled batches of valsartan exceeded these acceptable levels.<sup>94</sup>

312. The Environmental Protection Agency classified NDMA as a probable human carcinogen “based on the induction of tumors at multiple sites in different mammal species exposed to NDMA by various routes.”<sup>95</sup>

313. The World Health Organization’s (“WHO”) International Agency for Research on Cancer classifies NDMA as one of sixty-six agents that are “probably carcinogenic to humans” (Classification 2A). The FDA’s 2008 Guidance for Industry titled “Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches” identified nitrosamines including NDMA as having extremely high carcinogenic potency, thus excluding nitrosamines from the threshold approach to control of genotoxic impurities. Similarly, European Medicines Agency’s Guideline on Limits of Genotoxic Impurities in effect from January 1, 2007 to January 31, 2018 included nitrosamines in a group of structural

---

<sup>94</sup> FDA, FDA UPDATES AND PRESS ANNOUNCEMENTS ON ANGIOTENSIN II RECEPTOR BLOCKER (ARB) RECALLS (VALSARTAN, LOSARTAN, AND IRBESARTAN), <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan> (last visited June 13, 2019).

<sup>95</sup> EPA, *Technical Fact Sheet – N-Nitroso-dimethylamine (NDMA)* (Nov. 2017), [https://www.epa.gov/sites/production/files/2017-10/documents/ndma\\_fact\\_sheet\\_update\\_9-15-17508.pdf](https://www.epa.gov/sites/production/files/2017-10/documents/ndma_fact_sheet_update_9-15-17508.pdf).

groups described as high potency genotoxic carcinogens, “to be of such high potency that intakes even below the Threshold of Toxicological Concern (“TTC”) would be associated with a high probability of significant carcinogenic risk.”

## 2. The Nitrosamine Contaminant NDEA

314. N-Nitrosodiethylamine, often referred to as NDEA, is a yellow, oily liquid that is soluble in water.<sup>96</sup>

315. Like NDMA, NDEA is also classified by DHHS and EPA as a probable human carcinogen and a known animal carcinogen.<sup>97</sup>

316. According to the U.S. Environmental Protection Agency, even short-term exposure to NDEA can damage the liver in humans. Animal studies also demonstrate that chronic ingestion of NDEA can cause liver tumors and other types of tumors as well, including in the kidneys.

317. Hematological effects were also reported in animal studies.<sup>98</sup>

---

<sup>96</sup> EPA, *Integrated Risk Information System: N-Nitrosodimethylamine*, <https://www.epa.gov/sites/production/files/2016-09/documents/n-nitrosodimethylamine.pdf>.

<sup>97</sup> Canada Department of Health, *Information Update - Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity* (Nov. 29, 2018), <https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/68448a-eng.php>; see also FDA, *FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm’s already recalled products* (Sept. 13, 2018), <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620499.htm>.

<sup>98</sup> EPA, *Integrated Risk Information System: N-Nitrosodimethylamine*, <https://www.epa.gov/sites/production/files/2016-09/documents/n-nitrosodimethylamine.pdf>.



318. Tests conducted on rats, mice, and hamsters demonstrated that NDEA has high-to-extreme toxicity from oral exposure.<sup>99</sup>

319. The New Jersey Department of Health notes that NDEA “should be handled as a CARCINOGEN and MUTAGEN – WITH EXTREME CAUTION.”<sup>100</sup>

320. The New Jersey Department of Health also states that “[t]here may be no safe level of exposure to a carcinogen, so all contact should be reduced to the lowest possible level.”<sup>101</sup>

321. The New Jersey Department of Health notes that NDEA is classified as a probable human carcinogen, as it has been shown to cause liver and gastrointestinal tract cancer, among others.<sup>102</sup>

322. The IARC of WHO classifies NDEA as one of sixty-six agents that are “probably carcinogenic to humans” (Classification 2A). The above cited FDA and EMA references apply to NDEA.

---

<sup>99</sup> *Id.*

<sup>100</sup> New Jersey Department of Health, *Right to Know Hazardous Substance Fact Sheet: N-Nitrosodiethylamine* (July 2008), <https://nj.gov/health/eoh/rtkweb/documents/fs/1404.pdf> (emphasis in original).

<sup>101</sup> *Id.*

<sup>102</sup> *Id.*

**3. Formation of NDMA and/or NDEA in Defendants’ Contaminated, Adulterated, Misbranded, and/or Unapproved VCDs**

323. NDMA and NDEA are both considered genotoxic compounds, as they both contain nitroso groups, which are gene-mutating groups.<sup>103</sup>

324. The reason Defendants’ manufacturing process produced these compounds is linked to the tetrazole group that most ARB drugs have, including VCDs. Solvents used to produce the tetrazole ring, such as N-Dimethylformamide (DMF), can result in the formation of drug impurities or new active ingredients, such as NDMA and NDEA, as a byproduct of the chemical reactions.<sup>104</sup>

325. The pharmaceutical industry has been aware of the potential for the formation of nitrosamines in pharmaceutical drugs at least as far back as 2005.<sup>105</sup>

326. The contaminated VCDs consumed by Plaintiffs and manufactured, labeled, marketed, distributed, and/or sold by Defendants was not therapeutically equivalent to their RLDs, and was not manufactured in compliance with cGMPs.

---

<sup>103</sup> Ketan Agravat, *Nitroso Impurities In Valsartan: How Did We Miss Them?*, PHARMACEUTICAL ONLINE (Oct. 30, 2018), <https://www.pharmaceuticalonline.com/doc/nitroso-impurities-in-valsartan-how-did-we-miss-them-0001>.

<sup>104</sup> *Id.*

<sup>105</sup> Lutz Muller et al., *A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity*, REGULATORY TOXICOLOGY & PHARMACOLOGY 44 (2006) 198–211, <http://www.pharma.gally.ch/UserFiles/File/proofs%20of%20article.pdf>.

327. Defendants illegally sold contaminated, adulterated VCDs to Plaintiffs.

328. As a result of the consumption of NDMA and NDEA, Plaintiffs have been harmed, including, but not limited to, suffering cellular and genetic injury which creates and/or increases the risk that Plaintiffs will develop cancer.

329. Medical monitoring of Plaintiffs' conditions is necessary and required because of the nature of cancer, including the need for diagnosis and treatment as early as possible.

330. In the absence of medical monitoring to diagnose and treat cancer as early as possible, Plaintiffs and other Class Members are at an increased risk of suffering from the development and progression of cancer, with delayed diagnosis significantly increasing the risk of harm and death.

**N. Defendants Had Actual and/or Constructive Notice of NDMA and/or NDEA Contamination of their Contaminated, Misbranded, Adulterated and/or Unapproved VCDs**

331. The FDA has concluded that "NDMA and NDEA are probable human carcinogens and should not be present in drug products." As set forth herein, the VCDs manufactured by the API and Finished Dose Manufacturer defendants were found to contain dangerously high levels of nitrosamines, including NDMA and NDEA, sometimes reaching levels hundreds of times higher than the FDA's interim safety limits.

332. NDMA and NDEA are not FDA-approved ingredients for DIOVAN, EXFORGE, or their generic equivalents, and are not included in the USP or Orange Book requirements. Moreover, none of Defendants' VCDs identify NDMA, NDEA, or other nitrosamines as an ingredient on the products' labels or elsewhere. This is because these nitrosamines are probable human carcinogens, unreasonably dangerous active ingredients and are not approved to be included in valsartan API. Their inclusion in Defendants' VCDs renders the VCDs contaminated, misbranded and adulterated compared to and in violation of Defendants' warranties and representations.

333. If Defendants had not routinely disregarded reasonable and safe manufacturing practices, quality processes, and cGMPs, including those discussed throughout this Complaint, and the FDA's investigation reports and warning letters, and not deliberately manipulated and disregarded sampling data suggestive of impurities, and had fulfilled their quality assurance obligations, Defendants would have prevented outright, or identified the presence of these nitrosamine contaminants almost immediately upon manufacture including during the development process and thereafter.

334. ZHP changed its valsartan manufacturing processes in or about 2012. Other Manufacturer Defendants similarly changed their manufacturing processes

in material ways which resulted in the formation of NDMA or NDEA in their respective valsartan APIs.

335. According to the European Medicines Agency (“EMA”) – which has similar jurisdiction to that of the FDA – “NDMA was an unexpected impurity believed to have formed as a side product after [ZHP] introduced changes to its manufacturing process in 2012.”<sup>106</sup>

336. Most assuredly, NDMA and NDEA are not FDA-approved ingredients for DIOVAN, EXFORGE, or their generic equivalents. None of Defendants’ VCDs identifies NDMA, NDEA, or any other nitrosamine as an ingredient on the products’ labels or elsewhere. Their inclusion in Defendants’ VCDs renders the VCDs misbranded and adulterated compared to Defendants’ warranties and representations. Their inclusion in Defendants’ VCDs renders the VCDs misbranded and adulterated compared to Defendants’ warranties and representations.

337. If Defendants had not routinely disregarded the FDA’s cGMPs and deliberately manipulated and disregarded sampling data suggestive of impurities,

---

<sup>106</sup> See European Medicines Agency, *Update on Review of Recalled Valsartan Medicines* (August 2, 2018), [http://www.ema.europa.eu/ema/index.jsp?curl=pages/news\\_and\\_events/news/2018/08/news\\_detail\\_003000.jsp&mid=WC0b01ac058004d5c1](http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/08/news_detail_003000.jsp&mid=WC0b01ac058004d5c1).

or had fulfilled their quality assurance obligations, Defendants would have found the NDMA and NDEA contamination almost immediately.

338. 21 C.F.R. § 211.110 contains the cGMPs regarding the “Sampling and testing of in-process materials and drug products[.]” Subsection (c) states the following:

In-process materials shall be tested for identity, strength, quality, and purity as appropriate, and approved or rejected by the quality control unit, during the production process, e.g., at commencement or completion of significant phases or after storage for long periods.

21 C.F.R. § 211.110(c). The requirement was violated by the Defendants.

339. And as shown above, Defendants’ own quality control units are and were responsible for approving or rejecting drug products manufactured, processed, packed, or held under contract by each API manufacturer.

340. If these sampling-related and quality-control-related cGMPs were properly observed by Defendants, the nitrosamine contamination in Defendants’ VCDs would have been prevented outright, or discovered in 2012 (or perhaps earlier for other API manufacturers). Defendants were thus on (at minimum) constructive notice that their VCDs were contaminated, adulterated and/or misbranded as early as 2012.

341. However, there are indications that Defendants had actual knowledge of their VCDs' contamination with NDMA and NDEA and unacceptable lack of quality, and made efforts to conceal or destroy the evidence.

342. As alleged above, FDA investigators visited ZHP's facilities in May 2017. In the words of FDA inspectors, ZHP "invalidat[ed] [OOS] results [without] scientific justification" and did not implement "appropriate controls ... to ensure the integrity of analytical testing," and routinely disregarded sampling anomalies suggestive of impurities.

343. These discoveries by the FDA's investigators suggest that ZHP and Defendants were specifically aware of impurities in the drugs being manufactured by ZHP, including specifically contamination of Defendants' VCDs with NDMA. The efforts to manipulate data constituted an explicit effort to conceal and destroy evidence and to willfully and recklessly introduce contaminated, adulterated and/or misbranded VCDs into the U.S. market, with specific disregard for human health concerns. ZHP's lack of interest in protecting the health and safety was further demonstrated by its attempts to re-sell returned, contaminated API to countries other than the United States.

344. Defendants were or should have been aware of ZHP's manufacturing, quality, and cGMP violations as early as 2012, if not earlier.

345. Indeed, Defendant Solco and ZHP (as well as Huahai US) are owned by the same corporate parent, ZHP. All of these entities should be imputed with actual knowledge of ZHP's willful deviations from cGMPs because of their corporate affiliations and overlapping operations and employees or agents. For instance, Solco and Huahai US have offices in the same office building in Cranbury, New Jersey.

346. And yet, Defendants knowingly, recklessly, and/or negligently introduced contaminated, adulterated, and/or misbranded VCDs containing dangerous amounts of nitrosamines into the U.S. market. Defendants failed to recall their generic VCDs because they feared permanently ceding market share to competitors. And Defendants issued the "voluntary" recall of their VCDs only after the FDA had threatened an involuntary recall.

**O. Other Contaminants**

347. Testing and evaluation is ongoing of VCDs manufactured, distributed, or sold by Defendants. Besides NDMA and NDEA, ongoing investigation suggests other impurities, such as NMBA, may exist as well in the VCDs at issue.



**P. FDA Announces Voluntary Recall of Defendants' Contaminated, Adulterated and/or Misbranded VCDs**

348. On or about July 13, 2018, the FDA announced voluntary recalls by Defendants and other manufacturers for their VCDs manufactured by ZHP.<sup>107</sup> The recall is for products distributed as early as October 2015. However, as alleged above, it is likely that Defendants' VCDs manufactured beginning in 2012 and beyond were also contaminated with nitrosamines including NDMA and NDEA.

349. On or about July 27, 2018, the FDA announced expanded recalls of additional VCDs manufactured by Defendants and non-parties, and repackaged by third parties.<sup>108</sup>

350. As stated in the FDA's July 13, 2018 statement:

The U.S. Food and Drug Administration is alerting health care professionals and patients of a voluntary recall of several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure. This recall is due to an impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled products. However, not all products containing valsartan are being recalled. NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. The presence of NDMA was unexpected and is thought to be

---

<sup>107</sup> FDA News Release, FDA ANNOUNCES VOLUNTARY RECALL OF SEVERAL MEDICINES CONTAINING VALSARTAN FOLLOWING DETECTION OF IMPURITY, *at* <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613532.htm> (last accessed January 26, 2021).

<sup>108</sup> FDA, FDA UPDATES ON ANGIOTENSIN II RECEPTOR BLOCKER (ARB) RECALLS INCLUDING VALSARTAN, LOSARTAN AND IRBESARTAN, <https://www.fda.gov/Drugs/DrugSafety/ucm613916.htm> (last visited June 5, 2019).

related to changes in the way the active substance was manufactured.

351. Subsequently, the FDA announced numerous additional recalls of VCDs and other similar products manufactured, distributed, or sold by Defendants as well as non-parties.<sup>109</sup> The FDA has not released the results of its investigation into when Hetero, Mylan, and Aurobindo started manufacturing contaminated, adulterated, and/or misbranded VCDs.

**Q. Defendants' Warranties and Fraudulent and Deceptive Statements to Consumers Regarding Their Generic VCDs**

352. Each Defendant made and breached express and implied warranties and also made affirmative misrepresentations and omissions of material facts to consumers about their contaminated, adulterated, and/or misbranded VCDs.

353. Plaintiffs, including the Class Representatives named herein, are natural persons who are reasonably expected to use, consume, or be affected by the contaminated, adulterated and/or misbranded VCDs manufactured and sold by Defendants.

**1. Warranties Common to All Manufacturer Defendants**

354. The FDA maintains a list of "Approved Drug Products with Therapeutic Equivalence Evaluations" commonly referred to as the Orange

---

<sup>109</sup> *Id.*

Book.<sup>110</sup> The Orange Book is a public document; Defendants sought and received the inclusion of their VCD products in the Orange Book upon approval of their ANDAs. In securing FDA approval to market generic VCDs in the United States as an Orange Book-listed drug, Defendants were required to demonstrate that their generic VCDs were therapeutically, pharmaceutically, and bioequivalent to their RLDs.

355. Therapeutic equivalence for purposes of generic substitution is a continuing obligation on the part of the manufacturer. For example, according to the FDA's Orange Book, therapeutic equivalence depends in part on the manufacturer's continued compliance with cGMPs.

356. Each Defendant's VCD(s) is/are accompanied by an FDA-approved label. By presenting consumers with an FDA-approved VCD label, Defendants, as generic manufacturers, made representations and express or implied warranties to consumers and TPPs of the "sameness" of their products to the VCD's RLD, and that their products were consistent with the safety, quality, purity, identity, and strength characteristics reflected in the FDA-approved labels and/or were not contaminated, adulterated and/or misbranded. The representations and warranties

---

<sup>110</sup> FDA, APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS (ORANGE BOOK) SHORT DESCRIPTION, <https://www.fda.gov/drugs/informationondrugs/approveddrugs/approveddrugproductswiththerapeuticequivalenceevaluationsorangebook/default.htm> (last visited June 5, 2019).

in the labels and packaging included the designation of the VCDs as USP, and thus in compliance with the compendial standards.

357. Each Defendant's VCDs also contained patient information leaflets (sometimes referred to as medication guides), which were authored by the Manufacturer Defendants and specifically addressed to the patients.

358. These medication patient information leaflets or medication guides made express warranties about the VCDs, including the identifying the active or inactive ingredients, and that it was Valsartan and was the same as brand RLD.

359. By introducing their respective VCDs into the United States market as a therapeutic equivalent to their RLDs, USP designated, and with the FDA-approved label that is the same as that of the RLDs, Defendants represented and warranted to end users that their VCDs were in fact the same as and were therapeutically interchangeable with their RLDs. Much of the generic drugs supply chain, including the most critical components of that supply chain (end-user patients) rely on these representations and warranties.

360. In addition, each Defendant affirmatively misrepresented and warranted to consumers through their websites, brochures, and other marketing or informational materials that their VCDs complied with cGMPs and did not contain (or were not likely to contain) any ingredients besides those identified on the

products' FDA-approved labels. None suggested that dangerous, unacceptable genotoxic impurities including nitrosamines were or possibly could be included.

361. The presence of nitrosamines in Defendants' VCDs: (1) renders Defendants' VCDs non-bioequivalent (*i.e.*, not the same) to their RLDs and thus non-therapeutically interchangeable with them, thus breaching Defendants' express warranties of sameness; (2) was the result of gross deviations from cGMPs rendering Defendants' VCDs non-therapeutically equivalent to their RLDs, thus breaching Defendants' express warranties of sameness; and (3) results in Defendants' VCDs containing an ingredient that is not also contained in their RLDs, also breaching Defendants' express warranty of sameness (and express warranty that the products contained the ingredients listed on and met the criteria set forth on each Defendant's FDA-approved label). Each Defendant willfully, recklessly, or negligently failed to ensure their VCDs' labels and other advertising or marketing statements accurately conveyed information about their products, which were not the generic equivalent of the RLDs.

362. The presence of nitrosamines in Defendants' VCDs and Defendants' serial and willful failures to comply with cGMPs and other shortcomings in Defendants' generic drug manufacturing processes have resulted in Defendants' VCDs being contaminated, misbranded and adulterated compared to and in violation of Defendants' representations and warranties.

363. At all relevant times, Defendants have also impliedly warranted that their VCDs were merchantable and fit for their ordinary purposes.

364. Naturally, due to their status as probable human carcinogens as listed by both the IARC and the U.S. EPA, NDMA and NDEA are not FDA-approved ingredients in VCDs. The presence of NDMA and other similar nitrosamines or impurities in Defendants' VCDs means that Defendants have violated implied warranties to Plaintiffs and Class Members. The presence of NDMA or NDEA in Defendants' VCDs results in Defendants' VCDs being non-merchantable and not fit for its ordinary purposes (i.e., as a therapeutically interchangeable generic version of their RLDs), breaching Defendants' implied warranty of merchantability and/or fitness for ordinary purposes.

365. For these and other reasons, Defendants' VCDs are therefore dangerously contaminated, adulterated, misbranded, and/or unapproved, and it was illegal for Defendants' to have introduced such VCDs in the United States. *See* 21 U.S.C. §§ 331(a), 351(a)(2)(B), 331(g).

366. Contaminated, adulterated, misbranded, and/or unapproved VCDs contaminated with cancer-causing nitrosamine compounds are worthless. No reasonable consumer (including Plaintiffs), would have consumed or purchased these nitrosamine-laden VCDs, nor would any manufacturer knowingly market or sell VCDs contaminated with nitrosamines. Nor could they, as a nitrosamine

contaminated, adulterated, misbranded, and/or unapproved VCD cannot even be legally sold or purchased within the United States. At a minimum, contaminated, adulterated, misbranded, and/or unapproved VCDs were worthless. Further, contaminated, adulterated, misbranded, and/or unapproved VCDs do not possess the same safety and efficacy profile as their branded equivalents. As such, the VCDs were not what they were supposed to be.

367. Moreover, every consumer who purchased and ingested a contaminated VCD has been exposed to a nitrosamine, a carcinogenic agent with potent mutagenic properties that operates at the cellular and sub-cellular levels, that caused cellular and genetic injury creating and/or increasing the risk that Plaintiffs will develop cancer.

368. The recalls were meant to quickly remove unsafe products from the market. While FDA advised patients to continue taking VCDs, it only did so as an interim measure because of a potential shortage of the medication and the more immediate risks associated with untreated high blood pressure. Moreover, FDA's advice was only until pharmacists could find a replacement, or their doctor prescribed a different medication for the same condition.

369. In response to the recall, pharmacies and health care providers throughout the United States contacted affected patients to advise them of the

recall and to recommend that they contact their doctors to request a replacement or an alternative treatment option.

370. Because of the seriousness of the impurity—unsafe levels of a carcinogen— all or virtually all patients immediately stopped taking the tainted drug products after receiving notice of the recall. They were prescribed a safe alternative. The contaminated and potentially contaminated VCDs had no use and were discarded.

## **2. ZHP Defendants' Warranties**

371. On its January 29, 2019 website,<sup>111</sup> which was fully consistent with and representative of ZHP's representations and warranties throughout the entire period that ZHP was marketing and selling VCDs, ZHP stated that it “has established an independent, strict and sound quality mangement [sic] system in accordance with GMP.” ZHP further claims that it “ensure[s] that production is operated in accordance with GMP and product quality meets the required specifications,” and that ZHP's “workshops of formulation are designed in strict compliance with the international cGMP standard, where the most advanced automatic pharmaceutical production equipment in the world was introduced.”

372. Huahai US assisted Prinстон in obtaining approval of its ANDA for its VCDs.

---

<sup>111</sup> ZHP completely changed its website sometime in February or March 2019.



373. Prinston lists its valsartan as equivalent to Diovan on its website.<sup>112</sup>

Prinston's website, and its other marketing materials, have at all times relevant represented that the drugs sold by Prinston were manufactured by ZHP in accordance with the highest quality standards, and all cGMP requirements.

374. Furthermore, Solco states on the "About Solco" page of its website that "[b]y using the same active ingredients, [Solco] produce[s] products which are identical (equivalent) to the branded medication."<sup>113</sup> Solco's website, and its other marketing materials, have at all times relevant represented that the drugs sold by Prinston were manufactured by ZHP in accordance with the highest quality standards, and all cGMP requirements.

375. On the "Drug Safety" page of its website, Solco states that "Solco Healthcare is committed in providing ... its patients with high quality, FDA-approved generic medications."<sup>114</sup>

---

<sup>112</sup> Prinston, PRODUCT LIST, [http://www.prinstonpharm.com/Products\\_List.html#v](http://www.prinstonpharm.com/Products_List.html#v) (last visited Apr. 5, 2019).

<sup>113</sup> Solco, OVERVIEW, <http://solcohealthcare.com/about-solco.html> (last visited Apr. 5, 2019).

<sup>114</sup> Solco, TRADE PARTNER INFORMATION, <http://solcohealthcare.com/trade-partner-information.html#DrugSafety> (last visited Apr. 5, 2019).

376. Solco lists its valsartan products on its website with the statement that the “Reference Listed Drug” is “Diovan®” along with a link to download Solco’s valsartan Prescribing Information.<sup>115</sup>

### **3. Hetero Defendants’ Warranties**

377. In touting itself, Hetero has at all times relevant claimed that it was manufacturing high quality drugs in accordance with all applicable quality standards. For example, Hetero claimed that it has “over 36 advanced manufacturing facilities strategically located across the world –including India, USA, China, Russia, Egypt, Mexico and Indonesia. Approved by stringent global regulatory authorities, Hetero facilities have integrated quality systems and processes to ensure adherence to cGMP (current Good Manufacturing practices). They are also vertically integrated and can be utilized for large-scale production of APIs, formulations in various dosage forms rapidly. We make continuous investments in upgradation of manufacturing facilities with special emphasis on deploying advanced machinery and adopting latest technologies to comply with 21 CFR. Besides enabling us consistently produce high quality medicines at an affordable cost, it also helps us in passing through regulatory audits with relative

---

<sup>115</sup> Solco, VALSARTAN TABLETS, <http://www.solcohealthcare.com/product/valsartan-tablets#NDC-43547-367-03> (last visited Apr. 5, 2019).

ease. It is these advantages that make us the partner of choice for major global pharmaceutical companies.”<sup>116</sup>

378. Indeed, Hetero further describes itself as “a research-driven pharmaceutical company, is committed to the development, manufacturing and marketing of active pharmaceutical ingredients (APIs), intermediates and finished dosages. Today, Hetero is recognized as a world leader in process chemistry, API manufacturing, formulation development, manufacturing and commercialization. Hetero has around 18 state-of-the-art manufacturing facilities, which are cGMP compliant and have been approved by various Ministries of Health and regulatory authorities like US FDA, WHO, MCC - South Africa, MHRA-UK, TGA – Australia, PMDA – Japan, KFDA (Korea) among others. The company has a rich manufacturing product portfolio of over 200 products across a wide range of therapeutic categories. Hetero has a strong global presence in over 120 countries and has been offering API’s and generic formulations to partners across the globe.... Hetero, a privately-owned company, is recognized as one of the top 10 companies in the Indian pharmaceutical industry with an annual turnover of US\$ 1.2 billion. With a dedication and support of its 15,000 employees, Hetero

---

<sup>116</sup> Hetero, MANUFACTURING CAPABILITIES, <https://www.heteroworld.com/manufacturing.php> (last visited June 6, 2019).

continues its commitment to manufacture high-quality drugs and save millions of lives across the world.”<sup>117</sup>

379. Specifically, with respect to its manufacturing of API, Hetero purports to be “proficient in achieving regulatory approvals worldwide of both APIs and formulations. With an integrated quality system to ensure adherence to cGMP practices, Hetero is committed to quality and its manufacturing facilities are approved by global regulatory agencies. In addition, Hetero continues to invest in its state-of-the-art manufacturing facilities and capabilities to ensure that it is able to provide the highest level of quality standards in the pharmaceutical industry.”<sup>118</sup>

380. Hetero likewise goes to great lengths in describing its products as the same as the brand drug. It states that its generic drugs are “copies of brand-name drugs and are the same as those brand name drugs in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use. Health care professionals and consumers can be assured that FDA approved generic drug products have met the same rigid standards as the innovator drug. All generic drugs approved by FDA have the same high quality, strength, purity and stability as brand-name drugs. And, the generic manufacturing, packaging, and

---

<sup>117</sup> Camber, OUR PARENT COMPANY: HETERO, <http://camberpharma.com/about-us/hetero> (last visited June 6, 2019).

<sup>118</sup> Camber, GLOBAL RESOURCES, <http://camberpharma.com/global-resources> (last visited June 6, 2019).

testing sites must pass the same quality standards as those of brand name drugs....

Generic drugs look different because certain inactive ingredients, such as colors and flavorings, may be different. These ingredients do not affect the performance, safety or effectiveness of the generic drug. They look different because trademark laws in the U.S. do not allow a generic drug to look exactly like other drugs already on the market.... To find out if there is a generic equivalent for your brand-name drug, visit FDA.gov to view a catalog of FDA-approved drug products, as well as drug labeling. Since there is a lag time after generic products are approved and they appear in the "Orange Book", you should also consult the most recent monthly approvals for "First Generics" at FDA.gov.”<sup>119</sup>

381. Camber compares its valsartan to DIOVAN on its website’s product catalog.<sup>120</sup>

#### **4. Mylan Defendants’ Warranties**

382. Mylan has at all times relevant represented that its drugs were manufactured in accordance with strict quality standards. For example, a section of its website discussing generics, and claims that “[g]eneric pharmaceuticals are the same as existing approved brand-name drugs in active ingredient, dosage form,

---

<sup>119</sup> Camber, ABOUT GENERICS, <http://camberpharma.com/generics> (last visited June 6, 2019)

<sup>120</sup> Camber, PRODUCT, <http://camberpharma.com/products?&filter=V> (last visited January 26, 2021).

safety, strength, route of administration, quality and performance characteristics. Generic medications are just as safe and effective as their brand-name counterparts, and often cost less.”<sup>121</sup>

383. Mylan also guarantees that “consumers can be assured that FDA-approved generic products have the same rigid manufacturing standards as the innovator drug.”

384. According to its website as of November 2018, “Mylan offers one of the broadest portfolios of active pharmaceutical ingredients (API)—the ingredients responsible for the therapeutic effects of different medicines—to more than 100 countries. Quality begins at step one. Mylan uses an established testing and verification process to ensure the suitability of active ingredients used in our medicines. Direct access to API makes Mylan one of the few global generics companies with a comprehensive, vertically integrated supply chain and helps us maintain deep insight into diverse markets and therapeutic segments.... With a commitment to quality, state-of-the-art API manufacturing facilities, global regulatory accreditations, a strong pipeline and speed-to-market capabilities, Mylan is an ideal API partner.”<sup>122</sup>

---

<sup>121</sup> Mylan, GENERICS, <https://www.mylan.com/en/products/generics> (last visited January 26, 2021).

<sup>122</sup> Mylan changed this part of its website sometime after November 2018.

385. According to Mylan’s website, “[b]eing a manufacturer of API makes Mylan one of the few global generics companies with a comprehensive, vertically integrated supply chain” that Mylan touts as “provid[ing] us with an extra measure in the quality process that we can own[.]”<sup>123</sup>

386. Mylan’s online product catalog lists its generic VCDs as equivalent to their RLDs.<sup>124</sup>

## **5. Aurobindo Defendants’ Warranties**

387. At all times relevant, Aurobindo has represented and warranted that it manufactured drugs in accordance with strict quality standards. For example, Aurobindo’s website states that it is “[c]ommitted to Quality and Safety.”<sup>125</sup>

388. On January 6, 2015, Aurobindo announced that it had received FDA approval to manufacture and market valsartan, adding that valsartan is the “the generic equivalent to the reference listed drug product (RLD) Diovan®.”

---

<sup>123</sup> Mylan, ACTIVE PHARMACEUTICAL INGREDIENTS, <https://www.mylan.com/en/products/active-pharmaceutical-ingredients> (last accessed June 6, 2019).

<sup>124</sup> Mylan, PRODUCT CATALOG, <https://www.mylan.com/en/products/product-catalog/> (last visited June 6, 2019) (clicking on the relevant product shows the page and RLD reference for each VCD).

<sup>125</sup> Aurobindo, HOMEPAGE, <https://www.aurobindo.com/> (last visited June 5, 2019).

389. According to Aurobindo USA, “[a]s a truly integrated company, we assure continuity and quality from start to finish.”<sup>126</sup> Aurobindo also “[s]eek[s] to attain the highest quality standards.”<sup>127</sup>

390. Aurobindo USA’s website lists DIOVAN as its valsartan’s “Brand Reference.”<sup>128</sup>

391. Aurolife states, “[t]he Aurolife family consists of an experienced management team with expertise in manufacturing, R&D, Quality Assurance and Quality control, finance and regulatory affairs. Aurolife has 100,000 square feet state-of-the-art US FDA approved cGMP compliant manufacturing facility with an investment of over US \$50 million.”<sup>129</sup>

## **6. Teva Defendants’ Warranties**

392. At all times relevant, Teva has represented and warranted that it manufactured drugs in accordance with strict quality standards. For example,

---

<sup>126</sup> Aurobindo USA, AUROCONTROL, <https://www.aurobindousa.com/company/our-story/aurocontrol/> (last visited June 5, 2019).

<sup>127</sup> Aurobindo USA, OUR STORY, <https://www.aurobindousa.com/company/our-story/> (last visited June 5, 2019).

<sup>128</sup> Aurobindo USA, VALSARTAN TABLETS, <https://www.aurobindousa.com/product-category/valsartan-tablets/> (last visited June 5, 2019).

<sup>129</sup> Aurolife, ABOUT AUROLIFE, <http://aurolifepharma.com/aboutus.html> (last visited June 5, 2019).



Teva has a “Generics FAQs” on its website.<sup>130</sup> In response to the question “Are generic drugs safe?” Teva states the following:

A generic drug is bioequivalent to the original innovative drug and meets the same quality standards. The active ingredient, the content, the dosage form and the usage of a generic drug are similar to those of an innovative drug. Generic drugs are essentially the same as the original drug, but are offered at a lower price.

393. In response to the question “How do you ensure generic drug safety, having tried it in only a limited number of patients?” Teva states the following:

The generic product's active pharmaceutical ingredient (API) is identical to that of the innovative drug, its purity profile is similar and it is found to be bioequivalent; therefore its safety and efficacy are also comparable.

394. Similarly, under the webpage titled “Uncompromising Quality,” Teva states that it knows that its products affect patient health. Teva further states that it “guarantee[s] the quality of our products” through Teva’s “impeccable adherence to ... [cGMPs][.]”

395. Teva’s website states that “Our state-of-the-art manufacturing facilities feature the most advanced testing equipment to guarantee the quality of our products. Equipment is tested and certified, and every manufacturing process is

---

<sup>130</sup> Teva, PRODUCTS, [http://www.tevapharm.com/our\\_products/generic\\_qa/](http://www.tevapharm.com/our_products/generic_qa/) (last visited June 5, 2019).

validated. All supplier procedures are strictly supervised to ensure that only the highest grade materials are used in our products.”<sup>131</sup>

396. According to Teva, “[o]ur manufacturing network is continuously optimized so that our customers can have full confidence in our supply chain. This is enabled by high-volume, technologically-advanced distribution facilities. These facilities allow us to deliver new products swiftly and reliably. We continually review our capabilities and capacity. This ensures that we can consistently deliver best-in-class products. Our customers know that their end-consumers are receiving high-quality healthcare and wellness pharmaceuticals.”<sup>132</sup>

397. In a May 16, 2018 catalog of “all Teva and Actavis products,” Teva, Actavis, Teva USA, and Actavis Pharma all stated that their VCDs were “bioequivalent” to their RLDs.

398. Teva USA’s website states, “Teva’s commitment to quality is uncompromising and we manufacture according to the highest quality and compliance standards. This focus is evident at every stage of the development and production of our medicines. All of our manufacturing processes are validated and products are tested and certified, using state-of-the-art testing equipment

---

<sup>131</sup> Teva, COMPANY PROFILE: UNCOMPROMISING QUALITY, [https://www.tevapharm.com/about/profile/quality\\_assurance/](https://www.tevapharm.com/about/profile/quality_assurance/) (last visited June 5, 2019).

<sup>132</sup> *Id.*

throughout the manufacturing process designed to ensure adherence to the highest quality and compliance standards.”<sup>133</sup>

399. Teva USA’s Code of Conduct affirms, “To ensure we are in compliance and working in accordance with sound quality principles in our research laboratories, in our clinical trials, and in our manufacturing plants and distribution centers, we adhere to the systems and internal controls for ‘Good Operating Practices,’ or ‘GxP,’ including Good Laboratory Practices (GLP), Good Clinical Practices (GCP), Good Manufacturing Practices (GMP) Good Pharmacovigilance Practices (GVP) and Good Distribution Practices (GDP).”<sup>134</sup>

400. Teva USA maintains a Brand-to-Generic Medication Reference on its website.<sup>135</sup> Before its recall of VCDs, this Reference included VCDs and their RLD equivalents.

## **7. Warranties Common to All Retail Pharmacy Defendants**

401. Retail pharmacies are where consumers purchase and fill prescriptions for pharmaceuticals. As a result, retail pharmacies and consumers have direct privity of contract. With each sale of prescription drugs, retail pharmacies

---

<sup>133</sup> Teva USA, ABOUT TEVA: QUALITY YOU CAN TRUST, <https://www.tevausea.com/About-Teva/article-pages/quality/> (last visited June 5, 2019).

<sup>134</sup> Teva USA, TEVA CODE OF CONDUCT, <https://www.tevausea.com/About-Teva/article-pages/Code-of-Conduct/> (last visited June 5, 2019).

<sup>135</sup> Teva USA. PATIENTS: RESOURCES, <https://www.tevagenerics.com/patients/resources/> (last visited June 5, 2019).

impliedly warrant to consumers that the prescription drugs being sold to them are merchantable and/or fit for its ordinary uses.

402. Pharmacy Defendants receive shipments of pharmaceutical products, including VCDs, from the Wholesaler Defendants. Pharmacy Defendants then dispense these products into prescription bottles as needed. When filling a prescription bottle, Pharmacy Defendants affix a label with an electronic bar code that serves as a record of the product's description and details. For example, CVS states that it includes "a description of what the medication looks like on each and every prescription label. . .[and] a detailed drug description information sheet."<sup>136</sup>

403. Pharmacy Defendants also state that they implement quality assurance methods, including electronic prescribing, electronic pill imaging, and quality assurance training.<sup>137</sup> Accordingly, Pharmacy Defendants received shipments of VCDs from the Wholesaler Defendants and dispensed VCDs into prescription bottles. On each of these bottles, Pharmacy Defendants affixed a label and created an electronic record stating that the product was pure valsartan, when in fact it was adulterated and/or misbranded VCDs.

---

<sup>136</sup> <https://cvshealth.com/thought-leadership/ensuring-quality-and-safety-in-the-pharmacy>

<sup>137</sup> <https://cvshealth.com/thought-leadership/ensuring-quality-and-safety-in-the-pharmacy>

404. Each dispensation, affixing of a label, and creation of corresponding electronic record represents an explicit warranty made by the Pharmacy Defendants to Medical Monitoring Class Plaintiffs, that the dispensed product was pure valsartan when in fact, it was adulterated and/or misbranded VCDs. In each instance that the Pharmacy Defendants provided a prescription bottle containing VCDs to Plaintiffs, Pharmacy Defendants impliedly warranted that the dispensed product was pure valsartan when in fact it was adulterated and/or misbranded VCDs. At all times, Pharmacy Defendants intended that Medical Monitoring Class Plaintiffs rely on the representation that the dispensed prescription bottles of VCDs were pure.

405. By selling pharmaceutical prescription drugs in the stream of commerce, each retail pharmacy defendant warrants that the generic drugs for which they receive payments are the same as existing brand-named drugs in active ingredient, dosage form, safety, strength, methods of administration, quality, and performance characteristics. More generally, retail pharmacy defendants warrant that prescription drugs they sell are of a standard quality.

406. On account of the existence of these strict liability implied warranties, most retail pharmacies secure indemnification from manufacturer defendants for breach of such warranties.

407. Further, each retail pharmacy defendant is obligated under the Drug Supply Chain Security Act to quarantine and investigate potentially illegitimate (including contaminated, adulterated, and/or misbranded) drugs.

**8. Wholesale Distributor Defendants' Warranties**

408. Each distributor defendant is obligated under the Drug Supply Chain Security Act to quarantine and investigate potentially illegitimate (including contaminated, adulterated, and/or misbranded) drugs. Wholesaler Defendants knew or should have known, based on their risk assessments and the information provided or available from each Manufacturing Defendant, of the actual or potential adulteration, misbranding, or contamination of VCDs they purchased from Manufacturing Defendants. Wholesaler Defendants expressly or impliedly warranted the VCDs they sold were not adulterated, misbranded, or contaminated, when in fact that was not the case.

409. Wholesaler Defendants receive shipments of pharmaceutical products, including VCDs, from manufacturers such as the API and Finished Dose Manufacturers. In order to comply with the DSCSA, Wholesaler Defendants require manufacturers to prepare electronic records and manifests that provide the details of the product being shipped.<sup>138</sup> These records are sometimes called

---

<sup>138</sup> 21 U.S.C. § 360eee.

“transaction data.”<sup>139</sup> For example, Cardinal Health requires manufacturers to provide Cardinal with a record of the product’s ship date, contents, NDC code, Lot number, and the name of the product itself.<sup>140</sup> When Wholesaler Defendants receive shipments of VCDs, they distribute these shipments into smaller pallets sometimes referred to as “totes,” which are then sent to the Pharmacy Defendants.<sup>141</sup>

410. To comply with the DSCSA, Wholesaler Defendants also prepare an electronic record or manifest, in which the Wholesaler Defendants warrant that the tote contains a certain product. For example, Cardinal Health provides Pharmacy Defendants with transaction data that describes the shipping date of the tote, the number of containers, the Lot Numbers, the NDC codes, the name of the API or Finished Dose Manufacturer, and the description of the product itself.<sup>142</sup> A sample record provided by Cardinal Health on its website includes an affirmative statement by Cardinal Health, warranting that “Cardinal Health has complied with

---

<sup>139</sup> <https://www.cardinalhealth.com/en/services/acute/pharmacy-services/pharmaceutical-distribution.html> (last accessed Apr. 6, 2021).

<sup>140</sup> <https://www.cardinalhealth.com/content/dam/corp/web/documents/brochure/CardinalHealth-transaction-data-elements-requirements.pdf>

<sup>141</sup> <https://www.cardinalhealth.com/content/dam/corp/web/documents/brochure/CARDINAL-HEALTH.Cold-Chain-Pallet-Shipper.pdf>

<sup>142</sup> <https://www.cardinalhealth.com/content/dam/corp/web/documents/brochure/CardinalHealth-DrugTransactionDataUserGuide.pdf>

each applicable subsection of FDCA Sec. 581(27)(A)-(G).”<sup>143</sup> The statement refers to the Drug Supply Chain and Security Act, 21 U.S.C. § 351 *et seq.*, which requires, *inter alia*, that wholesalers have practices and protocols in place to ensure the quality and integrity of the pharmaceuticals they distribute, and require them to affix labels on their totes that describe the product being distributed.<sup>144</sup>

411. The affirmative statement of compliance, as well as the creation and transmittal of the electronic transaction data record, represent an explicit warranty made by the Wholesaler Defendants to their downstream customers, including Medical Monitoring Class Plaintiffs, that the shipped product was pure valsartan when in fact, it was adulterated and/or misbranded VCDs. In each instance that the Wholesaler Defendants shipped a tote containing VCDs to the Pharmacy Defendants, the Wholesaler Defendants impliedly warranted that the shipped product was pure valsartan when in fact it was adulterated and/or misbranded VCDs.

412. At all times, Wholesaler Defendants intended that their downstream customers, including Medical Monitoring Class Plaintiffs, rely on the representation that the distributed totes of VCDs were pure.

---

<sup>143</sup> *Id.*

<sup>144</sup> 21 U.S.C. § 351(27)(A)-(G).



**a. Cardinal Defendants' Warranties**

413. Cardinal's Standards of Business Conduct state, "We have quality systems in place to ensure that we manufacture, handle, store and distribute products in accordance with applicable legal and regulatory requirements. Every employee is responsible for following our quality processes when working with the products we sell."<sup>145</sup> The Standards also require Cardinal to "[u]nderstand and comply with the policies that cover the manufacture, storage, handling and distribution of products we sell."<sup>146</sup>

**b. McKesson Defendants' Warranties**

414. McKesson's Code of Conduct provides that it only does "business fairly and with integrity."<sup>147</sup> McKesson touts that it "compl[ies] with applicable laws everywhere we do business around the world," and requires action by the company when it is "aware of (or even suspect[s]) illegal or unethical behavior or violations of the Code, other local policies or applicable laws."

---

<sup>145</sup> Cardinal, STANDARDS OF BUSINESS CONDUCT, <https://www.cardinalhealth.com/content/dam/corp/web/documents/fact-sheet/cardinal-health-standards-of-business-conduct-booklet-english.pdf> (last visited Apr. 5, 2019).

<sup>146</sup> *Id.*

<sup>147</sup> McKesson, CODE OF CONDUCT, <https://www.mckesson.com/documents/investors/mckesson-code-of-conduct/> (last visited June 5, 2019).

c. **AmerisourceBergen Defendants' Warranties**

415. AmerisourceBergen's Code of Ethics and Business Conduct states that the company shall engage in "fair dealing" and will not "take unfair advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts or any other unfair dealing practice."<sup>148</sup>

9. **Repackager and Relabeler Defendants' Warranties**

416. By selling drugs in the stream of commerce, each repackager and relabeler defendant warrants that the generic drugs they sell are same as existing brand-named drugs in active ingredient, dosage form, safety, strength, methods of administration, quality, and performance characteristics.

417. Further, each repackager and relabeler defendant is obligated under the Drug Supply Chain Security Act to quarantine and investigate potentially illegitimate (including adulterated and/or misbranded) drugs.

R. **Wholesalers and Retail Pharmacy Defendants' Obligations to Ensure that the Product they Sell and Distribute Throughout the Stream of Commerce is Not Suspected to be Adulterated or Misbranded and therefore Illegal to Sell**

418. The three leading wholesalers, Defendants McKesson, AmerisourceBergen and Cardinal Health, ("Wholesaler Defendants") dominate

---

<sup>148</sup> AmerisourceBergen, CODE OF ETHICS AND BUSINESS CONDUCT, <http://investor.amerisourcebergen.com/static-files/469bd747-6c88-405d-a6eb-00a9b82053d8> (last visited June 5, 2019).

close to 95% of the total market, a feat they achieved during the years that the VCDs were launched onto the market and sold.

419. This included an increase in revenues of over \$100 billion.

**Big Three Wholesalers, Market Share for U.S. Drug Distribution and Related Revenues, 2012 vs. 2018**

Company (Stock Ticker)	Share of Total U.S. Market <sup>1</sup>	
	2012	2018
AmerisourceBergen Corp. (ABC)	24%	34%
Cardinal Health, Inc. (CAH)	29%	26%
McKesson Corporation (MCK)	34%	35%
Other / Direct distribution	13%	5%
<b>Total share</b>	<b>100%</b>	<b>100%</b>
<b>Total distribution revenues (billions)<sup>2</sup></b>	<b>\$317.8</b>	<b>\$482.8</b>

Dollar figures in billions. Total may not sum due to rounding.  
 1. Revenue share based on calendar year. Note that fiscal years and segment definitions differ among the three companies. Share of revenue data includes certain related businesses that are not reported separately. Data exclude international drug distribution. Market share is not adjusted for acquisitions or divestitures.  
 2. Total market includes sales via wholesale distribution and direct sales by manufacturers.  
 Source: Drug Channels Institute analysis

This chart appears as Exhibit 11 in *The 2019–20 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors* (<https://drugch.nl/wholesale>)

 **DRUG CHANNELS**  
INSTITUTE

420. It is estimated that four out of every five drugs sold in the United States passes through one of the Wholesaler Defendants.

421. Given their unique position between the Manufacturer Defendants and the Retailer Defendants, the Wholesaler Defendants are uniquely situated in the supply chain, and provide valuable data both in terms up the upstream supply, as well as the downstream needs.

422. Wholesalers also increase their buying power in the larger drug supply chain by forming strategic partnerships with retail chains.

423. It is estimated that 90% of generic pharmaceuticals provided to consumers are procured through generic sourcing programs.

424. These generic sourcing programs include AmerisourceBergen's Walgreens Boots Alliance Development program, Cardinal's "Red Oak Sourcing" joint venture with CVS, and McKesson's ClarusOne Sourcing Services program.

425. Because these three entities control 90% or more of the generic market, this structure makes it difficult for generics to stay profitable, which in turns, leads generic manufacturers to either make serious changes to the manufacturing process to save cost, or leave the market.<sup>149</sup>

426. Indeed, in assessing the drug supply chain, the FDA cited the role of the market conditions created by the consolidation of market power from the Wholesaler Defendants has a cause for reduction of generic pharmaceutical company's motivation to "to invest in manufacturing quality."<sup>150</sup>

427. Manufacturer Defendants, including Defendant ZHP, often make presentations to both Wholesalers and Retailers before entering into contractual

---

<sup>149</sup> The generic drug industry has brought huge cost savings. That may be changing, Washington Post (Aug. 1, 2017) ([https://www.washingtonpost.com/business/economy/the-generic-drug-industry-has-brought-huge-costsavings-that-may-be-changing/2017/08/01/ee128d0a-68cf-11e7-8eb5-cbccc2e7bfbf\\_story.html](https://www.washingtonpost.com/business/economy/the-generic-drug-industry-has-brought-huge-costsavings-that-may-be-changing/2017/08/01/ee128d0a-68cf-11e7-8eb5-cbccc2e7bfbf_story.html))

<sup>150</sup> <https://www.fda.gov/media/131130/download>

arrangements with them for the purchase of bulk generic pharmaceutical products, including VCDs.

428. Employees at manufacturing companies, such as Defendants ZHP, Mylan, Teva, Aurobindo, and Hetero often met with Wholesalers and Retail Pharmacies seeking generic drug products at yearly industry conferences, including the National Association of Chain Drug Store (“NACDS”) Conference, the Healthcare Distribution Management Association (“HDMA”) Conference, the Generic Pharmaceutical Association (“GPhA”) Conference and the Efficient Collaborative Retail Marketing (“ECRM”) Conference.

429. Defendants Camber and Solco, as one example, each met with numerous wholesalers and Retailer Pharmacies, including the meetings described below, during the 2017 NACDS.

430. During such presentations and contractual negotiations, Wholesalers and Retail Pharmacies are afforded a unique opportunity to probe the manufacturers for their manufacturing practices in order to assess whether those manufacturing practices are up to the industry standard.

431. During these presentations made by the Manufacturer Defendants to Wholesalers and Retail Pharmacy customers, many Defendants often tout their track records with FDA inspections as part of describing their commitment to quality and the security of their supply chain.

432. As evidence of this due diligence the Wholesalers and Retail Pharmacy Defendants ostensibly do into the generic Manufacturers, many Wholesalers and Retailers bestow awards to Manufacturers they believe are abiding by best practices.

433. Receipt of these awards allows pharmaceutical manufacturers, including the Manufacturer Defendants in this case, to tout their industry vetted excellence to other participants in the drug supply chain.

434. Drugs entering the U.S. Supply Chain can pose a threat to public health and safety, especially if they are contaminated.

435. In 2008, contaminated heparin sourced from Chinese API resulted in the deaths of as many as 81 people.

436. This incident, and others, spurred the Congress to take action to improve the security of the U.S. drug supply chain.

437. These legislative efforts resulted in the Congressional enactment of the Drug Supply Chain Security Act (DSCSA) as part of the Drug Quality and Security Act (DQSA), aimed at addressing vulnerabilities in the drug supply train, and the facilitate the tracing of certain prescription drugs in finished dosage form through the supply chain.

438. As part of the DSCSA, Wholesaler Defendants and Retailer Pharmacy Defendants must develop verification methods to determine whether a product is a valid, suspect or illegitimate product.

439. Upon determining it is in possession of such a product, a participant in the secure drug supply chain must notify its trading partners in order to prevent further circulation of potentially compromised medication.

440. Authorized participants in the drug supply chain must also respond within 48 hours to requests from appropriate federal or state officials — in the event of a recall or for the purpose of investigating suspect product or an illegitimate product — for the transaction history of the pharmaceutical product.

441. Further, Wholesaler Defendants and Retail Pharmacy Defendants were obligated to comply with both cGMPs as well as Good Distribution Practices (“GDP”).

442. One aspect of the GDP is the implementation of a strong quality management system.

443. A robust quality management system program would include processes and procedures in place for managing risk, documentation, storage, transport and temperature.

444. The World Health Organization’s guidance on GDPs delineates that distributors should have adequate quality assurance measures in place to “ensure

adequate confidence that a product or service and its documentation will satisfy given requirements for quality.”<sup>151</sup>

445. These measures include “[a]uthorized procurement and release procedures for all administrative and technical operations performed should be in place to ensure that appropriate pharmaceutical products are sourced only from approved suppliers and distributed by approved entities. The approval should come from the competent authority of the individual country where the legal entity is registered.” *Id.*

446. This obligation did not end upon confirmation that a pharmaceutical supplier was manufacturing product in a facility that had been approved by a regulatory body. Indeed, Good Distributor Practices dictate that: “Distributors should from time to time conduct risk assessments to assess potential risks to the quality and integrity of pharmaceutical products. The quality system should be developed and implemented to address any potential risks identified. The quality system should be reviewed and revised periodically to address new risks identified during a risk assessment.” *Id.*

447. A good faith risk assessment would undoubtedly identify the dangers of product contamination in this case. The Defendants have long known that FDA

---

<sup>151</sup>[https://www.who.int/medicines/areas/quality\\_safety/quality\\_assurance/GoodDistributionPracticesTRS957Annex5.pdf](https://www.who.int/medicines/areas/quality_safety/quality_assurance/GoodDistributionPracticesTRS957Annex5.pdf)



oversight alone is inadequate to ensure the safety of prescription drug products. In fact, the FDA conceded as much in a 2015 report, stating that it “has no formal means for quality surveillance, except through inspections” and admitted that “inspection findings have not been a reliable predictor of the state of quality.”<sup>152</sup> The FDA further noted that “product recall and defect reporting data demonstrate unacceptably high occurrences of problems attributed to inherent defects in product and process design; these data further indicate failures in the implementation of manufacturing process scale-up as well as routine production.”<sup>153</sup>

448. The limitations of FDA oversight, and the accompanying risks to consumers, are particularly serious where the drugs are manufactured overseas, as is the case here. Repeated United States Government Accountability Office reports warned of the FDA’s lack of oversight concerning overseas manufacturers.<sup>154</sup> For example, a 2008 investigation estimated that only 8% of foreign drug manufacturing establishments subject to FDA inspection were inspected.<sup>155</sup>

449. Even where the FDA manages to inspect an overseas manufacturing facility, the value of these investigations pale in comparison to those conducted

---

<sup>152</sup> <https://www.fda.gov/media/91721/download>

<sup>153</sup> *Id.*

<sup>154</sup> <https://www.gao.gov/assets/gao-20-262t.pdf> p. 4

<sup>155</sup> *Id.*

onshore. For example, while most domestic manufacturing inspections are unannounced, overseas inspections are usually preceded by a warning of up to twelve weeks in advance.<sup>156</sup> Moreover, FDA inspectors utilize translators provided by the companies being inspected, further undermining the reliability of the information being questioned.

450. The risks associated with inadequately regulated overseas manufacturers were not abstract to the Defendants. The Ranbaxy Laboratories scandal, which featured an injunctive consent decree in early 2012<sup>157</sup> and 500 million dollar criminal and civil settlement for the distribution of adulterated drugs in 2013,<sup>158</sup> represented a warning more than sufficient to put the Defendants on constructive notice.

451. In light of well-documented regulatory enforcement failures, numerous prescription drug recalls, and high-profile cases of adulterated drugs, the Wholesaler Defendants and Retail Pharmacy Defendants knew very well that the drug products they sold presented serious risks of contamination.

---

<sup>156</sup> <https://www.gao.gov/assets/gao-20-262t-highlights.pdf>

<sup>157</sup> <https://wayback.archive-it.org/7993/20170113105916/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289224.htm> (FDA Press Release)

<sup>158</sup> <https://www.justice.gov/opa/pr/generic-drug-manufacturer-ranbaxy-pleads-guilty-and-agrees-pay-500-million-resolve-false>

452. Even where prescription drug products are produced without adulteration, the risk of contamination in the supply chain remains. As a result, the testing of prescription drug products before sale to consumers is doubly important. David Light, CEO of the retail pharmacy Valisure testified before the Senate on June 2, 2020 and explained his company's rationale for testing drugs as follows:

“A useful metaphor for understanding the immense complexity of the drug supply chain and the critical need for independent analysis is to think of a bottle of medication like a used car. When you go to pick up a medication from your local pharmacy, it will often be a year or two old, have traveled thousands of miles, and touched dozens of hands all around the world. No one who buys a used car is satisfied to know that the original manufacturer vouched for its quality. Buyers want a Carfax report; a 100-point inspection on that specific car, or more. None of that transparency is available for medications. To ensure quality, we must do more than just review a manufacturer's paperwork and facilities: we need independent chemical analysis of the medication itself.”<sup>159</sup>

## 2. **Defendant McKesson**

453. At all times relevant, McKesson has represented and warranted that it sells drugs manufactured in accordance with quality standards. For example, and consistent with representations throughout the relevant time period, on its website, McKesson touts that it complies with “applicable laws and regulations concerning

---

159

[https://www.finance.senate.gov/imo/media/doc/02JUN2020.VALISURE.LIGHT.S  
TMNT.pdf](https://www.finance.senate.gov/imo/media/doc/02JUN2020.VALISURE.LIGHT.STMNT.pdf)

product quality in the countries where we do business. These include the Drug Supply Chain Security Act in the U.S., the Food and Drugs Act in Canada, and the Good Distribution Practice and Good Manufacturing Practice guidelines in Europe.

454. These laws and regulations commit us to keeping our products traceable, handling hazardous products appropriately and continuing to work with authorized trading partners.”<sup>160</sup>

455. McKesson further proudly proclaims that “suppliers must agree to the McKesson Sustainable Supply Chain Principles (MSSP). The MSSP covers compliance with appropriate laws along with adherence to our strict policies on protecting workers, preparing for emergencies, identifying and managing environmental risk, and protecting the environment.”

456. McKesson also claims these quality assurance efforts are ongoing: “Adherence by suppliers to MSSP is not optional. McKesson Global Procurement & Sourcing Limited (MGPSL) is stringent in regard to remediation efforts. These are made by suppliers when audits reveal any gaps in working conditions, health and safety, or environmental standards. To maintain high sustainable principles

---

<sup>160</sup> <https://www.mckesson.com/documents/about-mckesson/corporate-citizenship/fy18-mckesson-corporate-responsibility-report/> (2018 McKesson Corporate Responsibility Report)

standards in factories we purchase products from, we follow up periodically on initial audits and closely monitor corrective actions.”

457. McKesson repeated their primary concern in making sure that patients are not exposed to “counterfeit and harmful drugs” in a letter to the HHS Secretary opposing a change in the DSCSA.

458. In fact, in briefing before Congress, McKesson described itself as “protecting the safety and security of the supply chain.”<sup>161</sup>

459. However, in practice, McKesson’s oft touted quality assurance programs in place to monitor the facilities and suppliers it was sourcing its VCDs from was woefully lacking.

460. For instance, McKesson has the unenviable position of being the first Wholesaler to receive a warning letter from the FDA for non-compliance with the DSCSA.<sup>162</sup>

461. During a twenty-four day inspection of McKesson’s corporate headquarters, the FDA observed failures in having quality systems in place to

---

<sup>161</sup> <https://www.warren.senate.gov/imo/media/doc/2018-08-17%20Response%20from%20PBMs%20and%20Drug%20Distributors.pdf>

<sup>162</sup> <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mckesson-corporation-headquarters-2719-565854-02072019>

enable regulatory compliance and were deficient in identifying, or quarantining suspect or illegitimate product.<sup>163</sup>

462. The FDA further found that McKesson did not had an adequate policy in place regarding suspect or illegitimate product.<sup>164</sup>

463. McKesson, for its part, recognized that these deficiencies were only the tip of the iceberg, and stated that the “specific incidents referenced in the Warning Letter and the underlying FDA Form 483 issued on July 3, 2018, are only examples of deficiencies” and conceded that McKesson did not provide “sufficient information” during its FDA inspection.<sup>165</sup>

464. McKesson also entered into arrangements with Retail Pharmacies including Defendant Rite Aid, Defendant Walmart, and others, to provide generic drug sourcing services for these retailers.

465. McKesson failed to ensure that the VCDs it purchased from Manufacturer Defendants were properly made in a cGMP-compliant manner, non-contaminated, unadulterated, and not misbranded.

466. Ordinary diligence by McKesson would have revealed that the VCDs it purchased from Manufacturer Defendants were improperly made, contaminated,

---

<sup>163</sup> FDA Form 483 for July 25-July 3, 2018 Inspection of McKesson Corporate Headquarters.

<sup>164</sup> *Id.*

<sup>165</sup> <https://www.mckesson.com/documents/about-mckesson/corporate-citizenship/fda-warning-letter-response/>

adulterated, or misbranded. For example, McKesson knew or should have known that Manufacturer Defendants utilized different manufacturing and quality practices or controls than those used by the brand-reference drug manufacturer, on account of the public availability of the regulatory submissions on file with the FDA, the information available to McKesson upon request to each Defendant Manufacturer, the information available to McKesson upon request to manufacturers of Diovan or other valsartan, and the price differential between Manufacturer Defendants' VCDs and other properly made, non-contaminated, non-adulterated, or non-misbranded valsartan.

467. But for McKesson's wrongful actions or inactions, at a minimum, at least some of the product used by Plaintiffs Judson, Zehr, Kruk, Roger Tasker, Judy Tasker, Silberman, and others similarly situated, would not have been of improperly made, contaminated, adulterated, or misbranded VCDs. McKesson's wrongful actions or inactions were a substantial factor in Plaintiffs Judson, Zehr, Kruk, Roger Tasker, Judy Tasker, Silberman, and other similarly situated individuals' use of improperly made, contaminated, adulterated, or misbranded VCD.

**2. Defendant Cardinal Health**

468. At all times relevant, Cardinal Health has represented and warranted that it sells drugs manufactured in accordance with quality standards. For

example, and consistent with representations throughout the relevant time period, Cardinal Health proudly proclaims that it is their responsibility, as a distributor, to “provide a safe and secure channel to deliver medications of all kinds, from the hundreds of manufacturers who make them to the thousands of government-authorized pharmacies that fill doctors’ prescription for patients.”<sup>166</sup>

469. Cardinal describes the business practice of supplying “a safe, cost-efficient and secure channel” between the manufacturers who make drugs and the pharmacies who dispense them as Cardinal’s “obligation to society.”<sup>167</sup>

470. In a letter to Senator Elizabeth Warren, Cardinal claimed that because of their efforts, “[t]he supply chain for pharmaceuticals in the United States is as safe, secure, effective and efficient as anywhere in the world.”<sup>168</sup>

471. In Cardinal Health’s Vendor Code of Conduct, Cardinal mandates that all with whom they do business must follow the “industry practices” even if the legal requirements of the jurisdiction in which they are operating require less.<sup>169</sup>

---

<sup>166</sup>

<https://www.cardinalhealth.com/content/dam/corp/web/documents/infographic/cardinal-health-anti-diversion-infographic.pdf>

<sup>167</sup>

[https://s1.q4cdn.com/238390398/files/doc\\_financials/annual/2017/2017\\_Cardinal-Health\\_AR-FINAL.pdf](https://s1.q4cdn.com/238390398/files/doc_financials/annual/2017/2017_Cardinal-Health_AR-FINAL.pdf) (last accessed January 18, 2021)

<sup>168</sup> <https://www.warren.senate.gov/imo/media/doc/2018-08-17%20Response%20from%20PBMs%20and%20Drug%20Distributors.pdf>

<sup>169</sup>

<https://www.cardinalhealth.com/content/dam/corp/web/documents/Policy/cardinal-health-vendor-code-of-conduct-policy.pdf>



472. Moreover, Cardinal claims that in addition to its own obligation to society to provide “safe” channels for drug, they also are “continually working to provide [their] pharmacy customers with the resources they need to ensure the drugs in the supply chain are safe.”<sup>170</sup>

473. Cardinal describes its quality management practices as a “sustainable quality management system that...establishes a culture of engagement and participation where our employees are driven by the highest quality objectives.”<sup>171</sup>

474. For partners who Cardinal believes abide by the rigorous standards it sets forth, Cardinal Health bestows an annual “Supply Chain Excellence Award.”

475. Cardinal Health bestowed this honor to Defendant Solco in 2014, and 2017. Employees of Cardinal Health also met with Defendant Solco on numerous occasions throughout the class period, including at an October 2017 National Association of Chain Drug Stores meeting as well as the ECRM Meetings.

476. Cardinal Health also entered into agreements with large Retail Pharmacies, including Defendant CVS, to provide generic drug sourcing services for those retailers.

---

<sup>170</sup> <https://cardinalhealth.pr/includes/pdfs/DTDRGuideEN.pdf>

<sup>171</sup> <https://www.cardinalhealth.com/en/services/manufacturer/packaging-solutions/quality-assurance-and-compliance.html>

477. Cardinal Health failed to ensure that the VCDs it purchased from Manufacturer Defendants were properly made in a cGMP-compliant manner, non-contaminated, unadulterated, and not misbranded.

478. Ordinary diligence by Cardinal Health would have revealed that the VCDs it purchased from Manufacturer Defendants were improperly made, contaminated, adulterated, or misbranded. For example, Cardinal Health knew or should have known that Manufacturer Defendants utilized different manufacturing and quality practices or controls than those used by the brand-reference drug manufacturer, on account of the public availability of the regulatory submissions on file with the FDA, the information available to Cardinal Health upon request to each Defendant Manufacturer, the information available to Cardinal Health upon request to manufacturers of Diovan or other valsartan, and the price differential between Manufacturer Defendants' VCDs and other properly made, non-contaminated, non-adulterated, or non-misbranded valsartan.

479. But for Cardinal Health's wrongful actions or inactions, at a minimum, at least some of the product used by Plaintiffs Daring, O'Neill, Silberman, and others similarly situated would not have been of improperly made, contaminated, adulterated, or misbranded VCDs. Cardinal Health's wrongful actions or inactions were a substantial factor in Plaintiffs Daring, O'Neill,

Silberman, and other similarly situated individuals' use of improperly made, contaminated, adulterated, or misbranded VCD.

**3. Defendant AmerisourceBergen**

480. At all times relevant, AmerisourceBergen has represented and warranted that it sells drugs manufactured in accordance with quality standards. For example, and consistent with representations throughout the relevant time period, AmerisourceBergen Corp. states that it “understands the important role our supply chain plays in achieve our purpose of creating healthier futures.”<sup>172</sup>

481. In a letter to Senator Elizabeth Warren, AmerisourceBergen described their commitment to providing “secure” and “efficient” access to medicines, describing their operations at the “highest level” as helping patients “obtain medicines when and where they need them.”<sup>173</sup>

482. To this end, AmerisourceBergen purports to utilize a “third-party supply chain risk management tool” which allows AmerisourceBergen to ensure they are “sourcing [their] products from reliable, stable and responsible suppliers.

174

---

172

[https://s24.q4cdn.com/386340686/files/doc\\_downloads/2020/02/AmerisourceBergen-Supplier-Statement.pdf](https://s24.q4cdn.com/386340686/files/doc_downloads/2020/02/AmerisourceBergen-Supplier-Statement.pdf)

<sup>173</sup> <https://www.warren.senate.gov/imo/media/doc/2018-08-17%20Response%20from%20PBMs%20and%20Drug%20Distributors.pdf>

174

483. Employees of AmerisourceBergen met with Manufacturer Defendants, including Defendant Solco at the 2017 NACDS Annual Conference.

484. AmerisourceBergen also entered into agreements with large Retail Pharmacies, including Defendants Walgreens, to provide generic drug sourcing services for those retailers.

485. AmerisourceBergen failed to ensure that the VCDs it purchased from Manufacturer Defendants were properly made in a cGMP-compliant manner, non-contaminated, unadulterated, and not misbranded.

486. Ordinary diligence by AmerisourceBergen would have revealed that the VCDs it purchased from Manufacturer Defendants were improperly made, contaminated, adulterated, or misbranded. For example, AmerisourceBergen knew or should have known that Manufacturer Defendants utilized different manufacturing and quality practices or controls than those used by the brand-reference drug manufacturer, on account of the public availability of the regulatory submissions on file with the FDA, the information available to AmerisourceBergen upon request to each Defendant Manufacturer, the information available to AmerisourceBergen upon request to manufacturers of Diovan or other valsartan, and the price differential between Manufacturer Defendants' VCDs and other properly made, non-contaminated, non-adulterated, or non-misbranded valsartan.

487. But for AmerisourceBergen’s wrongful actions or inactions, at a minimum, at least some of the product used by Plaintiff Judson, and other similarly situated individuals would not have been of improperly made, contaminated, adulterated, or misbranded VCDs. AmerisourceBergen’s wrongful actions or inactions were a substantial factor in Plaintiff Judson and other similarly situated individuals’ use of improperly made, contaminated, adulterated, or misbranded VCDs.

**4. Defendant CVS Pharmacy**

488. At all times relevant, CVS has represented and warranted that it sells drugs manufactured in accordance with quality standards. For example, and consistent with representations throughout the relevant time period, CVS loftily claims that their “purpose” in helping people on a path to better health means ensuring “a safe working environment” for the “suppliers worldwide.”<sup>175</sup>

489. To achieve this goal CVS claims it was the first health care retailer to join the “Responsible Factory Initiative” which is dedicated to the corporate social responsibility in global supply chains.

490. This partnership includes training on what CVS purports are the “most critical risks” in the manufacturing supply chain, including health and safety,

---

<sup>175</sup> <https://cvshealth.com/news-and-insights/articles/strengthening-our-commitment-to-ethical-sourcing-across-our-supply-chain>

chemical management, environmental sustainability, recognizing forced labor and corrective action planning.

491. CVS proclaims that it maintains the “highest level of performance” in the areas of supply chain responsibility.<sup>176</sup>

492. In December of 2013, CVS entered into an agreement with Defendant Cardinal Health to form, at that time, the largest generic drug sourcing operating in the United States.<sup>177</sup>

493. CVS’s CEO described the agreement as allowing CVS to maintain its “leadership role in navigating the dynamic U.S. generics market.”<sup>178</sup>

494. CVS stated that all customers would “benefit from the enhanced volume and sourcing capabilities created by this partnership.”<sup>179</sup>

495. CVS failed to ensure that the VCDs it purchased from Manufacturer Defendants were properly made in a cGMP-compliant manner, non-contaminated, unadulterated, and not misbranded.

496. Ordinary diligence by CVS would have revealed that the VCDs it purchased from Manufacturer Defendants were improperly made, contaminated,

---

<sup>176</sup> <https://cvshealth.com/sites/default/files/2018-csr-full-report.pdf>

<sup>177</sup> <https://www.reuters.com/article/us-cvs-cardinalhealth/cvs-cardinal-health-form-u-s-generic-drug-venture-idUSBRE9B90VB20131210>

<sup>178</sup> <https://www.prnewswire.com/news-releases/cvs-caremark-and-cardinal-health-announce-creation-of-largest-generic-sourcing-entity-in-us-235240881.html>

<sup>179</sup> <https://www.prnewswire.com/news-releases/cvs-caremark-and-cardinal-health-announce-creation-of-largest-generic-sourcing-entity-in-us-235240881.html>

adulterated, or misbranded. For example, CVS knew or should have known that Manufacturer Defendants utilized different manufacturing and quality practices or controls than those used by the brand-reference drug manufacturer, on account of the public availability of the regulatory submissions on file with the FDA, the information available to CVS upon request to each Defendant Manufacturer, the information available to CVS upon request to manufacturers of Diovan or other valsartan, and the price differential between Manufacturer Defendants' VCDs and other properly made, non-contaminated, non-adulterated, or non-misbranded valsartan.

497. But for CVS's wrongful actions or inactions, at a minimum, at least some of the product used by Plaintiffs Daring, O'Neill, Silberman, Cotton, and other similarly situated individuals would not have been of improperly made, contaminated, adulterated, or misbranded VCDs. CVS's wrongful actions or inactions were a substantial factor in Plaintiffs Daring, O'Neill, Silberman, Cotton, and other similarly situated individuals' use of improperly made, contaminated, adulterated, or misbranded VCDs.

##### **5. Defendant Walgreens**

498. At all times relevant, Walgreens has represented and warranted that it sells drugs manufactured in accordance with quality standards. For example, and consistent with representations throughout the relevant time period, Walgreens

states that it understands that consumers “want to feel confident the products they use are safe for their intended purposes.”<sup>180</sup>

499. Walgreens claims it aims to do “business fairly and with integrity” which has led Walgreens to “drive responsible sourcing practices throughout our supply chain, protecting human rights and engaging with suppliers around ethical and environmental issues.”<sup>181</sup>

500. According to Walgreens, “[p]atient safety lies at the heart of our management of pharmacy operations, and we strive to be the industry leader by continuously seeking ways to minimize risks to patients in our dispensing, pharmacy services and advance and pharmacy supply chain operations.”<sup>182</sup>

501. Walgreens claims it engages in “ongoing supplier ethical compliance assessments” which includes “engaging with suppliers to improve when issues are detected.”

502. Walgreens also claims to screen suppliers against a matrix, which assess the suppliers’ management systems to discern whether they are operating in any way which violates Walgreens’ ethical sourcing commitments.<sup>183</sup>

---

<sup>180</sup> [https://www.walgreens.com/topic/sr/sr\\_product\\_integrity\\_home.jsp](https://www.walgreens.com/topic/sr/sr_product_integrity_home.jsp)

<sup>181</sup> [https://www.walgreensbootsalliance.com/sites/www/files/asset/Walgreens-Boots-Alliance-2019-Corporate-Social-Responsibility-Report\\_2.pdf](https://www.walgreensbootsalliance.com/sites/www/files/asset/Walgreens-Boots-Alliance-2019-Corporate-Social-Responsibility-Report_2.pdf)

<sup>182</sup> [https://www.walgreensbootsalliance.com/sites/www/files/asset/Walgreens-Boots-Alliance-2019-Corporate-Social-Responsibility-Report\\_2.pdf](https://www.walgreensbootsalliance.com/sites/www/files/asset/Walgreens-Boots-Alliance-2019-Corporate-Social-Responsibility-Report_2.pdf)

<sup>183</sup> [https://www.walgreensbootsalliance.com/sites/www/files/asset/Walgreens-Boots-Alliance-2019-Corporate-Social-Responsibility-Report\\_2.pdf](https://www.walgreensbootsalliance.com/sites/www/files/asset/Walgreens-Boots-Alliance-2019-Corporate-Social-Responsibility-Report_2.pdf)



503. Walgreens entered into an agreement with Defendant AmerisourceBergen in 2014 to begin sourcing generic drug products.<sup>184</sup>

504. The CEO of Walgreens called the agreement “an unprecedented and efficient global pharmacy-led, health and wellbeing network” and served Walgreens’ ultimate goal of becoming “the first choice in health and daily living for everyone in America and beyond.”

505. For its part, AmerisourceBergen described the agreement as “a unique opportunity to unlock value in the pharmaceutical supply chain by collaborating to leverage our proven strengths.”<sup>185</sup>

506. Walgreens failed to ensure that the VCDs it purchased from Manufacturer Defendants were properly made in a cGMP-compliant manner, non-contaminated, unadulterated, and not misbranded.

507. Ordinary diligence by Walgreens would have revealed that the VCDs it purchased from Manufacturer Defendants were improperly made, contaminated, adulterated, or misbranded. For example, Walgreens knew or should have known that Manufacturer Defendants utilized different manufacturing and quality practices or controls than those used by the brand-reference drug manufacturer, on

---

<sup>184</sup> <https://drugstorenews.com/pharmacy/walgreens-alliance-boots-announce-blockbuster-partnership-amerisourcebergen> (last accessed January 24, 2021)

<sup>185</sup> <https://drugstorenews.com/pharmacy/walgreens-alliance-boots-announce-blockbuster-partnership-amerisourcebergen>

account of the public availability of the regulatory submissions on file with the FDA, the information available to Walgreens upon request to each Defendant Manufacturer, the information available to Walgreens upon request to manufacturers of Diovan or other valsartan, and the price differential between Manufacturer Defendants' VCDs and other properly made, non-contaminated, non-adulterated, or non-misbranded valsartan.

508. But for Walgreens' wrongful actions or inactions, at a minimum, at least some of Plaintiff Berkson, and other consumers purchases of valsartan would not have been of improperly made, contaminated adulterated, or misbranded VCDs. Walgreens' wrongful actions or inactions were a substantial factor in Plaintiff Berkson, and other consumers' purchases of improperly made, contaminated, adulterated, or misbranded VCD.

## **6. Defendant Rite Aid**

509. At all times relevant, Rite Aid has represented and warranted that it sells drugs manufactured in accordance with quality standards. For example, and consistent with representations throughout the relevant time period, Ride-Aid states that its mission is to "improve the health and wellness of our communities

through engaging in experiences that provide our customers with the best products, services and advice to meet their unique needs.”<sup>186</sup>

510. To further their goal of providing their customers with the “best” products, on February 18, 2014, Rite Aid entered into a five-year agreement with Defendant McKesson to expand generic distribution.<sup>187</sup>

511. As part of the agreement, McKesson assumed responsibility for the sourcing and distribution of generic pharmaceuticals for Rite Aid as part of McKesson’s One Stop proprietary generics program.<sup>188</sup>

512. McKesson claimed that because of the strength of its “global sourcing and supply chain capabilities,” it would be able to deliver “the right products at the right time” to customers of Rite Aid.<sup>189</sup>

513. Rite Aid failed to ensure that the VCDs it purchased from Manufacturer Defendants were properly made in a cGMP-compliant manner, non-contaminated, unadulterated, and not misbranded.

---

<sup>186</sup> <https://www.riteaid.com/about-us/mission-statement> (last accessed January 24, 2021).

<sup>187</sup> <https://drugstorenews.com/pharmacy/mckesson-rite-aid-re-generic-distribution-deal-new-five-year-agreement> (last accessed January 24, 2021).

<sup>188</sup> <https://drugstorenews.com/pharmacy/mckesson-rite-aid-re-generic-distribution-deal-new-five-year-agreement>

<sup>189</sup> <https://drugstorenews.com/pharmacy/mckesson-rite-aid-re-generic-distribution-deal-new-five-year-agreement>

514. Ordinary diligence by Rite Aid would have revealed that the VCDs it purchased from Manufacturer Defendants were improperly made, contaminated, adulterated, or misbranded. For example, Rite Aid knew or should have known that Manufacturer Defendants utilized different manufacturing and quality practices or controls than those used by the brand-reference drug manufacturer, on account of the public availability of the regulatory submissions on file with the FDA, the information available to Rite Aid upon request to each Defendant Manufacturer, the information available to Rite Aid upon request to manufacturers of Diovan or other valsartan, and the price differential between Manufacturer Defendants' VCDs and other properly made, non-contaminated, non-adulterated, or non-misbranded valsartan.

515. But-for Rite Aid's wrongful actions or inactions, at a minimum, at least some of Plaintiff Butler, and other individuals' purchases of valsartan would not have been of improperly made, contaminated, adulterated, or misbranded VCDs. Rite Aid's wrongful actions or inactions were a substantial factor in Plaintiff Butler and other consumers' purchases of improperly made, contaminated, adulterated, or misbranded VCD.

7. **Defendant Walmart**

516. At all times relevant, Walmart has represented and warranted that it sells drugs manufactured in accordance with quality standards. For example, and

consistent with representations throughout the relevant time period, Walmart Pharmacy requires all suppliers that provide prescription pharmaceutical products to its Pharmacy Distribution Centers, either directly or indirectly, to abide by its Responsible Sourcing Standards for Suppliers.<sup>190</sup>

517. This includes requiring all suppliers to provide “transparency” about the facilities used to produce any materials sold in Walmart stores.<sup>191</sup>

518. Walmart claims that the transparency “allows Walmart to assess supply chain risk, monitor for compliance...and deploy resources in a risk-based manner.”<sup>192</sup>

519. In order to ship any pharmaceutical product into any of Walmart’s Pharmacy Distribution Centers, Walmart claims that the supplier must meet or exceeded all applicable laws and requirements, as well as adhere to any additional requirements stated in the agreement.<sup>193</sup>

---

<sup>190</sup>

<https://cdn.corporate.walmart.com/cc/a8/5def88ed41bd82ece9d82124c4ce/final-02212017-prescription-product-supplier-requirements.pdf>

<sup>191</sup>

[https://one.walmart.com/content/dam/responsiblesourcing/guidancedocuments/disclosure\\_policy\\_and\\_guidance-/Resource\\_DisclosurePolicyGuidance\\_ENG.pdf](https://one.walmart.com/content/dam/responsiblesourcing/guidancedocuments/disclosure_policy_and_guidance-/Resource_DisclosurePolicyGuidance_ENG.pdf)

<sup>192</sup>

[https://one.walmart.com/content/dam/responsiblesourcing/guidancedocuments/disclosure\\_policy\\_and\\_guidance-/Resource\\_DisclosurePolicyGuidance\\_ENG.pdf](https://one.walmart.com/content/dam/responsiblesourcing/guidancedocuments/disclosure_policy_and_guidance-/Resource_DisclosurePolicyGuidance_ENG.pdf)

<sup>193</sup>

<https://cdn.corporate.walmart.com/cc/a8/5def88ed41bd82ece9d82124c4ce/final-02212017-prescription-product-supplier-requirements.pdf>

520. Walmart also claims that “Facility disclosure is essential to achieving true supply chain transparency.” To this end, Walmart requires that each facility that engages in the manufacture, preparation, propagation, compounding, processing, packaging, labeling, storage, and distribution of sourced product must be disclosed to Walmart’s “Health & Wellness Product Safety” department.<sup>194</sup>

521. Walmart also requires any wholesalers, such as Defendants McKesson, Cardinal Health or AmerisourceBergen, to ensure the “integrity, legitimacy, and authenticity of prescription drug and device purchase orders and deliveries.”<sup>195</sup>

522. As part of this commitment, prior to sourcing materials from the Manufacturer Defendants, Walmart often required that pharmaceutical companies provide to it certificates of conformance for each product it purchased, information regarding CAPAs submitted to the FDA, inspection documents related to regulatory inspections, and audits conducted by third-party companies which contracted with Walmart.

---

194

<https://cdn.corporate.walmart.com/cc/a8/5def88ed41bd82ece9d82124c4ce/final-02212017-prescription-product-supplier-requirements.pdf> (last accessed January 26, 2021).

195

<https://cdn.corporate.walmart.com/cc/a8/5def88ed41bd82ece9d82124c4ce/final-02212017-prescription-product-supplier-requirements.pdf> (last accessed January 26, 2021).

523. Walmart also requires any wholesalers, such as Defendants McKesson, Cardinal Health or AmerisourceBergen, to ensure the “integrity, legitimacy, and authenticity of prescription drug and device purchase orders and deliveries.”<sup>196</sup>

524. Walmart partnered with Defendant McKesson to form ClarusOne, which is described as a partnership for “strategic pharmaceutical sourcing services” which builds on the “25-year history of the two companies working together.”<sup>197</sup>

525. ClarusOne states that it “ensures both companies have access to the right generic pharmaceuticals to meet customer demand at market competitive costs.”<sup>198</sup>

526. Multiple Manufacturer Defendants, including Defendant ZHP, made presentations to ClarusOne in an attempt to secure their business, and made representations regarding the quality of their facilities and their track record with regulatory inspections.

---

<sup>196</sup>

<https://cdn.corporate.walmart.com/cc/a8/5def88ed41bd82ece9d82124c4ce/final-02212017-prescription-product-supplier-requirements.pdf> (last accessed January 26, 2021).

<sup>197</sup> <https://www.clarusonesourcing.com/> (last accessed February 5, 2021)

<sup>198</sup> <https://www.clarusonesourcing.com/> (last accessed February 5, 2021)

527. However, despite what they claimed, Walmart failed to ensure that the VCDs it purchased from Manufacturer Defendants were properly made in a cGMP-compliant manner, non-contaminated, unadulterated, and not misbranded.

528. Ordinary diligence by Walmart would have revealed that the VCDs it purchased from Manufacturer Defendants were improperly made, contaminated, adulterated, or misbranded. For example, Walmart knew or should have known that Manufacturer Defendants utilized different manufacturing and quality practices or controls than those used by the brand-reference drug manufacturer, on account of the public availability of the regulatory submissions on file with the FDA, the information available to Walmart upon request to each Defendant Manufacturer, the information available to Walmart upon request to manufacturers of Diovan or other valsartan, and the price differential between Manufacturer Defendants' VCDs and other properly made, non-contaminated, non-adulterated, or non-misbranded valsartan.

529. But for Walmart's wrongful actions or inactions, at a minimum, at least some of the produced used by Plaintiffs Cotton, Roger Tasker, Judy Tasker, Zehr, Kruk, and other similarly situated individuals would not have been of improperly made, contaminated, adulterated, or misbranded VCDs. Walmart's wrongful actions or inactions were a substantial factor in Plaintiffs Cotton, Roger



Tasker, Judy Tasker, Zehr, Kruk, and other similarly situated individuals' use of improperly made, contaminated, adulterated, or misbranded VCDs.

**S. New Revelations Continue to Unfold About Other Manufacturing Plants**

530. The initial recall of Defendants' VCDs was only the tip of the iceberg. Just two weeks after the FDA's initial recall announcement, the FDA issued another announcement expanding the recall to other VCDs manufactured at another plant in India, and by other non-parties. On August 20, 2018 the FDA announced that it was going to test all VCDs for NDMA.<sup>199</sup> Because of Defendants' and non-parties' ongoing fraud and deception, the full scope of Defendants' and non-parties' unlawful conduct is not yet known. Indeed, grossly inadequate manufacturing processes have been observed in Aurobindo's facility as recently as *one month ago* (May 2019), nearly a year after the recall of the VCDs.

**T. Fraudulent Concealment and Tolling**

531. Plaintiffs' and Class Members' causes of action accrued, at the earliest, on the date the FDA announced the recall of Defendants' generic VCDs.

532. Alternatively, any statute of limitation or prescriptive period is equitably tolled on account of fraudulent concealment. Defendants each

---

<sup>199</sup> FDA, *Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research on FDA's ongoing investigation into valsartan impurities and recalls and an update on FDA's current findings* (Aug. 30, 2018), <http://freepdfhosting.com/1c7e5ed26e.pdf>.

affirmatively concealed from Plaintiffs and other Class Members their unlawful conduct. Each Defendant affirmatively strove to avoid disclosing their knowledge of their and other Defendants' cGMP violations with respect to their VCDs, and of the fact that their VCDs were adulterated and/or misbranded and contaminated with nitrosamines, and were not the equivalent of their RLDs.

533. For instance, no Defendant revealed to the public that their VCDs contained nitrosamines or was otherwise contaminated, adulterated, misbranded, and/or unapproved, or non-therapeutically equivalent to their RLDs until the FDA's recall announcement in July 2018. The inspection report which preceded the recall announcement was heavily redacted (including the names of the drugs affected by ZHP's cGMP violations), and prior inspection reports or warnings were not fully available to the public, if at all.

534. To the contrary, each Defendant continued to represent and warrant that their generic VCDs were the same as and therapeutically interchangeable with their RLDs.

535. For instance, Huahai US publicly announced on its website that, contrary to the FDA's pronouncements, that no impurity was discovered until June 2018.<sup>200</sup>

---

<sup>200</sup> Huahai US, PRESS RELEASE – UPDATE ON VALSARTAN API – A STATEMENT FROM THE COMPANY, <https://www.huahaius.com/media.html> (last visited June 5, 2019).

536. Because of this, Plaintiffs and other Class Members did not discover, nor could they have discovered through reasonable and ordinarily diligence, each Defendant's deceptive, fraudulent, and unlawful conduct alleged herein. Defendants' false and misleading explanations, or obfuscations, lulled Plaintiffs and Class Members into believing that the purchase and use of their VCDs were appropriate for what they believed to be quality, non-contaminated non-adulterated or misbranded drugs despite their exercise of reasonable and ordinary diligence.

537. As a result of each Defendant's affirmative and other acts of concealment, any applicable statute of limitations affecting the rights of Plaintiffs and other Class Members has been tolled. Plaintiffs and/or other Class Members exercised reasonable diligence by among other things promptly investigating and bringing the allegations contained herein. Despite these or other efforts, Plaintiffs were unable to discover, and could not have discovered, the unlawful conduct alleged herein at the time it occurred or at an earlier time so as to enable this Third Amended Master Complaint to be filed sooner.

#### **V. CLASS ACTION ALLEGATIONS**

538. Plaintiffs Berkson, Kruk, Martinez, Rives, Rodich-Annese, J. Tasker, and R. Tasker bring this action on behalf of themselves and, under Federal Rule of Civil Procedure 23(a), (b)(2), (b)(3), (g), and (c)(4), as representatives of the Medical Monitoring Independent Claim Class defined as follows:

All individuals residing in Alaska, Arizona, Colorado, Delaware, District of Columbia, Florida, Hawaii, Idaho, Illinois, Iowa, Maine, Massachusetts, Minnesota, Missouri, Montana, Nevada, New Hampshire, New Mexico, New York, North Dakota, Oregon, Pennsylvania, Rhode Island, South Dakota, Utah, Vermont, West Virginia, Wyoming and who consumed a sufficiently high Lifetime Cumulative Threshold of NDMA, NDEA, or other nitrosamine, in generic valsartan-containing drugs manufactured by or for Defendants and marketed in the United States and its territories and possessions, at least since January 1, 2012. This is the “Medical Monitoring Independent Claim Class.”

539. All Plaintiffs bring this action on behalf of themselves and, under Federal Rule of Civil Procedure 23(a), (b)(2), (g), and (c)(4), as representatives of the Medical Monitoring Remedy Class defined as follows:

All individuals residing in every state, territory, and possessions of the United States of America except Mississippi and who consumed a sufficiently high Lifetime Cumulative Threshold of NDMA, NDEA, or other nitrosamine, in generic valsartan-containing drugs manufactured by or for Defendants and marketed in the United States and its territories and possessions, at least since January 1, 2012. This is the “Medical Monitoring Remedy Class.”

540. For both the Medical Monitoring Independent Claim Class and Medical Monitoring Remedy Classes, the determination of whether the class member consumed a Lifetime Cumulative Threshold sufficient for class membership is based on objective and ascertainable factors.

541. Specifically, (A) at a dose of 320 mg, the class member needs to have taken a combination of three (3) months of ZHP API, OR 18 months of Hetero

API, OR 54 months of Mylan and/or Aurobindo API; (B) at a dose of 160 mg, the class member needs to have taken a combination of six (6) months of ZHP API, OR 32 months of Hetero API, OR 108 months of Mylan and/or Aurobindo API; (C) at a dose of 80 mg, the class member needs to have taken a combination of 12 months of ZHP API, OR 64 months of Hetero API, OR 216 months of Mylan and/or Aurobindo API; and (D) at a dose of 40 mg, the class member needs to have taken a combination of 24 months of ZHP API, OR 128 months of Hetero API, OR 432 months of Mylan and/or Aurobindo API;

542. The reference to combination above means that the class member need not have only taken Valsartan manufactured by only one manufacturer. For example, by way of illustration only, a class member who was prescribed 320 mg and who consumed two (2) months of ZHP APO and six (6) months of Hetero API qualifies.

543. Excluded from the Independent Claim and Remedy Classes, and from the other additional and alternative classes defined below, are Defendants and their subsidiaries and affiliates; all persons who make a timely election to be excluded from the Classes to the extent any class is an opt-out class or a hybrid opt-out class; governmental entities; and any judicial officers who preside over this case and their immediate family members. Also excluded from the Classes are those

consumers of VCDs who have been diagnosed with cancers as a result of taking Defendants' NDMA-, NDEA-, or other nitrosamine-contaminated VCDs.

544. Plaintiffs allege additional classes for all individuals in each United States territory, or possession, as well as individuals in the following states: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming. Plaintiffs further allege additional sub-classes for individuals in combinations of the above States, territories, and possessions to the extent Class Members from jurisdictions can be grouped together for purposes of class treatment given that Rule 23 and choice of law principles permit certification of subgroups of states and provide that relatively minor differences in state law that can be overcome by grouping similar laws together.<sup>201</sup>

---

<sup>201</sup> See also, e.g., *Phillips Petro. Co. v. Shutts*, 472 U.S. 797, 816 (1985) (“[t]here can be no injury in applying Kansas law if it is not in conflict with that of any other jurisdiction connected to this suit”).

545. These additional sub-classes include sub-classes of all individuals who, since at least January 1, 2012 to the present, consumed generic valsartan-containing drugs contaminated with NDMA, NDEA, or other nitrosamine, manufactured by or for Defendants and marketed in the United States and its territories and possessions. These include but are not limited to the following:

- a. Plaintiffs Judson and Hamel seeks to represent a California class or class(es) of states with similar applicable laws to California.
- b. Plaintiff Bell seeks to represent an Arkansas class or class(es) of states with similar applicable laws to Arkansas.
- c. Plaintiff Martinez seeks to represent a Colorado class or class(es) of states with similar applicable laws to Colorado.
- d. Plaintiff Zehr seeks to represent a Florida class or class(es) of states with similar applicable laws to Florida.
- e. Plaintiffs Kruk, Rives, and Berkson seek to represent an Illinois class or class(es) of states with similar applicable laws to Illinois.
- f. Plaintiff O'Neill seeks to represent a Kansas class or class(es) of states with similar applicable laws to Kansas.
- g. Plaintiff Silberman seeks to represent a New Jersey class or class(es) of states with similar applicable law to New Jersey.

h. Plaintiffs Fields, Daring, and Butler seek to represent a Maryland class or class(es) of states with similar applicable laws to Maryland.

i. Plaintiff Rodich-Annese seeks to represent a Pennsylvania class or class(es) of states with similar applicable laws to Pennsylvania.

j. Plaintiff Cotton seeks to represent a Texas class or class(es) of states with similar applicable laws to Texas.

k. Plaintiffs Roger and Judy Tasker seek to represent a West Virginia class or class(es) of states with similar applicable laws to West Virginia.

546. Collectively, the foregoing Independent Claim Class, the Remedy Class, and their alternative classes and are referred to as the “Classes.”

547. As alleged throughout this Complaint, the Defendants engaged in uniform and standardized conduct towards the Classes. The Defendants did not differentiate, in its degree of care or candor, its actions or inactions or in the content of its statements or omissions, among individual Class Members. The objective facts on these subjects are the same for all Class Members. Within each Claim for Relief asserted by the respective Classes, the same legal standards govern. Additionally, many states share the same legal standards and elements of proof, facilitating the certification of multi-state classes for some or all of the claims.



548. No actual conflict of laws exists between the laws of Plaintiffs' home states, and the laws of other Class Members' states. Or alternatively, any potential conflict is a false one. The lack of conflict, or the false conflict, between the laws of Plaintiffs' home states and the laws of other Class Members' states means it is appropriate to certify the Independent Claim and Remedy Classes under the laws of the aforementioned states, District of Columbia, and District of Puerto Rico.

549. Plaintiffs reserve the right to narrow or expand the foregoing class definition, or create subclasses, in light of future fact discovery, and including as the Court deems necessary. These may include, by way of example, bellwether classes or state or other sub-classes.

**B. The Classes Meet the Rule 23 Requirements**

550. Plaintiffs meet the prerequisites of Rule 23(a), (b), and (c) to bring this action on behalf of the Class and Classes.

551. **Numerosity (Rule 23 (a)(1)):** While the exact number of Class Members cannot be determined without discovery, the proposed Independent Claim and Remedy Classes potentially reach millions, and there is no proposed class with fewer than thousands or more of members. The Class Members are therefore so numerous that joinder of all members is impracticable as to the Classes and/or as to the subclasses.

552. **Commonality (Rule 23(a)(2)):** Even a single common question can drive a litigation and warrant certification. Here, material common questions of law and fact exist as to all Class Members, including but not limited to:

- a. Whether each Defendant's VCDs were contaminated with NDMA or NDEA and thus contaminated, adulterated, and/or misbranded;
- b. Whether Defendants violated cGMPs regarding the manufacture of their VCDs;
- c. Whether Defendants negligently or defectively manufactured the VCDs consumed by Plaintiffs and other Class Members;
- d. Whether Defendants misrepresented facts or failed to warn as to the contamination;
- e. Whether each Defendant made and breached express or implied warranties of "sameness" to Plaintiff and other Class Members regarding their generic VCDs, representing they were the same as their RLDs;
- f. Whether each Defendant affirmatively misrepresented that its VCDS were the same as their RLDs and thus therapeutically interchangeable, or omitted the fact that it was not;
- g. Whether each Defendant affirmatively misrepresented that it was compliant with cGMPs, or omitted the fact that it was not;

h. Whether Plaintiffs and other Class Members have suffered cellular and/or genetic injury and are at increased risk of developing cancer as a result of each Defendant's unlawful conduct;

i. Whether testing is available for the cancers to which Plaintiffs and the Class Members are at increased risk;

j. The nature and extent of medical monitoring, testing, examinations, and treatment necessary to address the risks created by Plaintiffs and other Class Members' consumption of VCDs contaminated with NDMA or NDEA;

k. When Plaintiffs' and other Class Members' claims for relief accrued;

l. Whether Defendants fraudulently concealed Plaintiff's and other Class Members' causes of action.

553. **Typicality (Rule 23(a)(3)):** Plaintiff's claims are typical of Class Members' claims. Plaintiff and other Class Members all suffered the same type of harm, including exposure to NDMA and/or NDEA, cellular and/or genetic injury, cancer, and/or an increased risk of developing cancer, but have not yet been diagnosed with cancer. Plaintiffs bring claims under the same legal and remedial theories as the class. Plaintiffs' claims arise out of the same set of facts and conduct as all other Class Members.

554. **Adequacy of Representation (Rule 23(a)(4) and Rule(g)):** Plaintiffs are committed to pursuing this action and have retained competent counsel experienced in pharmaceutical and products liability litigation, medical monitoring, consumer litigation, and class actions. Accordingly, Plaintiffs and their counsel will fairly and adequately protect the interests of Class Members. Plaintiffs' claims are coincident with, and not antagonistic to, those of the other Class Members and Plaintiffs will fairly and adequately represent the interests of Class Members

555. **Rule 23(b)(2):** Defendants have acted on grounds that apply generally to Class Members so that preliminary and/or final injunctive relief and corresponding declaratory relief is appropriate respecting the Classes as a whole. Each named Plaintiff and Class Representative has suffered exposure to VCDs at levels sufficient to necessitate the medical monitoring and other relief sought in this Complaint, and can establish such sufficiency through common proof and evidence.

556. **Rule 23(b)(3) Predominance and Superiority:** Here, the common questions of law and fact enumerated above predominate over the questions affecting only individual Class Members, and a class action is the superior method for fair and efficient adjudication of the controversy. Each named Plaintiff and Class Representative has suffered exposure to VCDs at levels sufficient to

necessitate the medical monitoring and other relief sought in this Complaint, and can establish such sufficiency through common proof and evidence. The likelihood that individual Class Members will prosecute separate actions for medical monitoring is remote due to the time and expense necessary to conduct such litigation. Serial adjudication in numerous venues is furthermore not efficient, timely or proper. Judicial resources will be unnecessarily depleted by resolution of individual claims. Joinder on an individual basis of thousands of claimants in one suit would be impractical or impossible. In addition, individualized rulings and judgments could result in inconsistent relief for similarly situated plaintiffs. Plaintiffs' counsel, highly experienced in pharmaceutical and product liability litigation, consumer litigation, class actions, and federal court litigation, foresee the efficient management of this case as a class action.

557. **Rule 23(c)(4) Issues Class:** To the extent the Court determines there are material differences in the relevant laws and that such differences present class manageability issues precluding Independent Claim and/or Remedy class certification for all purposes, Plaintiffs submit that an Independent Claim and a Remedy issue class is appropriate for determination of common material fact issues in the case, and are predicates for the entitlement to medical monitoring (such as exposure, contamination, misconduct, increased risk, existence of testing and benefit of testing, among others).

**VI. CLAIMS FOR RELIEF**

**FIRST CLAIM FOR RELIEF**

**NEGLIGENCE**

**(Individually and on Behalf of the Class)**

558. Plaintiffs repeat and re-allege the preceding paragraphs as if fully set forth herein.

559. Consistent with the Special Master's Opinion and Order, Dkt. No. 1614, Plaintiffs bring this claim against all Manufacturer, Finished Dose, and Repackager Defendants, and do not bring this claim against the Wholesaler or Retail Pharmacy Defendants. Plaintiffs bring this claim on behalf of themselves and absent class members residing in all U.S. jurisdictions except for Connecticut, Indiana, Kansas, Louisiana, Mississippi, New Jersey Ohio, Tennessee, and Washington.

560. Each Defendant owed a duty to Plaintiffs and the Classes to use and exercise reasonable and due care in the manufacturing, testing, distribution, labeling, marketing, warnings, disclosures, and sale of its VCDs.

561. Each Defendant owed a duty to Plaintiffs and the Classes to ensure that the VCDs it sold in the United States were not contaminated with NDMA or NDEA, contained only the ingredients stated in the label, were therapeutically equivalent to brand Diovan, and/or complied with cGMPs, and/or was not contaminated or adulterated.

562. Each Defendant owed a duty of care to Plaintiffs and the Classes because they were the foreseeable, reasonable, and probable users of VCDs. Each Defendant knew, or should have known, that its Valsartan product was contaminated with NDMA and/or NDEA, did not contain only the ingredients stated, was not therapeutically equivalent to brand Diovan and/or did not comply with cGMPs, and/or were contaminated, adulterated, and each was in the best position to uncover and remedy these shortcomings.

563. Defendants negligently manufactured the Valsartan at issue, causing contamination with NDMA and NDEA, which are carcinogens.

564. Each Defendant failed to discharge its duties of reasonable care. Each Defendant inadequately conducted or oversaw the manufacture, testing, labeling, distribution, marketing, warnings, disclosures, and sale of the VCDs. Each Defendant knew that the aforesaid wrongdoing would damage Plaintiffs and other Class Members.

565. Each Defendant negligently failed to promptly and immediately warn and disclose to Plaintiffs and other Class Members, and the medical and regulatory communities, of the potential and actual contamination with NDMA and/or NDEA as soon as it was discovered, delaying notice of this harmful and potentially fatal toxic exposure to a carcinogen and thus causing continued exposure to the

carcinogenic contamination, and delaying necessary testing, examinations, surveillance, and treatment.

566. Defendants' negligent or grossly negligent conduct created and then exacerbated an unreasonable, dangerous condition for Plaintiffs and other Class Members.

567. Defendants acted with recklessness and willful and wanton disregard for the health of Plaintiffs and other Class Members.

568. Each Defendant's own unreasonable, negligent actions and inactions were taken or not taken with willful and wanton disregard for the health of Plaintiffs and other Class Members and created a foreseeable risk of harm to Plaintiff and other Class Members.

569. As a direct and proximate result of each Defendant's negligent conduct, Plaintiffs and other Class Members have suffered cellular and genetic injury that creates and/or increases the risk that Plaintiffs will develop cancer, necessitating notice to all Class Members, sufficient funding for the tests and evaluations of each Class Member, and sufficient funding for necessary ongoing tests, evaluations, and treatment.

570. Plaintiffs and Class Members seek compensatory damages for, and the creation of a fund to adequately finance the costs of, medical monitoring procedures (1) to notify and alert all people exposed to NDMA or NDEA



contaminants as aforesaid of their exposure and the potential consequences, (2) to provide for necessary testing and screening including but not limited to blood tests, physical examinations, imaging, colonoscopies, endoscopies, and other similar methods for examination, biopsies, pathologic, histologic, and oncologic evaluations, oncologic, histologic, surgical and other necessary medical consultations, (3) to provide for necessary medical and surgical procedures for diagnosis and treatment, (4) to provide for all necessary evaluations and treatment, attorneys' fees, costs, interest, and such further relief as the Court deems equitable and just.

## **SECOND CLAIM FOR RELIEF**

### **NEGLIGENCE PER SE (Individually and on Behalf of the Class)**

571. Plaintiffs re-allege and incorporate the preceding paragraphs as if fully set forth herein.

572. Consistent with the Special Master's Opinion and Order, Dkt. No. 1614, Plaintiffs bring this claim against the Manufacturer, Finished Dose, and Repackager Defendants, and do not bring this claim against the Wholesaler or Retail Pharmacy Defendants. Plaintiffs bring this claim on behalf of themselves and absent class members residing in all U.S. jurisdictions except for: Arkansas, Arizona, California, Connecticut, Indiana, Kansas, Louisiana, Maine,

Massachusetts, Nebraska, New Jersey, Mississippi, Ohio, Rhode Island, Tennessee, Texas, and Washington.

573. Each Defendant owed a duty to Plaintiffs and the Class to use and exercise reasonable and due care in the manufacturing of its VCDs.

574. Each Defendant owed a duty to Plaintiffs and the Class to ensure that the VCDs it sold in the United States were therapeutically equivalent to brand Diovan and complied with cGMPs and were not adulterated or misbranded.

575. Each Defendant owed a duty to Plaintiffs and the Class because each state, territory, and possession has adopted /or adheres to federal cGMP and adulteration standards.

576. Each Defendant failed to comply with federal cGMPs and federal adulteration standards.

577. Each Defendant's own actions and inactions created a foreseeable risk of harm to Plaintiffs and the Class.

578. As a direct and proximate result of each Defendant's negligent conduct, Plaintiffs and other Class Members have suffered cellular and genetic injury which creates and/or increases the risk that Plaintiffs will develop cancer, necessitating notice to all Class Members, sufficient funding for the tests and evaluations of each Class Member, and sufficient funding for necessary ongoing tests, evaluations, and treatment.

579. Plaintiffs and Class Members seek compensatory damages for, and the creation of a fund to adequately finance the costs of, the creation of a fund to adequately finance the costs of medical monitoring procedures (1) to notify and alert all people exposed to NDMA or NDEA contaminants as aforesaid of their exposure and the potential consequences, (2) to provide for necessary testing and screening including but not limited to blood tests, physical examinations, imaging, colonoscopies, endoscopies, and other similar methods for examination, biopsies, pathologic, histologic, and oncologic evaluations, oncologic, histologic, surgical and other necessary medical consultations, (3) to provide for necessary medical and surgical procedures for diagnosis and treatment, (4) to provide for all necessary evaluations and treatment, attorneys' fees, costs, interest, and such further relief as the Court deems equitable and just.

### **THIRD CLAIM FOR RELIEF**

#### **NEGLIGENT MISREPRESENTATION AND OMISSION (Individually and on Behalf of the Class)**

580. Plaintiffs re-allege and incorporate the preceding paragraphs as if fully set forth herein.

581. Consistent with the Special Master's Opinion and Order, Dkt. No. 1614, Plaintiffs bring this claim against the Manufacturer, Finished Dose, and Repackager Defendants, and do not bring this claim against the Wholesaler or Retail Pharmacy Defendants. Plaintiffs bring this claim on behalf of themselves

and absent class members residing in all U.S. jurisdictions except for: Connecticut, Indiana, Kansas, Louisiana, New Jersey, and Tennessee.

582. Each Defendant had or undertook a duty to accurately and truthfully represent to the quality, nature, and characteristics of its VCDs.

583. Each Defendant further had the opportunity to investigate, make appropriate inquiries, and test the VCDs to ensure their safety.

584. The API and Finished Dose Manufacturer Defendants knew, or should have known that the VCDs they produced were not therapeutically equivalent to their RLDs and did not comply with cGMPs and/or were contaminated, adulterated, misbranded, and/or unapproved.

585. As set forth herein, the Wholesaler Defendants, and the Retail Pharmacy Defendants knew, or should have known that the VCDs were not therapeutically equivalent to their RLDs and did not comply with cGMPs and/or were contaminated, adulterated, misbranded, and/or unapproved.

586. Despite their awareness of the risk to consumers, and the information asymmetry between the Defendants and the patients utilizing the VCDs, each Defendant failed to exercise ordinary care in making representations (or in failing to disclose facts) concerning the quality, nature, and characteristics of its VCDs.

587. Each Defendant negligently misrepresented or omitted facts regarding the quality, nature, and characteristics of its VCDs. The Defendants affirmatively

misrepresented material facts including, *inter alia*, that their VCDs were therapeutically equivalent to their RLDs and/or complied with cGMPs and/or were not adulterated and/or misbranded. These misrepresentations were present on, among other things, the VCD labels, patient package inserts, medication guides, and instructions for use. The Defendants, as explained in Sections N.1-11, further misrepresented material facts by lauding their safety and risk mitigation approaches on their websites.

588. Each Defendant's statements were false at the time the misrepresentations were made (or at the time omissions were not made).

589. Each Defendant knew, or reasonably should have known, that its representations alleged herein were materially false or misleading, or that omission of material facts rendered such representations false or misleading. Each Defendant also knew, or had reason to know, that its misrepresentations and omissions would induce Class Members to make purchases of each Defendant's VCDs.

590. As a direct and proximate result of each Defendant's acts and omissions described herein, Plaintiffs and other Class Members have suffered harm, and will continue to do so.

591. Each Defendant's misrepresentations or omissions were material and a substantial factor in Plaintiffs' and other Class Members' consumption of VCDs.

592. Each Defendant intended its misrepresentations or omissions to induce Plaintiff and Class Members to consumer VCDs, or had reckless disregard for same.

593. But for these misrepresentations (or omissions), Plaintiffs and other Class Members would not have consumed Defendants' VCDS.

594. Plaintiffs and other Class Members were justified in relying on Defendants' misrepresentations or omissions. The same or substantively identical misrepresentations were communicated, and/or the same or substantively identical omissions were not communicated, to each Class Member.

595. As a direct and proximate result, Plaintiffs and other Class Members have been injured and suffered damages, in that Defendants' VCDs they consumed were contaminated with NDMA or NDEA and thus created and/or increased the risk that Plaintiff and other Class Members will develop cancer.

#### **FOURTH CLAIM FOR RELIEF**

##### **MEDICAL MONITORING (Individually and on Behalf of the Class)**

596. Plaintiffs repeat and re-allege the preceding paragraphs as if fully set forth herein.

597. Pursuant to the Court's Motion to Dismiss Order No. 5, *see* Dkt. No. 838 at 33, and consistent with the Special Master's Opinion and Order, Dkt. No. 1614, Plaintiffs bring an independent claim of medical monitoring against all

Defendants. Plaintiffs bring this claim on behalf of themselves and absent class members residing in all U.S. jurisdictions except for: Alabama, Arkansas, California, Connecticut, Georgia, Indiana, Kansas, Kentucky, Louisiana, Maryland, Michigan, Mississippi, Nebraska, New Jersey, Ohio, Oklahoma, South Carolina, Tennessee, Texas, Virginia, Washington, and Wisconsin. Should the law change in any of the foregoing states, Plaintiffs reserve the right to amend accordingly.

598. As a proximate result of Defendants' acts and omissions, the Class is at an increased risk of developing cancer above the normal base-level risk.

599. As alleged above, Defendant's Valsartan product was contaminated with NDMA/NDEA, an agent known to cause cancer in humans.

600. The Class Members may not develop cancer for many years.

601. The Class Members are at an increased risk as they consumed and/or ingested Defendants' VCDs for extended periods of time, some as many as several years, and as a result were exposed to a contaminant.

602. Upon information and belief, and based upon the internal and external investigations now made public, the Class is at an increased risk as they were exposed to NDMA/NDEA.

603. NDMA/NDEA is a hazardous, life-threatening, toxic substance that is known to cause cancer in humans.

604. The Class Members are at an increased risk of cancer as they were exposed to, consumed, and/or ingested Defendants' VCDs in quantities, and over periods of time sufficient to establish an exposure level that is considered to be hazardous to health, and that is considered to be sufficient to cause cancer or increase the risk of developing cancer.

605. The exposure was caused solely and proximately by Defendants' failure to adequately manufacture their VCDs to be therapeutically equivalent to brand Diovan; their failure to address discrepancies in batches/doses of Valsartan during quality control testing; their material misrepresentations, false statements, and other deceptive practices in continuing to claim that their Valsartan product was safe for consumption and/or ingestion and therapeutically equivalent to Diovan.

606. Defendants had a duty to the Class Members to: ensure and warrant that their Valsartan product was indeed therapeutically equivalent to brand Diovan as claimed and advertised to the Class Members; to disclose to the Class Members any defect, contamination, impurity or other potential health hazard known or discoverable by Defendants; and to ensure that their Valsartan product was not safe, reliable, and non-hazardous for human consumption—its intended purpose.

607. As alleged above, Defendants' own negligent acts and omissions resulted in cancer, or an increased risk of developing cancer for all members of the



Class. Cancer is a serious disease-causing life-threatening illness and debilitating cellular, genetic, and physical injury. Technology, analytical tools, test and/or monitoring procedures exist and are readily available to provide for the testing and early detection of cancer in patients. These technologies, tools tests and/or monitoring procedures are accepted and widely used by the scientific and medical community. These existing scientific methods include, but are not limited to, guaiac-based fecal occult blood test (gFOBT), fecal immunochemical test (FIT), FIT-DNA test, Flexible Sigmoidoscopy, Colonoscopy, and CT Colonography (Virtual Colonoscopy).

608. Early detection of cancer in patients is one of the best, and sometimes the only means to treat cancer such that it does not cause lasting, permanent injury, illness, or death.

609. Early detection of cancer in patients necessarily allows patients to avail themselves of myriad forms of treatment, each of which is capable to altering the course of the illness, such as bringing the cancer into remission, removal of any malignant tumors, and other treatment to alleviate injury.

610. The tests and treatments for the early detection and treatment of cancer must be prescribed by a qualified physician, and are conducted according to the latest, contemporary, and widely accepted scientific principles. Because NDMA/NDEA -associated cancer screenings may not be conducted with the

frequency necessary to identify cancer in the absence of exposure to NDMA/NDEA, the prescribed monitoring regime is different from that normally recommended in the absence of exposure. Plaintiff and Class Members require more frequent screenings not within the purview of routine medical exams.

611. The facts alleged above are sufficient or more than sufficient to plead a claim for medical monitoring as a cause of action.

612. Plaintiffs seek, on behalf of themselves and the Class Members whom they seek to represent, injunctive and monetary relief, including compensatory damages for, and the creation of a fund to adequately finance the costs of, medical monitoring procedures (1) to notify and alert all people exposed to NDMA or NDEA contaminants as aforesaid of their exposure and the potential consequences, (2) to provide for necessary testing and screening including but not limited to blood tests, physical examinations, imaging, colonoscopies, endoscopies, and other similar methods for examination, biopsies, pathologic, histologic, and oncologic evaluations, oncologic, histologic, surgical and other necessary medical consultations, (3) to provide for necessary medical and surgical procedures for diagnosis and treatment, (4) to provide for all necessary evaluations and treatment, attorneys' fees, costs, interest, and such further relief as the Court deems equitable and just.

**FIFTH CLAIM FOR RELIEF**

**PRODUCTS LIABILITY-MANUFACTURING DEFECT  
(Individually and on Behalf of the Class)**

613. Plaintiffs repeat and re-allege the preceding paragraphs as is fully set forth herein.

614. Consistent with the Special Master's Opinion and Order, Dkt. No. 1614, Plaintiffs bring this claim against the Manufacturer, Finished Dose, and Repackager Defendants, and do not bring this claim against the Wholesaler or Retail Pharmacy Defendants. Plaintiffs bring this claim on behalf of themselves and absent class members residing in all U.S. jurisdictions except for: Connecticut, Indiana, Kansas, Louisiana, Mississippi, New Jersey, Ohio, Tennessee, and Washington.

615. The Valsartan at issue was defectively manufactured, as the manufacturing process caused contamination of the Valsartan with NDMA and NDEA.

616. Valsartan contaminated with NDMA and/or NDEA is by definition defectively manufactured.

617. Defendants' conduct in defectively manufacturing Valsartan was reckless and taken with wanton and willful disregard for the health of Plaintiffs and other Class Members.

618. Defendants are strictly liable for the harm caused by or contributed to by the defectively manufactured Valsartan.

619. As a direct and proximate result, Plaintiffs and other Class Members have been injured and suffered damages, in that Defendants' VCDs they consumed were contaminated with NDMA or NDEA and thus created and/or increased the risk that Plaintiff and other Class Members will develop cancer.

620. Plaintiffs seek, on behalf of themselves and the Class Members, injunctive and monetary relief, including compensatory damages for, and the creation of a fund to adequately finance the costs of, medical monitoring procedures (1) to notify and alert all people exposed to NDMA or NDEA contaminants as aforesaid of their exposure and the potential consequences, (2) to provide for necessary testing and screening including but not limited to blood tests, physical examinations, imaging, colonoscopies, endoscopies, and other similar methods for examination, biopsies, pathologic, histologic, and oncologic evaluations, oncologic, histologic, surgical and other necessary medical consultations, (3) to provide for necessary medical and surgical procedures for diagnosis and treatment, (4) to provide for all necessary evaluations and treatment, attorneys' fees, costs, interest, and such further relief as the Court deems equitable and just.

**SIXTH CLAIM FOR RELIEF**

**FAILURE TO WARN  
(Individually and on Behalf of the Class)**

621. Plaintiffs repeat and re-allege the preceding paragraphs as is fully set forth herein.

622. Consistent with the Special Master's Opinion and Order, Dkt. No. 1614, Plaintiffs bring this claim against the Manufacturer, Finished Dose, and Repackager Defendants, and do not bring this claim against the Wholesaler or Retail Pharmacy Defendants. Plaintiffs bring this claim on behalf of themselves and absent class members residing in all U.S. jurisdictions except for: Connecticut, Indiana, Kansas, Louisiana, Mississippi, New Jersey, Ohio, Tennessee, and Washington.

623. Defendants failed to warn Plaintiffs and the Class Members, and the medical and regulatory communities, of the potential or actual contamination of the Valsartan with NDMA and NDEA, as soon as this was suspected or known.

624. Defendants' failure to warn was intentional, reckless, and in wanton and willful disregard for the rights and health of Plaintiffs and other Class Members, causing exposure to carcinogens and delay of diagnosis and treatment.

625. As a direct and proximate result of each Defendant's failure to warn or disclose information, Plaintiffs and other Class Members have been injured and suffered damages, in that Defendants' VCDs they consumed were contaminated

with NDMA or NDEA and thus created and/or increased the risk that Plaintiffs and other Class Members will develop cancer.

626. Plaintiffs seek, on behalf of themselves and the Class Members, injunctive and monetary relief, including compensatory damages for, and the creation of a fund to adequately finance the costs of, medical monitoring procedures (1) to notify and alert all people exposed to NDMA or NDEA contaminants as aforesaid of their exposure and the potential consequences, (2) to provide for necessary testing and screening including but not limited to blood tests, physical examinations, imaging, colonoscopies, endoscopies, and other similar methods for examination, biopsies, pathologic, histologic, and oncologic evaluations, oncologic, histologic, surgical and other necessary medical consultations, (3) to provide for necessary medical and surgical procedures for diagnosis and treatment, (4) to provide for all necessary evaluations and treatment, attorneys' fees, costs, interest, and such further relief as the Court deems equitable and just.

### **SEVENTH CLAIM FOR RELIEF**

#### **BREACH OF IMPLIED WARRANTY OF MERCHANTABILITY (Individually and on Behalf of the Class)**

627. Plaintiffs repeat and re-allege the preceding paragraphs as if fully set forth herein.

628. Defendants are merchants with respect to Valsartan within the laws of each jurisdiction.

629. Consistent with the Special Master's Opinion and Order, Dkt. No. 1614:

a. Plaintiffs do not bring this claim against any Defendant on behalf of themselves and absent class members in the following states: New Jersey, Connecticut, Kansas, Louisiana, Mississippi, Ohio, Tennessee, and Washington.

b. Plaintiffs bring this claim against Manufacturer Defendants on behalf of themselves and absent class members residing in all U.S. jurisdictions except for: Alabama, Arizona, Idaho, Kentucky, North Carolina, Ohio, Tennessee.

c. Plaintiffs bring this claim against Wholesaler Defendants on behalf of themselves and absent class members residing in all U.S. jurisdictions except for: Arizona, Connecticut, Georgia, Idaho, Illinois, Kentucky, New York, Oregon, Tennessee, Vermont, Wisconsin.

d. Plaintiffs bring this claim against Retail Pharmacy Defendants on behalf of themselves and absent class members residing in all U.S. jurisdictions except for: Alabama, Arizona, Arkansas, California, Connecticut, the District of Columbia, Florida, Georgia, Hawaii, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North

Dakota, Ohio, Pennsylvania, Puerto Rico, South Carolina, Tennessee, Texas, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

630. At all times relevant all fifty States and the District of Columbia and Puerto Rico have codified and adopted the provisions of the Uniform Commercial Code governing the implied warranty of merchantability and fitness for ordinary purpose: Ala. Code § 7-2-314; Alaska Stat. § 45.02.314; Ariz. Rev. Stat. Ann. § 47-2314; Ark. Code. Ann. § 4-2-314; Cal. Com. Code § 2314; Colo. Rev. Stat. § 4-2-314; Conn. Gen. Stat. Ann. § 42a-2-314; 6 Del. Code. § 2-314; D.C. Code. § 28:2-314; Fla. Stat. Ann. § 672.314; Ga. Code. Ann. § 11-2-314; Haw. Rev. Stat. § 490:2-314; Idaho Code § 28-2-314; 810 Ill. Comp. Stat. Ann. 5/2-314; Kan. Stat. Ann. § 84-2-314; Ky. Rev. Stat. Ann. § 355.2-314; La. Civ. Code Ann. Art. § 2520; 11 Me. Rev. Stat. Ann. § 2-314; Md. Code. Ann. § 2-314; Mass. Gen. Law Ch. 106 § 2-314; Mich. Comp. Laws Ann. § 440.2314; Minn. Stat. Ann. § 336.2-314; Miss. Code Ann. § 75-2-314; Mo. Rev. Stat. § 400.2-314; Mont. Code Ann. § 30-2-314; Nev. Rev. Stat. U.C.C. § 104.2314; N.H. Rev. Ann. § 382-A:2-314; N.J. Stat. Ann. § 12A:2-314; N.M. Stat. Ann. § 55-2-314; N.Y. U.C.C. Law § 2-314; N.C. Gen. Stat. Ann. § 25-2-314; N.D. Stat. § 41-02-314; Ohio Rev. Code Ann. § 1302.27; Okla. Stat. tit. 12A § 2-314; Or. Rev. Stat. § 72.3140; 13 Pa. C.S. § 2314; P.R. Laws. Ann. Tit. 31, § 3841, *et seq.*; R.I. Gen. Laws § 6A-2-314; S.C. Code Ann. § 36-2-314; S.D. Stat. § 57A-2-314; Tenn. Code Ann. § 47-2-314; Tex.



Bus. & Com. Code Ann. § 2-314; Utah Code Ann. § 70A-2-314; Va. Code § 8.2-314; Vt. Stat. Ann. 9A § 2-314; W. Va. Code § 46-2-314; Wash. Rev. Code § 62A-2-314; and Wyo. Stat. § 34.1-2-314.

631. Each Defendant was a merchant within the meaning of the above statutes.

632. Each Defendant's Valsartan product constituted "goods" or the equivalent within the meaning of the above statutes.

633. Each Defendant's VCDs were goods that were meant to be consumed.

634. Manufacturer Defendants placed their VCDs in sealed packaging or other closed containers and placed them on the market.

635. Plaintiffs and each member of the Class are natural persons who are reasonably expected to use, consume, or be affected by the adulterated and/or misbranded VCDs manufactured and sold by Defendants.

636. Plaintiffs and each member of the Class are the intended third-party beneficiary recipients of all contracts between the Manufacturer Defendants and the downstream Wholesaler or Retailer Defendants.

637. Plaintiffs and each member of the Class are the intended third-party beneficiary recipients of all contracts that included express warranties between the Wholesaler Defendants and the Retailer Defendants who sold the VCDs.

638. Plaintiffs and each member of the Class are the persons for whose benefit any promises made in the contracts that included express warranties between Manufacturer Defendants and the downstream Wholesaler or Retailer Defendants.

639. For Plaintiffs and each member of the classes in Florida, Georgia, Illinois, and Vermont, because the Manufacturer has made express warranties to Plaintiffs and each member of those classes, privity exists.

640. Each Defendant was obligated to provide Plaintiffs and other Class Members reasonably fit VCDs for the purpose for which the products were sold, and to conform to the standards of the trade in which Defendants are involved such that the products were not contaminated with a carcinogen and were of fit and merchantable quality.

641. Each Defendant knew or should have known that its VCDs were being manufactured and sold for the intended purpose of human consumption as a therapeutic equivalent to brand Diovan (or is strictly liable in the event of lack of actual or constructive knowledge), and impliedly warranted that their VCDs were of merchantable quality and fit for that purpose.

642. As set forth herein, each Defendant breached its implied warranty because each Defendant's VCDs were contaminated with a carcinogen and not of

merchantable quality, nor fit for the product's ordinary purpose, and did not conform to the standards generally applicable to such goods.

643. Defendants were provided notice of these issues by numerous discrepancies in quality control testing results, evidence of contaminants in analyses of batches/doses of Valsartan, investigations conducted internally and by the FDA and communications sent by the Class before or within a reasonable amount of time after Defendants

644. As a direct and proximate result of each Defendant's breach of implied warranty, Plaintiffs and other Class Members have been injured and suffered damages, in that Defendants' VCDs they consumed were contaminated with NDMA or NDEA and thus created and/or increased the risk that Plaintiff and other Class Members will develop cancer.

645. Plaintiffs seek injunctive and monetary relief, including compensatory damages for, and the creation of a fund to adequately finance the costs of, medical monitoring procedures (1) to notify and alert all people exposed to NDMA or NDEA contaminants as aforesaid of their exposure and the potential consequences, (2) to provide for necessary testing and screening including but not limited to blood tests, physical examinations, imaging, colonoscopies, endoscopies, and other similar methods for examination, biopsies, pathologic, histologic, and oncologic evaluations, oncologic, histologic, surgical and other necessary medical

consultations, (3) to provide for necessary medical and surgical procedures for diagnosis and treatment, (4) to provide for all necessary evaluations and treatment, attorneys' fees, costs, interest, and such further relief as the Court deems equitable and just.

**EIGHTH CLAIM FOR RELIEF**

**BREACH OF EXPRESS WARRANTIES  
(Individually and on Behalf of the Class)**

646. Plaintiffs repeat and re-allege the preceding paragraphs as if fully set forth herein.

647. Consistent with the Special Master's Opinion and Order, Dkt. No. 1614, Plaintiffs bring this claim against the Manufacturer, Finished Dose, and Repackager Defendants, and do not bring this claim against the Wholesaler or Retail Pharmacy Defendants. Plaintiffs bring this claim on behalf of themselves and absent class members residing in all U.S. jurisdictions except for that claim is not brought against any Defendant under the laws of the following states: Connecticut, Kansas, Louisiana, Mississippi, Ohio, Tennessee, and Washington.

648. Each Defendant expressly warranted that its VCDs were fit for its ordinary use, i.e., as an FDA-approved generic pharmaceutical that is therapeutically to and interchangeable with their RLDs. In other words, Defendants expressly warranted that their products were the same as their RLDs.

649. Each Defendant sold VCDs that they expressly warranted were compliant with compendial standards, USP requirements, Orange Book requirements, cGMP and/or not contaminated, adulterated or misbranded.

650. Each Defendant's VCDs did not conform to each Defendant's express representations and warranties because the product was not manufactured in compliance with cGMP and/or was adulterated and/or misbranded.

651. Each Defendant's VCDs were goods that were meant to be consumed.

652. At all times relevant all of the Independent Claim and Remedy Class States and the District of Columbia and Puerto Rico have codified and adopted the provisions of the Uniform Commercial Code: Ala. Code § 7-2-313; Alaska Stat. § 45.02.313; Ariz. Rev. Stat. Ann. § 47-2313; Ark. Code. Ann. § 4-2-313; Cal. Com. Code § 2313; Colo. Rev. Stat. § 4-2-313; Conn. Gen. Stat. Ann. § 42a-2-313; 6 Del. Code. § 2-313; D.C. Code. § 28:2-313; Fla. Stat. Ann. § 672.313; Ga. Code. Ann. § 11-2-313; Haw. Rev. Stat. § 490:2-313; Idaho Code § 28-2-313; 810 Ill. Comp. Stat. Ann. 5/2-313; Ind. Code Ann. § 26-1-2-313; Kan. Stat. Ann. § 84-2-313; Ky. Rev. Stat. Ann. § 355.2-313; 11 Me. Rev. Stat. Ann. § 2-313; Md. Code. Ann. § 2-313; Mass. Gen. Law Ch. 106 § 2-313; Mich. Comp. Laws Ann. § 440.2313; Minn. Stat. Ann. § 336.2-313; Miss. Code Ann. § 75-2-313; Mo. Rev. Stat. § 400.2-313; Mont. Code Ann. § 30-2-313; Nev. Rev. Stat. U.C.C. § 104.2313; N.H. Rev. Ann. § 382-A:2-313; N.J. Stat. Ann. § 12A:2-313; N.M.

Stat. Ann. § 55-2-313; N.Y. U.C.C. Law § 2-313; N.C. Gen. Stat. Ann. § 25-2-313; N.D. Stat. § 41-02-313; Ohio Rev. Code Ann. § 1302.26; Okla. Stat. tit. 12A § 2-313; Or. Rev. Stat. § 72.3130; 13 Pa. C.S. § 2313; P.R. Laws. Ann. Tit. 31, § 3841, *et seq.*; R.I. Gen. Laws § 6A-2-313; S.C. Code Ann. § 36-2-313; S.D. Stat. § 57A-2-313; Tenn. Code Ann. § 47-2-313; Tex. Bus. & Com. Code Ann. § 2-313; Utah Code Ann. § 70A-2-313; Va. Code § 8.2-313; Vt. Stat. Ann. 9A § 2-313; W. Va. Code § 46-2-313; Wash. Rev. Code § 62A 2-313; Wis. Stat. Ann. § 402.313 and Wyo. Stat. § 34.1-2-313.

653. At the time that each Defendant marketed and sold its VCDs, it recognized the purposes for which the products would be used, and expressly warranted the products were the same as their RLDs, and cGMP compliant and/or not adulterated and/or misbranded. These affirmative representations became part of the basis of the bargain in every purchase by Plaintiffs and other Class Members, including but not limited to express representations made in referring to their VCDs as valsartan, valsartan HCT, amlodipine-valsartan, and and/or amlodipine-valsartan HCT.

654. Plaintiffs and each member of the Class are natural persons who are reasonably expected to use, consumer, or be affected by the adulterated and/or misbranded VCDs manufactured and sold by Defendants.

655. As set forth herein, each Defendant breached its express warranties with respect to its VCDs as it was contaminated and not of merchantable quality, was not fit for its ordinary purpose, did not comply with cGMP and/or was adulterated and/or misbranded.

656. As a direct and proximate result of each Defendant's breach of express warranty, Plaintiffs and other Class Members have been injured and suffered damages, in that the Defendants' VCDs they consumed were contaminated with NDMA or NDEA and thus created and/or increased the risk that Plaintiff and other Class Members will develop cancer.

657. Plaintiffs seek injunctive and monetary relief, including compensatory damages for, and the creation of a fund to adequately finance the costs of, medical monitoring procedures (1) to notify and alert all people exposed to NDMA or NDEA contaminants as aforesaid of their exposure and the potential consequences, (2) to provide for necessary testing and screening including but not limited to blood tests, physical examinations, imaging, colonoscopies, endoscopies, and other similar methods for examination, biopsies, pathologic, histologic, and oncologic evaluations, oncologic, histologic, surgical and other necessary medical consultations, (3) to provide for necessary medical and surgical procedures for diagnosis and treatment, (4) to provide for all necessary evaluations and treatment,

attorneys' fees, costs, interest, and such further relief as the Court deems equitable and just.

**NINTH CLAIM FOR RELIEF**

**FRAUD/FRAUDULENT CONCEALMENT  
(Individually and on Behalf of the Class)**

658. Plaintiffs repeat and re-allege the preceding paragraphs as is fully set forth herein.

659. Consistent with the Special Master's Opinion and Order, Dkt. No. 1614, Plaintiffs bring this claim against the Manufacturer, Finished Dose, and Repackager Defendants, and do not bring this claim against the Wholesaler or Retail Pharmacy Defendants. Plaintiffs bring this claim on behalf of themselves and absent class members residing in all U.S. jurisdictions except: Connecticut, Indiana, Kansas, Louisiana, New Jersey, and Tennessee.

660. This claim is brought on behalf of the Classes or, alternatively, under the laws of all the Classes' states, as there is no material difference in the law of fraud and fraudulent concealment as applied to the claims and questions in this case.

661. Defendants each concealed and suppressed material facts concerning the batches/doses of Valsartan they manufactured, distributed, and sold, that were later found to be contaminated with NDMA/NDEA.



662. The API and Finished Dose Manufacturer Defendants knew, or should have known that the VCDs they produced were not therapeutically equivalent to their RLDs and did not comply with cGMPs and/or were contaminated, adulterated, misbranded, and/or unapproved.

663. As set forth herein, the Wholesaler Defendants, and Retail Pharmacy Defendants knew, or should have known that the VCDs were not therapeutically equivalent to their RLDs and did not comply with cGMPs and/or were contaminated, adulterated, misbranded, and/or unapproved.

664. Despite this, Defendants each made material omissions and affirmative misrepresentations regarding the batches/doses of Valsartan they manufactured, distributed, and sold.

665. Defendants affirmatively misrepresented material facts including, *inter alia*, that their VCDs were therapeutically equivalent to their RLDs and/or complied with cGMPs and/or were not contaminated, adulterated and/or misbranded. These misrepresentations were present on, among other things, the VCD labels, patient package inserts, medication guides, and instructions for use. As laid out in Sections N.1-11 of this complaint, Defendants further misrepresented material facts by lauding their safety and risk mitigation approaches on their websites.

666. Defendants omitted material facts including, *inter alia*, that their VCDs contained NDMA contamination, were not therapeutically equivalent to their RLDs and did not comply with cGMPs and/or were contaminated, adulterated, misbranded, and/or unapproved.

667. The Defendants each knew these representations were false when made.

668. Valsartan purchased by Plaintiffs was, in fact, contaminated, hazardous, a health hazard, unsafe and unreliable, because the Valsartan manufactured by Defendants had not been properly manufactured nor properly tested for quality, and was later found to be contaminated with known carcinogen NDMA/NDEA.

669. The Defendants each had a duty to disclose that the Valsartan they manufactured, distributed, and sold, had been contaminated with NDMA/NDEA, had demonstrated such contamination and other analytical discrepancies when it underwent quality control, and that consequent to that contamination, those batches/doses of Valsartan were potentially hazardous to the Class Members' health and was unsafe for human consumption or ingestion. Plaintiffs relied on Defendants' representations that the Valsartan they were purchasing and ingesting was safe and free from contamination.

670. The aforementioned concealment was material, because if it had been disclosed Plaintiffs would not have purchased or otherwise obtained Valsartan from Defendants.

671. To the extent applicable, Plaintiffs and other Class Members were justified in relying on Defendants' misrepresentations and omissions. The same or substantively identical misrepresentations and omissions were communicated to each Class member, including through product labeling and other above-discussed statements by Defendants. No reasonable consumer would have purchased the tainted Valsartan but for Defendants' unlawful conduct. To the extent applicable, reliance may be presumed in these circumstances.

672. The aforementioned representations were also material because they were facts that would typically be relied on by a person purchasing or obtaining Valsartan. The Defendants each knew or recklessly disregarded that their representations were false because they knew that the Valsartan they were manufacturing, distributing, and selling was contaminated with NDMA/NDEA, a substance known to cause cancer and/or increase the risk of cancer. The Defendants each intentionally made the false statements in order to sell Valsartan and avoid the expense and public relations nightmare of a recall.

673. Plaintiffs relied on the Defendants' reputation, along with their failure to disclose the contamination of Valsartan and manufacturing and quality control

problems, and the Defendants' affirmative assurances that their Valsartan was safe for human consumption and/or ingestion.

674. However, Defendants each concealed and suppressed material facts concerning obligations to monitor and test their products.

675. Further, Defendants each had a duty to disclose the true facts about the contaminated Valsartan because they were known and/or accessible only to Defendants who had superior knowledge and access to the facts, and the facts were not known to or reasonably discoverable by Plaintiffs and the Classes.

676. As a direct and proximate result of each Defendant's breach of implied warranty, Plaintiffs and other Class Members have been injured and suffered damages, in that Defendants' VCDs they consumed were contaminated with NDMA or NDEA and thus created and/or increased the risk that Plaintiff and other Class Members will develop cancer.

677. As a result of the fraud, Plaintiffs have suffered direct and consequential damages, and they seek recovery of those damages, and the creation of a fund to adequately finance the costs of medical monitoring procedures (1) to notify and alert all people exposed to NDMA or NDEA contaminants as aforesaid of their exposure and the potential consequences, (2) to provide for necessary testing and screening including but not limited to blood tests, physical examinations, imaging, colonoscopies, endoscopies, and other similar methods for

examination, biopsies, pathologic, histologic, and oncologic evaluations, oncologic, histologic, surgical and other necessary medical consultations, (3) to provide for necessary medical and surgical procedures for diagnosis and treatment, (4) to provide for all necessary evaluations and treatment, attorneys' fees, costs, interest, and such further relief as the Court deems equitable and just.

678. to provide for necessary medical and surgical procedures for diagnosis and treatment, (4) to provide for all necessary evaluations and treatment, attorneys' fees, costs, interest, and such further relief as the Court deems equitable and just.

### **TENTH CLAIM FOR RELIEF**

#### **STATE-LAW PRODUCT LIABILITY ACT CLAIMS (Individually and on Behalf of the Class)**

679. Plaintiffs repeat and re-allege the preceding paragraphs as is fully set forth herein.

680. Consistent with the Special Master's Opinion and Order, Dkt. No. 1614, and the Court's MTD Opinion #5, Dkt. No. 838, Plaintiffs bring a statutory product liability claim against all Defendants on behalf of themselves and absent class members residing in: Connecticut, Indiana, Kansas, Louisiana, Mississippi, New Jersey, Ohio, Tennessee, and Washington. Plaintiffs do not bring any other claim against any Defendant under the laws of these states, unless explicitly stated below. Such additional claims are consistent with the rulings of the Court and the Special Master.

681. Plaintiffs note that to the extent any claims are deemed not to be subsumed, whether in prior or future orders by the Court, stipulations, or other court filings, Plaintiffs assert all available common law and statutory causes of action available to them under the laws of the states and territories upon which their claims rest.

682. ***Connecticut Product Liability Act, Conn Gen. Stat. §§ 52-572m.*** Connecticut Plaintiffs incorporate by reference all previous and subsequent paragraphs of this Complaint as if fully set forth herein and further allege as follows.

683. Connecticut Plaintiffs, based upon the facts previously alleged herein, allege causes of action under the Connecticut Product Liability Act, Conn Gen. Stat. §§ 52-572m under the theories of strict liability – manufacturing defect, strict liability – failure to warn, strict liability – design defect, negligence, negligence per se, breach of express warranty, breach of implied warranty, fraud, negligent misrepresentation, wrongful death, survival, loss of consortium, punitive damages, and consumer protection claims.

684. The claims above are brought against all defendants.

685. ***Indiana Product Liability Act, Ind. Code §§ 34-20-1-1.*** Indiana Plaintiffs incorporate by reference all previous and subsequent paragraphs of this Complaint as if fully set forth herein and further allege as follows.

686. Indiana Plaintiffs, based upon the facts previously alleged herein, allege causes of action under the Indiana Product Liability Act, Ind. Code §§ 34-20-1-1 under the theories of strict liability – manufacturing defect, strict liability – failure to warn, strict liability – design defect, negligence, negligence per se, fraud, negligent misrepresentation, wrongful death, survival, loss of consortium, and punitive damages.

687. The Indiana PLA does not subsume express or implied warranty claims asserted in this Complaint, and therefore Plaintiffs assert those claims under the common law and/or other applicable law causes of action enumerated herein.

688. The claims above are brought against the same defendants named in each common law cause of action preceding and following this Count.

689. ***Kansas Product Liability Act, Kansas Stat. Ann. 60:3301 et seq.*** Kansas Plaintiffs incorporate by reference all previous and subsequent paragraphs of this Complaint as if fully set forth herein and further allege as follows.

690. Kansas Plaintiffs, based upon the facts previously alleged herein, allege causes of action under the Kansas Product Liability Act, Kansas Stat. Ann. 60-3301 *et seq.* under the theories of strict liability – manufacturing defect, strict liability – failure to warn, strict liability – design defect, negligence, negligence per se, breach of express warranty, breach of implied warranty, fraud, negligent

misrepresentation, wrongful death, survival, loss of consortium, and punitive damages.

691. The claims above are brought against all defendants.

692. ***Louisiana Product Liability Act, La. Rev. Stat. § 9:2800.51, et seq.***

Louisiana Plaintiffs incorporate by reference all previous and subsequent paragraphs of this Complaint as if fully set forth herein and further allege as follows.

693. Louisiana Plaintiffs, based upon the facts previously alleged herein, allege causes of action under the Louisiana Product Liability Act, La. Rev. Stat. Ann. § 9:2800.51, *et seq.* under the theories of strict liability – manufacturing defect, strict liability – failure to warn, strict liability – design defect, negligence, negligence per se, breach of express warranty, breach of implied warranty, fraud, negligent misrepresentation, wrongful death, survival, loss of consortium, and punitive damages.

694. The claims above are brought against all defendants.

695. ***Mississippi Product Liability Act, Miss. Code Ann. § 11-1-63.***

Mississippi Plaintiffs incorporate by reference all previous and subsequent paragraphs of this Complaint as if fully set forth herein and further allege as follows.



696. Mississippi Plaintiffs, based upon the facts previously alleged herein, allege causes of action under the Mississippi Product Liability Act, Miss. Code Ann. § 11-1-63 under the theories of strict liability - manufacturing defect, strict liability - failure to warn, strict liability - design defect, negligence, negligence per se, breach of express warranty, breach of implied warranty, negligent misrepresentation, wrongful death, survival, loss of consortium, and punitive damages.

697. The Indiana PLA does not subsume claims alleging or sounding in fraud asserted in this Complaint, and therefore Plaintiffs assert those claims under the common law and/or other applicable law causes of action enumerated herein.

698. The claims above are brought against the same defendants named in each common law cause of action preceding and following this Count.

699. *New Jersey Product Liability Act, N.J.S.A. 2A:59C-2.* New Jersey Plaintiffs incorporate by reference all previous and subsequent paragraphs of this Complaint as if fully set forth herein and further allege as follows:

700. New Jersey Plaintiffs, based upon the facts previously alleged herein, allege causes of action under the New Jersey Product Liability Act, N.J.S.A. 2A:59C-2 under the theories of strict liability - manufacturing defect, strict liability - failure to warn, strict liability - design defect, negligence, negligence per se,

breach of implied warranty, fraud, negligent misrepresentation, wrongful death, survival, loss of consortium, punitive damages, and consumer protection claims.

701. The New Jersey PLA does not subsume express warranty claims asserted in this Complaint, and therefore Plaintiffs assert that claim under the common law and/or other applicable law causes of action enumerated herein.

702. The claims above are brought against the same defendants named in each common law cause of action preceding and following this Count.

703. ***Ohio Product Liability Act, Ohio Rev. Code § 2307.72(A) & (B).***

Ohio Plaintiffs incorporate by reference all previous and subsequent paragraphs of this Complaint as if fully set forth herein and further allege as follows.

704. Ohio Plaintiffs, based upon the facts previously alleged herein, allege causes of action under the Ohio Product Liability Act, Ohio Rev. Code § 2307.72(A) & (B) under the theories of strict liability - manufacturing defect, strict liability - failure to warn, strict liability - design defect, negligence, negligence per se, breach of express warranty, breach of implied warranty, negligent misrepresentation, wrongful death, survival, loss of consortium, punitive damages, and consumer protection claims.

705. The Ohio PLA does not subsume claims alleging or sounding in fraud asserted in this Complaint, and therefore Plaintiffs assert those claims under the common law and/or other applicable law causes of action enumerated herein.

706. The claims above are brought against the same defendants named in each common law cause of action preceding and following this Count.

707. ***Tennessee Product Liability Act, Tenn. Code Ann. § 29-28-101 et seq.*** Tennessee Plaintiffs incorporate by reference all previous and subsequent paragraphs of this Complaint as if fully set forth herein and further allege as follows.

708. Tennessee Plaintiffs, based upon the facts previously alleged herein, allege causes of action under the Tennessee Product Liability Act, Tenn. Code Ann. § 29-28-101 et seq. under the theories of strict liability - manufacturing defect, strict liability - failure to warn, strict liability - design defect, negligence, negligence per se, breach of express warranty, breach of implied warranty, fraud, negligent misrepresentation, wrongful death, survival, loss of consortium, and punitive damages.

709. The claims above are brought against all defendants.

710. ***Washington Product Liability Act, Wash. Rev. Code Ann. § 7.72.010 et seq.*** Washington Plaintiffs incorporate by reference all previous and subsequent paragraphs of this Complaint as if fully set forth herein and further allege as follows.

711. Washington Plaintiffs, based upon the facts previously alleged herein, allege causes of action under the Washington Product Liability Act, Wash. Rev.

Code Ann. § 7.72.010 et seq. under the theories of strict liability - manufacturing defect, strict liability - failure to warn, strict liability - design defect, negligence, negligence per se, breach of express warranty, breach of implied warranty, negligent misrepresentation, wrongful death, survival, loss of consortium, and punitive damages.

712. The Washington PLA does not subsume claims alleging or sounding in fraud asserted in this Complaint, and therefore Plaintiffs assert those claims under the common law and/or other applicable law causes of action enumerated herein.

713. The claims above are brought against the same defendants named in each common law cause of action preceding and following this Count.

### **PRAYER FOR RELIEF**

WHEREFORE, Plaintiffs pray for the following judgment:

1. Certifying this Action as a class action;
2. Appointing Plaintiff(s) as Class Representative(s), and appointing undersigned counsel as Class Counsel to represent the Class;
3. A finding that Defendants are liable pursuant to each and every one of the above-enumerated causes of action;
4. Awarding appropriate preliminary and/or final injunctive relief;

5. Directing the Defendants to fund medical monitoring in an amount sufficient to fund necessary notice and medical care, including but not limited to examinations, tests, pathology, blood tests, evaluations, and treatment, as necessary and appropriate;
6. Payment to Plaintiff and other Class Members of compensatory damages necessary for their monitoring and care;
7. An award of attorneys' fees and costs;
8. Interest as provided by law, including but not limited to pre-judgment and post-judgment interest; and
9. Such other and further relief as this Court may deem equitable and just.

**JURY DEMAND**

Plaintiffs respectfully request a trial by jury on all causes of action so triable.

Dated: November 1, 2021

Respectfully Submitted,

/s/ Ruben Honik  
Ruben Honik  
HONIK LLC  
1515 Market Street, Ste. 1100  
Philadelphia, PA 19102  
Phone: (267) 435-1300  
ruben@honiklaw.com

/s/ Daniel Nigh  
Daniel Nigh  
LEVIN, PAPANTONIO, THOMAS,  
MITCHELL RAFFERTY & PROCTOR, P.A.  
316 South Baylen Street  
Pensacola, FL 32502  
Phone: (850) 435-7013  
dnigh@levinlaw.com

/s/ Adam Slater

Adam Slater  
MAZIE, SLATER, KATZ & FREEMAN, LLC  
103 Eisenhower Pkwy, 2<sup>nd</sup> Flr.  
Roseland, NJ 07068  
Phone: (973) 228-9898  
[aslater@mazieslater.com](mailto:aslater@mazieslater.com)

/s/ Conlee S. Whiteley

Conlee S. Whiteley  
KANNER & WHITELEY, LLC  
701 Camp Street  
New Orleans, LA 70130  
Phone: (504)-524-5777  
[c.whiteley@kanner-law.com](mailto:c.whiteley@kanner-law.com)

***MDL Plaintiffs' Co-Lead Counsel***

/s/ Nicholas Migliaccio

Nicholas Migliaccio  
MIGLIACCIO & RATHOD LLP  
412 H Street NE, Suite 302  
Washington, DC 20002  
Phone: (202) 470-3520  
[nmigliaccio@classlawdc.com](mailto:nmigliaccio@classlawdc.com)

/s/ Rachel J. Geman

Rachel J. Geman  
LIEFF CABRASER HEIMANN &  
BERNSTEIN, LLP  
250 Hudson Street, 8<sup>th</sup> Floor  
New York, NY 10013-1413  
Phone: (212) 355-9500  
[rgeman@lchb.com](mailto:rgeman@lchb.com)

***Counsel for Plaintiffs Valerie Rodich-Annese  
and Kenneth Berkson***

/s/ Scott Morgan

Scott Morgan  
MORGAN LAW FIRM, LTD.  
55 W. Wacker Drive, 9th Floor  
Chicago, IL 60601  
Phone: (312) 327-3386  
[smorgan@smorgan-law.com](mailto:smorgan@smorgan-law.com)

***Counsel for Plaintiff Robert Kruk***

/s/ C. Brett Vaughn

C. Brett Vaughn  
THE HOLLIS LAW FIRM P.A.  
5100 West 95<sup>th</sup> Street  
Prairie Village, KS 66207

Phone: (913) 385-5400  
[brett@hollislawfirm.com](mailto:brett@hollislawfirm.com)

***Counsel for Plaintiffs Michael Rives, Robert  
Fields, & Celestine Daring***

*/s/ John R. Davis*

---

John R. Davis  
SLACK DAVIS SANGER LLP  
2705 Bee Cave Road  
Suite 220  
Austin, TX 78746  
Phone: (512) 795-8686  
[jdavis@slackdavis.com](mailto:jdavis@slackdavis.com)

***Counsel for Plaintiff John Judson***

*/s/ David J. Stanoch*

---

David J. Stanoch  
KANNER & WHITELEY, L.L.C.  
701 Camp Street  
New Orleans, LA 70130  
Phone: (504) 524-5777  
[d.stanoch@kanner-law.com](mailto:d.stanoch@kanner-law.com)

***Counsel for Plaintiff Josephine Bell***